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Abstract 
 
The factors leading to the creation and persistence of anal fistula in Crohn’s disease 
are poorly understood.  As with luminal Crohn’s disease genetic, microbiological and 
immunological factors are implicated but the immunological and microbiological 
composition of Crohn’s and idiopathic anal fistulae have been obscure. 
 
My data demonstrate a lack of clinically relevant organisms within fistula tracts, a 
luminally driven immune response and subtle differences in this response between 
Crohn’s and idiopathic fistulae which may provide the basis for diagnostic tests, 
interventions and further research.   
 
Surgical treatment of anal fistula is characterised by a compromise between risk of 
recurrence and impairment of continence.  In complex, recurrent and multiply 
operated anal fistulae, fistulotomy can still provide a high success rate with low 
additional risk of impairment of continence.  
 
Rectovaginal fistulae are also difficult to manage both surgically and medically.  In 
the infliximab era, successful healing of Crohn’s RVF remains disappointingly rare.  
Surgery for RVF requires a variety of approaches but remains a valuable tool in the 
treatment of both Crohn’s and non-Crohn’s tracts. 
 
Medical treatment of Crohn’s anal fistulae with combination thiopurine and anti-TNFα 
agents has demonstrated good short term results.  Clinical and radiological data to 3 
years follow up demonstrate that around a third of patients maintain healing on 
infliximab, radiological healing lags behind clinical remission by around a year, and 
cessation may lead to recurrence in spite of a healed tract on MRI. 
 
A treatment for anal fistula with high success and low risk of impairment of 
continence in complex anal fistulae eludes colorectal surgeons and 
gastroenterologists.    A treatment combining the best aspects of current fistula 
management with novel elements prompted by improved aetiological understanding 
must be the goal for fistula surgeons and is the inspiration behind this thesis. 
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1 Introduction 
 
The problems associated with fistula-in-ano have vexed sufferers and surgeons for 
thousands of years.  Civilisations from East and West have documented symptoms 
and medical and surgical treatments associated with perianal fistulation; authors on 
the subject include Hippocrates and John of Arderne.  The questions raised by these 
authors often mirror the ongoing dilemmas of fistula surgery: what is the optimal 
treatment method? How does one prevent recurrence? How does one avoid 
incontinence? 
 
Famous sufferers have included Louis XIV and Charles Dickens, the latter treated by 
Frederick Salmon at his Hospital for Fistula &c. founded in 1835 in the City of London 
(now relocated to Harrow) where patients with complex anal fistulae are still seen 
today, often having failed treatment elsewhere and seeking that elusive outcome 
desired by so many over the centuries: a cure without risk of incontinence. 
 
In searching for this Holy Grail of fistula surgery, one must understand what drives 
the creation of anal fistulae and also what allows them to persist, where the current 
treatments risk failure or incontinence and what makes this failure more likely.  One 
must also consider Crohn’s disease very carefully.  Although not a common disease, 
it is becoming more so, and the risk of perianal fistulation in this group is far higher 
than in the general population.  This group of patients is important not only because it 
is at such high risk of developing perianal fistulae, but also because it may help us 
understand the aetiology of anal fistulae, particularly when studied alongside patients 
without inflammatory bowel disease who also develop fistulae. 
 
Although rarely life threatening, perianal sepsis and in particular perianal fistulae are 
the source of enormous suffering to those afflicted and account for personal, work 
and social disruption which may be devastating.  In this thesis the aetiology and 
current management of perianal fistulae will be explored in order to help transform 
the outcome of patients. 
 
 
 
 
 
 19 
1.1 A background to Crohn’s-related perianal fistulae 
 
1.1.1 Historical context 
 
Crohn’s disease is a chronic inflammatory bowel disease characterised by transmural 
bowel involvement, anywhere from mouth to anus, which can lead to fistula 
development, particularly in the perianal region.  A perianal fistula is a pathological 
connection between the anorectal mucosal surface and the perianal skin causing 
pain and purulent discharge.  Perianal fistulae can be idiopathic or secondary to 
various diseases, including Crohn’s disease. 
 
 
Figure 1 - Intersphincteric and low transsphincteric perianal fistulae (a), high 
transsphincteric fistula and transsphincteric perianal fistula with multiple 
external openings and associated abscess (b), in coronal section 
Penner and Crohn described the first case of perianal fistula in a patient with regional 
enteritis in 1938 (1) and subsequently noted perianal lesions in 14% of a cohort of 
patients. It is now recognised that perianal fistulae are a common complication of 
Crohn’s disease, occurring in around a third of all patients with Crohn’s disease (2). 
(a) (b) 
IAS = Internal anal sphincter, EAS = External anal sphincter, IS Glands = 
intersphincteric glands 
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In a recent community based study there was a cumulative risk of developing a 
fistula of 50%, including a perianal fistula in 26% at 20 years (3). 
 
Figure 2 - Sagittal section showing the proportions of fistulae in Crohn’s 
patients (63).  SB = small bowel, B = bladder, U = uterus, R = rectum. 
 
It is now known that perianal fistulating Crohn’s disease represents a distinct disease 
phenotype (4), which appears to be separate from luminal fistulating disease with 
differing disease behaviour and which often requires different therapeutic strategies. 
The Vienna Classification for Crohn’s disease was devised in 1998 to categorise 
diverse Crohn's disease phenotypes (5) recognising the heterogeneity of the 
disease, but did not distinguish between perianal and luminal fistulae. The recent 
Montreal modification to the Vienna Classification provides a separate modifier for 
perianal disease (6) and this underlines the now recognised importance of this 
phenotype with regard to impact on disease prognosis and treatment options. 
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1.1.2 The impact of perianal disease on Crohn’s 
 
While Crohn's disease is classically described as progressing from inflammatory to 
penetrating and/or stricturing disease (7), this does not necessarily apply to perianal 
disease. Many patients are diagnosed with perianal fistulae before or at the time of 
diagnosis of Crohn's disease. In one cohort of Crohn's disease patients, 25% of 
patients with fistulating disease had perianal fistulae which predated their diagnosis 
of Crohn’s disease (8). Another 46% developed fistulae soon after.  
Perianal disease generally denotes a more aggressive Crohn's disease phenotype. If 
perianal disease is present at initial diagnosis, the disease is more likely to follow a 
severe course, progress more quickly from inflammatory to stricturing or penetrating 
complications and require several medical therapies and surgical interventions (9-
11).  Beaugerie and colleagues in 2006 reported that perianal lesions at diagnosis 
were independently associated with a more disabling course, even when there were 
other factors such as age below 40 years at onset or need for steroids for the first 
flare of disease (9). Lakatos and colleagues in 2009 reported that perianal disease 
(in addition to other factors such as small bowel disease, smoking, prior steroid or 
early azathioprine/anti-TNF therapy) is a predictor of disease behaviour change (from 
inflammatory to stricturing or penetrating) over time in patients with Crohn's disease 
(12). 
The natural history of perianal fistulae in Crohn’s patients at St Mark’s Hospital, 
London before the introduction of anti-TNF drugs was examined by Bell and 
colleagues in 2003 (13). On long term follow-up 76% of perianal fistulae had healed, 
16% were persistent and 7% had a seton in situ. Relapse occurred with 32% of 
simple fistulae (defined as low, single external opening, no evidence of abscess, 
rectovaginal fistula or anorectal stricture [figure 1a]) and 23% of complex fistulae 
(defined as high, multiple external openings, perhaps associated with perianal 
abscesses and/or rectovaginal fistulae, anorectal strictures or active rectal 
inflammation [figure 1b]). Median time to healing of perianal fistulae was 44 months 
with a median of 3 (simple) or 6 (complex) treatments per patient. Complex fistulae 
required more complex surgery; 50% ultimately underwent proctectomy, stoma or 
resection, while only 6% of those with simple fistulae ever required a major operation. 
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1.1.3 Factors associated with perianal Crohn’s disease 
 
There are several factors that influence development of perianal disease, including 
gender, age, race and disease location. The data regarding gender are conflicting, 
with some reports of an increased incidence of perianal fistulae in males (8), while 
other patient cohorts demonstrated no difference between males and females (4). 
Age at disease onset appears to influence development of perianal disease, with 
younger patients at the greatest risk. One study found age less than 40 years to be a 
significant risk factor for penetrating complications, including perianal disease, and 
another suggested that patients diagnosed after age 50 were less likely to present 
with perianal complications (7), although duration of disease and age at diagnosis 
may represent the same risk factor for perianal disease.  
 
Non-Caucasian race appears to be associated with perianal disease (4;7). Sephardic 
Jews have a higher risk for perianal disease than Ashkenazi Jews (14). Fistulae are 
most common when colonic disease, in particular distal colonic disease, is present 
(8). For example, patients with Crohn's colitis were more than three times as likely to 
develop perianal fistulae as those with ileitis (4).  Anti-Saccharomyces cerevisiae 
antibodies (ASCA) are associated with Crohn’s disease and also predict a higher 
likelihood of (oral and) perianal Crohn’s (odds ratio 1.89) (15).  Whether these 
antibodies to saccharomyces cerevisiae are part of a genetic predisposition to 
Crohn’s or an adaptive immune response to an unknown microbe or environmental 
factor is not known. 
 
1.1.4 Hidradenitis Suppurativa  
 
Hidradenitis Suppurativa (HS) is associated with perianal Crohn’s disease, can 
coexist with it, and causes diagnostic difficulty in some patients.  The clinical and 
histological features of the two diseases can be similar and it is possible to confuse 
HS with Crohn’s perianal sepsis or with the cutaneous manifestations of Crohn’s.  
Early series highlighted the diagnostic difficulty (16;17); the presence of granulomas 
in the submucosal layer of cutaneous biopsies led to a diagnosis of Crohn’s disease 
but the appearance of abscesses in the axillae suggested HS and subsequent 
intestinal inflammation confirmed the dual diagnoses.  Epithelioid granulomas, known 
to occur in systemic granulomatous disease such as Crohn’s and sarcoid, were 
subsequently shown also to exist in patients with HS alone (18).   
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Further series not only reinforced the association between HS and perianal Crohn’s 
disease and the potential for missing one or other diagnosis but also described their 
outcome - in one series 23 of 24 had had a laparotomy, 22 had a stoma and 17 had 
undergone proctectomy (19;20).  Further evidence of a link between the diseases 
comes from two case reports in which concurrent luminal Crohn’s and HS responded 
to treatment with infliximab with improvement at all HS sites (21;22). 
 
Clinical and radiological features may be valuable in distinguishing the two diseases.  
The presence of abscesses at other sites including the groin and axillae are clearly 
suggestive of HS.  Case reports in the literature suggest that MRI may be valuable; 
skin thickening and subcutaneous induration away from the perianal area, 
subcutaneous abscesses remote from the rectum or anus, enlarged inguinal lymph 
nodes, and no communication with pelvic organs are all consistent with HS rather 
than Crohn’s anal fistulae (23). 
 
1.2 Aetiological factors 
The aetiology of perianal fistulating Crohn’s disease is unclear.  Historically, these 
lesions have been considered infective entities, as in the Parks cryptoglandular 
theory (discussed later). Professor L Hughes, in 1978, divided anorectal lesions in 
Crohn’s disease into primary and secondary lesions.  Primary lesions included ulcers 
and fissures which, under mechanical influences, would lead to secondary lesions 
such as strictures and epithelialised fistula tracts.  His contention was that a deep 
fissure, caused by a flare of proximal disease, created a pocket into which faeces 
would pass.  As the flare of proximal disease resolved and under the pressure of 
defecation, this pocket would erode into the subcutaneous tissues leading to abscess 
formation (24). 
 It is now believed that, as with luminal Crohn’s disease, the aetiology of perianal 
Crohn’s disease involves interaction between microbiological, immunological and 
genetic factors (Table 1). 
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Table 1  - A summary of differences and similarities in the suggested 
aetiological factors in Crohn’s-related and idiopathic perianal fistulae 
 
 Crohn’s perianal fistulae Idiopathic perianal fistulae 
Genetics IBD5 
Armuzzi et al., Vermeire et 
al., Palmieri et al. 
5q31, OCTN variants 
associated with perianal 
disease 
Not assessed 
IRGM rs4958847 
Latiano et al. 
Predisposes to perianal 
and non-perianal fistulae 
Not assessed 
NOD2/CARD15 
Brant et al., Angleberger et 
al. 
No predisposition to 
perianal disease but wild 
type positively influences 
response to antibiotics 
Not assessed 
Microbiology Microbiota found in 
fistula tracts 
Gram positive organisms 
(predominantly Corynebacteria spp., 
Streptococci, Coagulase negative 
staphylococci)  
West et al. 
Gram negative (gut 
deived) > Gram positive  
(E. coli, Bacteroides fragilis, Proteus, 
mirabilis, Enterococcus spp., few 
streptococci) Multiple refs, see text 
Efficacy of 
antibiotics 
Partial efficacy 
demonstrated, implies a 
role for microbiota 
(Bernstein et al., Turunen et al.) 
 
Efficacy of faecal 
diversion 
Partial therapeutic efficacy 
demonstrated, implies a 
role for the luminal stream 
 (Yamamoto et al.) 
 
Efficacy of 
immunomodulators 
Partial therapeutic efficacy 
demonstrated; no overt 
infection unmasked; implies 
microbiology is not the 
exclusive aetiological factor 
 
Immunology 
  
T cells 
Bataille et al. 2004 
 
Interior wall of fistula 
infiltrated by CD45RO+ T 
cells 
Outer 2 thirds of fistula 
wall infiltrated by 
CD45RO+ T cells 
Macrophages 
Bataille et al. 2004 
 
Small band of CD68+ cells 
between inner and outer 
walls 
CD68+ cells throughout 
wall of fistula 
B cells 
Bataille et al. 2004 
Dense infiltrate of CD20+ B 
cells 
Few CD20+ B cells only 
Monocytes 
Bataille et al. 2004 
 
Not known Monocytes surrounded by 
fibrosis 
Epithelial to 
mesenchymal 
transition (EMT) 
Bataille et al. 2008 
EMT occurs 
 
EMT occurs 
 
Myofibroblasts  
 
Increased activity and 
proliferation, decreased 
migration and abnormal 
distribution 
Multiple refs, see text 
Not known 
Defensins 
 
Not known High levels of hBD2 and 3 
Kiehne et al. 
Matrix 
Metalloproteinases 
Kirkegaard et al. 
Increased expression of 
MMPs 3 and 9 
Increased expression of 
MMPs 3 and 9 
TNFα 
 
Elevated serum and 
intestinal mucosal levels. 
Efficacy of anti-TNFα 
treatment Multiple refs, see text 
Serum and intestinal 
levels of TNFα  
unknown.  
 
Epithelialisation 
Bataille et al. 2004 
About 1/3 are epithelialised About 1/3 are 
epithelialised 
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1.2.1 Genetic factors 
 
An association of perianal Crohn’s disease with a susceptibility locus on 
chromosome 5 has been described (25;26).  On 5q31 (IBD5), the carnitine/organic 
cation transporter (OCTN) is associated with Crohn's disease and particular OCTN 
variants are associated with perianal disease (25;27;28). It is not clear how these 
variants may relate to disease, but impaired OCTN activity or expression may reduce 
carnitine transport. This can lead to defects in oxygen burst mediated pathogen 
killing which may partially explain how the previously implicated altered handling of 
bacteria is relevant in the pathogenesis of Crohn’s disease. Reduced carnitine 
transport may also lead to impaired fatty acid β-oxidation in intestinal epithelium, as 
carnitine is an essential co-factor for β-oxidation of long chain fatty acids in 
mitochondria.  Impaired fatty acid β-oxidation is exacerbated by bacterial metabolites 
and causes colitis in experimental models (26). It has also been shown that impaired 
OCTN activity may diminish uptake of physiologic compounds while increasing 
uptake of potential toxins derived from bacterial catabolism. Overall, a role for 
OCTNs in handling enteric bacteria or their products and interacting with the 
epithelial barrier/mucosal immune system appears to be important and it is 
hypothesised that aberrant stimulation through OCTN transporters may lead to 
inflammation characteristic of Crohn’s disease.  
 
More recently, another susceptibility locus has been described on chromosome 
5q33.1. IRGM rs4958847 is part of the autophagy pathway which eliminates 
intracellular organisms and polymorphism is associated with an increased risk of 
penetrating complications (odds ratio 1.48) and perianal fistulae (odds ratio 1.61) 
(29). 
 
Very few studies have investigated the association between NOD2/CARD15 
genotype and perianal CD.  The one study that has investigated this association was 
unable to show correlation between this genotype and perianal fistulating disease in 
a cross-sectional study of 275 patients (30), but there may be an influence of 
NOD2/CARD15 gene status with regards to the response of perianal fistulae to 
antibiotic therapy, greater response being noted in patients with NOD2/CARD15 wild-
type (31).   
 
Several studies have examined genetic associations with penetrating Crohn’s 
disease (including perianal fistulae) but they do not differentiate within their 
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penetrating disease cohorts so the implications for perianal disease specifically are 
not clear (32;33). There are no genome wide association scans for perianal Crohn’s 
disease and it is possible that other genetic associations exist that are currently 
unknown.  
1.2.2 Microbiological factors 
 
One theory for the aetiology of perianal fistulating Crohn’s disease is that fistulae 
occur following cryptoglandular infection, as with idiopathic anal fistulae.  This initially 
leads to abscess and finally to fistula formation caused by surgical or spontaneous 
rupture of the abscess through the perianal skin.  Surgical diversion of the faecal 
stream has been shown to lead to long term improvement in perianal fistulae in 26% 
of patients (34) implying that the luminal stream, and likely the microbiota within it, in 
some way contributes to or drives the pathogenic process.  Surgical diversion also 
improves luminal Crohn’s disease so the improvement seen in patients with perianal 
Crohn’s disease may reflect a decrease in Crohn’s activity rather than a direct effect 
on the perianal fistulae. Changes in the microbiota within perianal fistulae in the 
context of defunctioning do not seem to have been explored.  
 
In luminal Crohn’s disease, there is evidence that the antigens that drive the tissue-
damaging response in intestinal inflammation are derived from the normal bacterial 
microbiota. Proof of this concept has come from studies of at least 11 models of 
inflammatory bowel disease. In these models, inflammation is dependent on the 
presence of a normal microbiota; in its absence there is no disease. The 
phenomenon is seen in different species (mice, rats and guinea pigs) and occurs in 
manipulated systems, such as knockout or transgenic animals, as well as in induced 
models, such as indomethacin- or carrageenan-induced colitis.  
In addition, in humans diversion of the faecal stream after surgery prevents 
recurrence of Crohn's disease and re-anastomosis results in inflammation (35;36). 
Furthermore, this effect has been demonstrated directly by infusion of luminal 
contents into excluded ileum (37). The inflammatory lesions tend to occur in areas of 
bowel with the highest bacterial counts - the terminal ileum and colon. 
The search for a single organism as the causative agent has yielded inconsistent 
results. Entero-adherent strains of Escherichia coli in ileal mucosa have been found 
in patients with Crohn's disease (38;39). Other single organisms that have been 
associated with intestinal inflammation include Chlamydia, Listeria, and 
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Mycobacteria, (40-43), but whether these changes are primary or secondary to the 
disease process is not clear and as yet an infectious origin for Crohn’s disease has 
not been confirmed. Other evidence points to an alteration in the balance of microbes 
in inflammatory bowel disease, known as dysbiosis. Microbial studies have shown a 
persistent reduction in biodiversity of mucosa-associated flora in patients with active 
inflammatory bowel disease compared with the microbiota in controls (reviewed in 
(44)). A loss of normal anaerobic components (Bacteroides, Eubacterium, and 
Lactobacillus spp.) has contributed to this difference (45;46). A shift to an increased 
representation of Gram-negative bacteria appears to accompany a reduced bacterial 
diversity in Crohn's disease patients during remission, implying that it may represent 
a primary modification rather than a response to disease or inflammation (47). 
Decreased bifidobacteria are found in Crohn’s disease (48) as well as an overall 
increase in the number of mucosal adherent bacteria (49).  At relapse in a group of 
patients with ulcerative colitis, a decreased richness and diversity of the flora was 
found (50). 
However, studies assessing microbiological changes in Crohn’s fistulae are sparse. 
One study in which 13 Crohn’s patients with perianal disease had pus aspirated from 
their fistula tracts which was analysed by standard bacterial culture techniques 
reported that Gram-positive organisms, in particular staphylococci, streptococci and 
corynebacter, predominated over Gram-negative enteric organisms (51) which is  
different to the findings in idiopathic fistulae (52;53), where microbes found on 
excised granulation tissue were found to be largely of gastrointestinal origin.  These 
reports are limited by differences in the compartments analysed (exudates versus 
mucosa) and the use of bacterial culture as opposed to molecular techniques to 
quantify the microbes.  Bacterial culture techniques are inadequately selective and 
are unable to detect all the different types of microbes present within the GI tract 
(54).  Furthermore, there has been no comparison between microbes in Crohn’s 
perianal fistulae compared with idiopathic. 
 
Antibiotics temporarily work quite well when used in fistulating Crohn’s disease, 
supporting a role for the gut flora in the aetio-pathogenesis of Crohn’s fistulae. Case 
series and one placebo-controlled pilot trial supply the evidence for antibiotics in 
treating patients with fistulating CD. Metronidazole, with activity against anaerobic 
bacteria, was used in 21 consecutive patients with perianal CD and, of the 18 
patients who remained on therapy, 10 were considered to have complete healing of 
their fistulae at 10 weeks (55). However after stopping metronidazole, 78% had 
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symptomatic recurrence (56), so it would seem that the fistulae were suppressed 
rather than cured. Ciprofloxacin, with broad-spectrum activity including Gram 
negative aerobic organisms, has been used in a small uncontrolled study. Eight 
patients with perianal Crohn’s disease were treated with ciprofloxacin for 3-12 
months and all eight patients improved. However, half continued to have persistent 
drainage (57). A three month course of metronidazole and ciprofloxacin was 
assessed in 14 patients with perianal Crohn’s disease. Nine out of 14 patients 
improved and 3 patients had complete clinical healing of their fistulae (58).  
 
Even with attempts to provide broader spectrum antibiotic cover there is limited 
efficacy in true healing of Crohn’s fistulae, suggesting that optimal selection of 
antimicrobials may be lacking or that infection may not be the whole story. In routine 
clinical practice, antibiotic sensitivity of microbes from Crohn’s fistulae is not 
assessed or used to tailor appropriate antibiotic choice. It may be that an 
environmental factor exists (e.g. excess TNFα) that must be treated concurrently for 
antibiotics to be effective in treating Crohn’s fistulae, in a similar way to that in which 
eradication of gastric colonisation with Helicobacter Pylori requires reduction of acid 
secretion in addition to antimicrobial treatment.  Another explanation for the partial 
efficacy of antibiotics is that the underlying genotype of the patient may dictate 
antibiotic responsiveness versus non-responsiveness. For example, as described 
above, NOD2 status appears to predict responsiveness to ciprofloxacin in Crohn’s 
perianal fistulae (31).  
 
The microbiological environment of the anal fistula tract remains unknown and any 
influence of bacteria on the immunological status of the tract is also therefore entirely 
unclear.  Whether fistula tracts associated with Crohn’s disease contain different 
bacteria to idiopathic tracts, and whether the bacteria themselves are key to the 
creation or persistence of the tracts is based on an understanding of these facts.  
The microbiological status of the rectum in patients with anal fistulae is also poorly 
understood.  Chapter 2 explores the microbiology of Crohn’s and idiopathic fistula 
tracts and the rectal microbiota present in these patients.  
1.2.3 Immunological factors 
Histologically, Crohn’s fistulae seem to arise when a fissure penetrates the lamina 
propria and muscularis mucosae into the deeper layers of the underlying tissue.  
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They tend to be surrounded by granulation tissue with a cellular infiltrate and 
capillaries. 
There are sparse data exploring quantitative and qualitative changes in immune cells 
in perianal Crohn’s fistulae. Bataille et al. histologically examined the nature of fistula 
tracts from patients with Crohn’s disease and controls with fistulae of non-IBD origin 
(59). They examined a broad range of internal and external fistulae, including 14 
perianal fistulae (8 in the Crohn’s group and 6 in the non-IBD control group).  Using 
immunohistochemical techniques on surgical specimens they were able to 
demonstrate differences in the position and number of T and B cells and 
macrophages between the two groups, as summarised in Table 1 (Crohn’s vs. non-
IBD control fistulae). In the Crohn’s group there was an infiltrate of T cells in the 
internal wall of the fistula, then a small band of macrophages, and finally a dense 
infiltrate of B cells in the outer wall of the fistula.  In the non-IBD control group, the 
fistula wall was intensely infiltrated with macrophages throughout the wall with only a 
few B cells found.  T cells were found in the outer two thirds of the fistula wall.  Only a 
small number of patients with perianal Crohn’s disease were included in this study 
and it is not clear whether the described changes, which represent the entire cohort 
of patients studied so far, also apply to those patients with perianal disease 
specifically. 
 
Myofibroblasts are key cells in tissue injury and repair in the gut (60). They become 
activated, proliferate and migrate in the early stages of the injury and repair process. 
They can cause gut damage by secreting matrix metalloproteinases (MMPs) (61), 
which are involved in extracellular matrix degradation (62). There appears to be an 
aberrant healing process in Crohn’s fistulae, such that instead of optimal wound 
healing there is tissue destruction; myofibroblasts play a role in this aberrant process. 
In fistulae from patients with Crohn’s disease, there is an abnormal arrangement and 
distribution of myofibroblasts. CD myofibroblasts differ functionally from control 
myofibroblasts. They have a reduced ability to migrate (63), an enhanced 
proliferative capacity and they release increased amounts of TGFβ and TNFα 
(64;65). Increased tissue-degrading MMPs, in particular MMP3 and MMP9, are 
strongly expressed in patients with fistulae, both of Crohn’s and idiopathic origin (66), 
suggesting a role in fistulation in general.  
 
With defects in fibroblasts known to be present in Crohn’s fistulae, it is perhaps 
surprising that a novel approach used human autologous fibroblasts seeded onto 
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biocompatible scaffolds to treat Crohn’s fistulae. A case report described fistulectomy 
followed by insertion of autologous fibroblasts.  Complete healing was noted in 3 
weeks and the patient remained healed throughout a 20 month follow-up period (67).  
This study will be discussed in greater detail below (page 53). 
 
About one third of Crohn’s fistulae are (at least partially) epithelialised (59). In 
addition to being a physical barrier to bacterial invasion, the epithelium protects the 
host by secreting substances with anti-microbial activity, including defensins. 
Defensins form part of the innate immune system and can protect mucosal surfaces 
from infections with Gram-negative and -positive bacteria, fungi, enveloped viruses 
and protozoa. High levels of the defensins hBD2 and hBD3 have been found in 
idiopathic anal fistulae (68) and in levels similar to those found in the perianal skin.  
The rectal mucosa in these patients expressed almost no hBD2 or 3 and only low 
levels of hBD1.  The same study also indicated high levels of CK5/6 and low levels of 
CK8 in the fistulae examined which, again, is similar to the findings in a multi-layered 
epithelium like skin and quite the opposite to the findings typical in intestinal 
epithelium.  A comparative study in Crohn’s fistulae does not seem to have been 
performed, but there is evidence in luminal Crohn’s disease of impaired induction of 
human beta-defensins (HBD2 and 3) in Crohn’s colitis and the alpha-defensins HD5 
and 6 in ileal disease (69).  
 
In Crohn’s fistulae that are non-epithelialised (present in more than two-thirds of 
cases), there is a thin layer of myofibroblast-like transitional cells  with gap junctions 
that form a basement membrane-like structure. It has been shown that epithelial cells 
can change into mesenchymal cells, a process referred to as epithelial-mesenchymal 
transition (EMT), which has been seen in epithelial cancers and also in normal 
wound healing, and it appears that this occurs in Crohn’s fistulae (70). 
 
When a defect occurs in the intestinal barrier, epithelial cells migrate to the site of 
injury.  EMT, which is an essential component of tissue remodelling and wound 
repair, occurs and the epithelial cells, characterised by strong cell–cell junctions and 
polarity, are replaced by a mesenchymal phenotype, with reduced cell–cell 
adhesions, and a fibroblast morphology and function making them more mobile and 
able to migrate more easily to repair mucosal defects.  Markers of EMT include 
decreased E-cadherin and β-catenin (which translocates to the nucleus) expression, 
and increased expression of β6 integrin.  TGF- β is an inducer of EMT.  This pattern 
of markers has been shown in both Crohn’s-related and idiopathic perianal fistulae.  
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EMT may be a malfunctioning defence mechanism forming part of the aetiology of all 
perianal fistulae and may provide a target for novel therapies. 
 
Defects in our understanding of the immunology of Crohn’s anal fistula tracts include 
knowledge of the basic constituents of the immunological response in the tracts 
themselves, and the location of immune cells within the wall of the tract.  Whether 
immune cells are found in the superficial sections of the wall, perhaps in response to 
a luminal provocation, what level of inflammation is seen and which cells form this 
inflammatory response are not known.  Nor are any similarities or differences in 
dendritic cell function between luminal and perianal fistulating Crohn’s disease or 
between Crohn’s and idiopathic fistula tracts.  These issues will be explored in the 
immunology section of Chapter 2.  
1.2.4 Aetiological implications of immunosuppressant therapy 
 
The effect of immunosuppressants, such as azathioprine/6-mercaptopurine and most 
notably anti-TNFα antibodies, suggests that immune mediated mechanisms play a 
role in Crohn’s fistula formation.  Furthermore, the efficacy of immunosuppressants 
implies that a purely infective pathogenic process is unlikely in Crohn’s fistulae. Use 
of immunosuppressants to treat Crohn’s fistulae may be expected to exacerbate an 
infective origin.  Although perianal abscesses have been reported in trials of 
immunosuppressants and anti-TNFα antibodies, they do not appear to be a major 
problem. 
 
A meta-analysis of nine randomised controlled trials of azathioprine or 6-
mercaptopurine in Crohn’s disease (71) reported a 54% response to treatment in 
various Crohn’s related fistulae (including perianal fistulae) compared with only 21% 
in the placebo arms.  In another study, azathioprine was added to a 20 week 
antibiotic course and improved the rate of response from 15% to 48% in 49 patients 
(72). 
 
Anti-TNFα strategies have revolutionised the medical treatment of Crohn’s fistulae, 
not only in allowing complete healing of fistulae in about half of treated patients, but 
also in providing much more rapid resolution of the draining fistulae with patients 
often responding to infliximab in about 2 weeks. Nearly 10 years ago the first 
randomised double-blind placebo-controlled trial demonstrated efficacy of infliximab 
in the treatment of fistulating Crohn’s disease with approximately 62% of patients in 
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the infliximab group responding compared with 26% in the placebo group, and nearly 
50% of all patients in the infliximab group experiencing complete fistula closure (73). 
Furthermore, in the ACCENT II trial, regular infusions of infliximab, given every 2 
months, enabled 46% of infliximab-treated patients to continue responding and 36% 
of infliximab-treated patients to remain completely healed at 1 year (74). Not only 
systemic but also local injections of infliximab into the fistula tract itself have been 
shown to be efficacious (75;76). This may indicate a role for local TNFα production in 
initiating or perpetuating Crohn’s fistulae.  
 
Serum and rectal mucosal cytokines have been assessed.  One study, using ELISA 
techniques, demonstrated raised rectal mucosal IL-1β and IL-6, and raised serum IL-
6 and TNFα in perianal Crohn’s patients compared to healthy controls and Crohn’s 
patients with only small bowel disease (77).  The rectal mucosal levels of all three 
cytokines correlated with disease activity or severity. The cytokine milieu of idiopathic 
anal fistula tract tissue has been considered in a single study but local rectal and skin 
biopsies were used as control tissues (68). The validity of this control tissue is not 
clear. The study demonstrated elevated levels (vs. perianal skin or rectal mucosa) of 
IL-8 and IL-1β but normal levels of TNFα, IL-10 and IL-6. The cytokine milieu of 
Crohn’s anal fistula tracts themselves is not known and cytokines in Crohn’s and 
idiopathic fistula tracts have never been compared directly. 
 
It is not clear why some patients respond to infliximab and others do not, but the 
genotype may influence responsiveness. For example, polymorphisms in the Fas 
ligand -843 C/T may be a genotypic predictor of response to infliximab in fistulating 
perianal Crohn’s disease (78).   
 
Although infliximab appears to have altered the natural history of Crohn’s fistulae, 
radiological studies show that the fistula tract and associated disease process may 
persist (79;80); prolonged treatment appears to be necessary to optimise deep tissue 
healing. It may be that other cytokines are involved in this stage of the disease 
process, so other therapeutic options may be needed further to enable healing. 
 
The detailed cytokine milieu of both Crohn’s and idiopathic anal fistula tracts is poorly 
understood.  TNFα levels in the tracts themselves have not been described and 
cytokine profiles for both types of tract may represent valuable information, whether 
differences or similarities between the two are present.  An examination of the 
cytokine milieu of Crohn’s and idiopathic anal fistulae is described in Chapter 2. 
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1.2.5 Comparison with idiopathic fistulae 
 
The aetiology of idiopathic fistulae is also unclear.  The cryptoglandular hypothesis 
suggested by Parks in 1961 implicates infection of anal glands, a theory first 
proposed in 1878 by Chiari (81).  Specifically, it is the intersphincteric anal glands 
(representing between one and two thirds of the total number (82)) that are initially 
infected by an abscess which subsides but persists deep to the internal sphincter and 
leaves behind the now diseased gland which becomes the seat of chronic infection.  
This, in turn, leads to formation of a granulation tissue lined tract or fistula.  The 
intersphincteric component of the infected system is fed with bacteria from the 
gastrointestinal tract which leads to persistence of the tract. 
 
Henrichsen et al. showed that of 50 patients with idiopathic perianal, ischiorectal or 
intersphincteric abscesses, 21 grew coliforms or streptococcus faecalis (gut-derived 
organisms) from their cultures whereas 17 grew staphylococcus, proteus or 
streptococcus (skin-derived organisms).  None of those with skin-derived organisms 
had or developed associated fistulae whereas 13 of those with gut-derived organisms 
did, either at operation or within 6 months follow-up (83).   
 
Seow-Choen et al. studied granulation tissue from the tracts of idiopathic perianal 
fistulae in 18 patients and processed the samples using standard microbiological 
techniques. Sixty-nine isolates representing at least 17 species were obtained. The 
predominant organisms were Escherichia coli (22 per cent), enterococcus (16 per 
cent) and Bacteroides fragilis (20 per cent) with streptococci and staphylococci 
present in only a minority of cases (53).  
 
These findings support the infective process as an aetiological factor in idiopathic 
fistula formation.  However, Lunniss et al. commented on the paucity of organisms 
which led to enrichment techniques being required to grow organisms at all (52).  
This suggests that infection does not fully account for the persistence of idiopathic 
perianal fistulae.  Epithelialisation of the tract has been suggested as a possible 
cause of persistence (84), but this has never been substantiated.  There is limited 
published work investigating the immunological nature of idiopathic fistula tracts. 
 
By comparing idiopathic and Crohn’s-related anal fistulae a causative or at least 
permissive factor required for fistula formation or persistence may be identified, 
opening future therapeutic approaches.  
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1.3 Assessing perianal fistulae in Crohn’s disease 
1.3.1 Fistula classification 
  
Low intersphincteric fistulae, low transsphincteric fistulae and those with a single tract 
with no extensions or complicating abscesses are classified as ‘simple’.  Complex 
fistulae have extensions, high tracts (whether intersphincteric, transsphincteric or 
suprasphincteric) involve the vagina, or have an associated stricture or proctitis (85).  
The differentiation between simple and complex has prognostic relevance.  
Complexity worsens the prognosis, reduces the chance of healing and threatens 
continence (13).  As yet no medical trials have randomised specifically based on 
complexity of fistula.  Perhaps contrary to expectation, a prospective cohort of 
patients with perianal Crohn’s disease treated with anti-TNFα antibodies at St Mark’s 
Hospital showed no relation between fistula complexity and the likelihood of healing 
with anti-TNF agents (80). 
 
The Montreal classification recognition that perianal disease requires a separate sub-
classification because it is distinct from and is not usually associated with internal 
fistulating/penetrating disease (6), guides management and may have an aetiological 
basis as discussed above. 
 
1.3.2 Assessment of perianal Crohn’s disease 
 
There are three ways to assess a patient with perianal Crohn’s disease, besides 
thorough history and physical examination:   
 
1) Endoscopy, for evaluating proximal luminal disease and in particular the state of 
the rectum; 
2)  Local imaging with MRI or anal endosonography; 
3) Examination under anaesthesia with surgical drainage of any abscesses and 
seton placement as required.   
 
These assessment methods are generally complementary and are often undertaken 
in combination.  Endoscopy will assist in diagnosis and map the extent and severity 
of the known case. Additional small bowel imaging may be used fully to map the 
disease. 
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Pelvic MRI has been shown to be the most accurate method for classification of the 
primary tract and any secondary extensions (86).  Anal ultrasound, particularly when 
enhanced by hydrogen peroxide, is more accurate at determining the site of any 
internal opening (IO). Anal ultrasound (in combination with anorectal physiology 
tests) can also assess sphincter integrity and function which has been claimed by 
some surgeons to help them formulate an optimal surgical strategy. However, 
ultrasound will not reliably identify ischioanal fossa or supralevator sepsis because of 
rapidly declining resolution with distance from the probe. Furthermore, there is 
considerable variation in operator expertise and insertion of the ultrasound probe 
may be very uncomfortable in the setting of active sepsis, and impossible with 
stenosis. 
 
On the other hand, MRI can be performed without a radiologist needing to be present 
at the time the test is done.  Sequential images are easier to compare, particularly 
when monitoring treatment.  Interpretation is more intuitive and the strategic view is 
better, which can be helpful intra-operatively.  However, the test is expensive and the 
internal opening is less well seen (its position is usually inferred), and some patients 
feel claustrophobic in the confined space of the MRI scanner (and others with, for 
example cardiac pacemakers, are precluded).   
 
As well as being diagnostic, examination under anaesthetic (EUA) by an experienced 
surgeon allows infection to be drained and either definitive surgery (lay open or other 
curative procedures) or placement of a temporary loose seton for drainage while 
medical management is optimised.  However, injudicious probing may cause 
iatrogenic tracts, increasing the complexity of the fistula and thereby the risk of 
recurrence or subsequent incontinence. 
 
In 2001 Schwartz and colleagues reported 34 patients with perianal Crohn’s disease 
taking part in a prospective study comparing the accuracy of 3 methods: EUS, early 
generation MRI and EUA.  There was good agreement between all three.  EUS had 
91% accuracy, MRI 87% accuracy and EUA 91% accuracy.  A combination of any 2 
methods yielded an accuracy of 100% (87).   Two years earlier, Orsoni and 
colleagues had detected more abscesses and fistulae in 22 Crohn’s patients when 
using EUS compared to MRI (88).  However the quality of MRI in this era was 
relatively poor.   
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A later blinded study at St Mark’s hospital compared clinical examination, EUS and 
MRI in 104 patients (89).  Classification of fistula, presence of secondary 
tracts/abscesses and the site of internal openings were all most accurately assessed 
at MRI.  For example, tract accuracy was 90% with MRI, 81% with ultrasound and 
61% with clinical examination.  The question of which modality is best for 
discriminating simple and complex fistulae was specifically addressed using 
established Evidence Based Practice principles by Sahni and colleagues in 2008 
(86).  They found that MRI is the superior technique with sensitivity and specificity of 
97% and 96% compared with 92% and 85% for anal ultrasound and 75% and 64% 
for clinical examination.  MRI remains the bedrock of fistula imaging at St Mark’s 
Hospital, partly for this reason, partly because the surgeons and gastroenterologists 
are able to interpret them themselves to some degree in theatre or in clinic, and 
partly because, as a more objective (less operator-dependent) examination, MRI also 
facilitates serial assessment and comparison of images over different time points. 
 
This latter benefit is crucial in the medical management of Crohn’s anal fistulae and 
its utility is examined in Chapter 5.  How to monitor the efficacy of the medical 
treatment of Crohn’s anal fistulae, when to increase the dose, change to a new 
regime or declare healing and halt treatment, are unknown but vital to optimising the 
use of anti-TNFα agents in this group. 
 
1.4 Medical treatment of perianal Crohn’s disease 
 
The established principles are to drain infection, use setons as required, aggressively 
manage active proctitis, give antibiotics, immunosuppressants, and employ anti 
TNFα therapy, all of which demands significant co-operation between 
gastroenterologists and surgeons.   
 
Few patients improve without any therapy (10% in the placebo arms of the early 
trials) (73;90;91).  Also, improving, either spontaneously or with treatment, is not the 
same as being cured.  The majority of recent medical trials (particularly those 
assessing the anti-TNFα agents) use clinical assessments of healing such as Fistula 
Drainage Assessment, where response is defined as a reduction of 50% or more 
from baseline in the number of draining fistulae observed at 2 or more consecutive 
study visits ≥ 4 weeks apart (55;73;85). A fistula is considered to be closed when it 
no longer drains despite gentle finger compression at examination. Remission is 
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defined as the absence of any draining fistulae at two consecutive visits.  However, 
studies utilising MRI findings as a more rigorous end-point of deep tissue healing 
demonstrate undrained sepsis in these patients who, in turn, are very likely to recur 
or develop more complex sepsis (80). So fistula closure is not the same thing as 
fistula healing. 
 
1.4.1 Corticosteroids 
 
There is no demonstrable role for corticosteroids in perianal Crohn’s disease, 
although corticosteroids are sometimes used to treat concomitant luminal disease.   
 
1.4.2 Metronidazole and ciprofloxacin 
 
Both metronidazole and ciprofloxacin demonstrate slow and incomplete response, 
early recurrence and unwanted side effects.  In an uncontrolled series, Bernstein and 
colleagues reported 21 patients with perianal Crohn’s disease treated with 
Metronidazole 20mg per kg daily (55).  All had less discomfort and 10 of 18 (56%) 
had complete clinical healing.  Improvement typically occurred after 6 to 8 weeks.  
Brandt and colleagues followed up 17 of these patients and added another 9 (56).  
Three quarters relapsed on stopping metronidazole and side effects including 
peripheral neuropathy and nausea limited long term use.  Jakobovtis and colleagues 
reported clinical healing in 33 to 50% of metronidazole-treated patients (92).   
 
Ciprofloxacin has been used in a small open series.  Turunen and colleagues in 1989 
reported 8 patients with perianal fistulating Crohn’s disease resistant to 
metronidazole; all improved but half had persistent drainage (57).  Solomon and 
colleagues reported 14 patients with perianal Crohn’s disease treated with both 
metronidazole and ciprofloxacin with approximately two thirds of patients responding 
(58).  Metronidazole has been compared with ciprofloxacin or placebo in a small 
randomised double-blind placebo-controlled pilot study reported in 2008 (93).  
Twenty-five patients with perianal Crohn’s disease were randomised to ciprofloxacin 
500mg twice a day or metronidazole 500mg twice a day or placebo twice a day and 
were treated for ten weeks. Clinical remission and response rates were 30% and 
40% with Ciprofloxacin, 0% and 14% with Metronidazole and 12.5% and 12.5% with 
placebo, none of these differences being significant.  There were no differences seen 
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in the scores of PDAI, CDAI, IBDQ, and patient and physician global assessment at 
any time point during the study.  
 
Overall, antibiotics remain a mainstay of treatment for perianal Crohn’s disease 
despite the lack of controlled trial evidence. If metronidazole is used, a dose of 750–
1500 mg/day is suggested. Adverse events include metallic taste, glossitis, nausea 
and neuropathy. It should be discontinued if any signs of neuropathy occur, but 
generally therapy is continued for 3–4 months. If ciprofloxacin is used, a dose of 
500–1000 mg/day is adequate and again is usually required for 3-4 months. Adverse 
events include headache, diarrhoea, nausea and rash.  
 
1.4.3 Immunomodulators  
 
There are no controlled trials using the immunomodulators azathioprine and 6MP 
with fistula outcome assessed as primary end points.  Efficacy is suggested by a 
meta-analysis of controlled trials in which fistulae were assessed as secondary end 
points.  This meta-analysis reports a clinical fistula response of 54% in the 
azathioprine/6MP group compared with 21% in the placebo group (71).  There are 
two uncontrolled case series (one in children) that have been reported (94;95). The 
larger series by Korelitz and Present in 1985 included 18 patients with perianal 
fistulae. Six patients demonstrated complete fistula closure and 4 patients 
demonstrated clinical improvement of their fistulae. 
 
The combination of azathioprine and antibiotics has also been assessed (72).  Fifty-
two patients with predominantly simple Crohn’s perianal fistulae were given 
metronidazole or ciprofloxacin for 8 weeks.  Patients who received azathioprine as 
well had a better response at week 20 than those who had not, suggesting 
combination treatment was better.   
 
The slow initial response, side effects and relatively low remission and high 
recurrence rates with the drugs so far discussed have all left the door open to newer 
treatments. 
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1.4.4 Infliximab 
 
With the anti-TNF drugs, comes a change in treatment options for perianal fistulating 
Crohn’s disease.  The potential not only to improve quality of life but also to heal the 
fistula tracts has been realised and the time to clinical improvement has changed 
from the order of several months to a few weeks.   
 
The first placebo controlled trial using infliximab was reported by Present and 
colleagues in 1999 (73).  Ninety-four patients were given three infusions of infliximab 
at 0, 2 and 6 weeks.  Sixty-eight percent of patients had a clinical response and 
approximately 50% of patients closed all fistulae.  The median time to achieve 
response was 2 weeks.   
 
In the maintenance trial of infliximab in patients with perianal fistulating Crohn’s 
disease (ACCENT II), 282 patients initially received 3 infusions of infliximab at 0, 2 
and 6 weeks and responders at week 14 were randomised to receive placebo or 
maintenance infliximab 8 weekly for 54 weeks (74).  There was a significant 
difference in the primary outcome measure, which was time to loss of response.  
Among patients who had a response at the time of randomisation, those given 
infliximab maintenance therapy had a significantly longer time to loss of response 
(greater than 40 weeks) than those who received placebo maintenance (14 weeks) 
(p< 0.001). Forty-six percent of patients in the infliximab maintenance group had a 
fistula response at 54 weeks and 36% of patients had a complete response at 54 
weeks. In the placebo maintenance group, 23% of patients still had a response at 
week 54 and 19% had a complete response.  
 
The impact of infliximab maintenance in the ACCENT II patients on hospital 
admissions and the need for surgery was examined by Lichtenstein in 2005 (96).  
The treatment maintenance group had a reduction of >50% in hospital admissions 
compared with the placebo maintenance group and their length of stay was also 
significantly reduced (2.5 to 0.5 days).  The treatment group also had an 
approximately 50% reduction in the mean number of all operations and procedures, 
rising to >80% for major procedures. Not only does infliximab influence the number of 
hospital admissions and operations that a patient with perianal Crohn’s disease 
undergoes, but there is evidence that anti-TNF therapy improves health-related 
quality of life in patients with Crohn’s perianal fistulae (97). 
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When infliximab is stopped, however, the risk of recurrence is high and it is higher in 
perianal than luminal disease.  Domenech and colleagues followed patients with 
perianal Crohn’s disease for 1 year after they had stopped a one year course of 
infliximab (induction plus maintenance).  They found 83% of luminal CD patients 
were free of relapse compared to only 34% of perianal CD patients (98). 
 
More recently, a large open label case series from Hungary of 148 Crohn’s anal 
fistula patients reported a remission rate of 49% at 12 weeks follow-up but longer 
term follow-up and confirmed healing on MRI were lacking (99).  An Italian 
multicentre group reported an initial response to induction with infliximab in 76% of 
188 patients with perianal Crohn’s disease and a 44% clinical remission rate (100). In 
a prospective study from St Mark’s Hospital, 34 patients with perianal Crohn’s fistulae 
were followed up long term. At 6 months, 58% of the infliximab treated patients were 
in clinical remission, 37% were in clinical response and 5% had had no response 
(80).   
 
The question of whether infliximab should be used with concomitant 
immunomodulators such as thiopurines to achieve a better outcome, is difficult to 
answer in the setting of perianal Crohn’s disease. It is interesting to note that the 
majority in remission in the Hungarian study were on a concurrent immunomodulator, 
most frequently Azathioprine. In the Accent II trial, about one third of patients were on 
concomitant immunomodulators. A post-hoc analysis of the ACCENT II data by 
Lichtenstein and colleagues published in 2009 identified that approximately one third 
of patients in both placebo and infliximab arms were on concomitant 
immunomodulators at baseline and it appeared that there was no major benefit of 
dual therapy (101). However, in a recent study to assess whether concomitant 
immunomodulators are useful in patients with Crohn’s disease, it was found that 
perianal complications were less frequently observed at times when patients were on 
concomitant immunomodulators (102). The balance of risk and benefit of dual 
therapy needs to be considered in individual cases. In the recent SONIC trial, which 
assessed efficacy of infliximab monotherapy, azathioprine monotherapy and the two 
drugs combined in over 500 adults with moderate to severe Crohn’s disease who had 
not had previous immunomodulator or anti-TNF therapy, overall about 12% of 
patients had perianal fistulae - but no separate analysis was performed in this group 
to determine the relative benefits of single or dual therapy (103).  
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The presence of proctitis has been shown to be a predictor of poor response to anti-
TNFα (80).  There are no other clear predictors of failure or success of anti-TNFα in 
Crohn’s perianal fistulae. However, it is interesting to note that perianal fistulae heal 
more commonly than other fistulae, particularly internal fistulae, with this treatment 
(104).   
 
The long term use of anti-TNF agents such as infliximab is costly and although rare, 
side effects of these drugs can be serious and may include septic complications, 
autoimmune phenomena such as drug induced lupus, demyelinating disease and 
malignancy (74).  Their efficacy over the longer term, particularly with reference to 
true healing of fistula tracts, remains unknown with most reports detailing follow-up to 
several months rather than years.  In Chapter 5 the efficacy of anti-TNF agents after 
3 years of maintenance treatment will be examined with both clinical and radiological 
assessment. 
 
1.4.5 Local injection of infliximab  
 
Two open label studies have used infliximab as a local instillation in situations where 
disease is limited to the anus or there are contraindications to systemic infliximab.  
Poggioli and colleagues in 2005 reported the results of 3 to 12 infusions of infliximab 
(15 to 20mg) directly injected into the tissue surrounding both openings and into the 
wall of the tract (76).  Healing of fistulae was noted in 10 of 15 patients. 
 
Asteria and colleagues in 2006 reported 6 of 11 patients treated with local infliximab 
achieving a clinical response and 4 of the 11 remained healed at a median of 10 
months follow-up (75). 
 
1.4.6 Adalimumab 
 
In the CHARM (Crohn's trial of the fully Human Antibody Adalimumab for Remission 
Maintenance) study, 113 patients with Crohn’s fistulae were given adalimumab at 
week 0 (80mg), week 2 (40mg) and then maintenance with either weekly or 
fortnightly adalimumab or placebo (105).  Fistula response and fistula remission 
(cessation of drainage from all orifices) were secondary endpoints. At 26 weeks, 30% 
of patients treated with adalimumab had complete closure and this rose to 33% at 56 
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weeks compared with 13% in the placebo arm.  In CLASSIC-1 (Clinical Assessment 
of Adalimumab Safety and Efficacy Studied as an Induction Therapy in Crohn's 
disease) adalimumab at 80/40 mg, 160/80 mg or placebo was administered and 
short term effects were assessed. 32 of the 299 patients had draining perianal 
fistulae and no difference was found between placebo and any of the ADA induction 
doses for fistula response or remission (106).  
 
Other studies have considered adalimumab in patients who have already failed an 
anti-TNF drug.  In GAIN (Gauging Adalimumab efficacy in Infliximab Non-
responders), Crohn’s disease patients who had lost response or who were intolerant 
to infliximab were treated with an induction regime of 160/80 mg adalimumab or 
placebo (107). Forty-five of the 325 patients had perianal fistulae and no difference 
was found between placebo and any of the ADA induction doses for fistula response 
or remission. In an open label trial in which 22 patients with perianal fistulae who had 
lost response or showed intolerance to infliximab were treated with adalimumab 
160/80 mg, remission was noted in 23% at 4 weeks (108). The study of fistulating 
Crohn’s disease, described above, in which 34 patients with fistulating perianal 
disease (85% anal fistulae, 15% rectovaginal fistulae) were followed up at St Mark’s 
hospital, also evaluated the response to adalimumab in patients who lost response to 
or were intolerant of infliximab (80). At 6 months, 14% of the adalimumab treated 
patients (who had failed infliximab) were in clinical remission, 43% in clinical 
response and 43% having had no response.  The data suggest that a second anti-
TNF agent is effective in patients who have failed one anti-TNF therapy already, but 
the effect is reduced.   
 
The long term use of adalimumab is shown in the CHARM extension study to 2 years 
in which 60% of adalimumab-treated patients who completed follow-up throughout 
both trials maintained fistula healing at 2 years, although the non-responder 
imputation efficacy at 2 years, which includes those patients who started on 
Adalimumab but left the trials for any reason (including stopping the drug due to lack 
of efficacy, adverse events, protocol violations etc.), was 31% (109).  A further 
snapshot of efficacy at 3 years indicated that over 90% of those patients with healed 
fistulae at the end of CHARM, maintained healing for a further 2 years on either 
weekly or fortnightly adalimumab (110). 
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Table 2 - Randomised Controlled Trials (RCT) or meta-analyses of medical 
treatments of Crohn’s-related perianal fistulae 
 
Drug Study Type of study n FU at end 
point 
Fistula remission 
Rx Placebo 
Metronidazole Thia 
2009 (93) 
RCT 7 10 weeks 0%  12.5% 
Ciprofloxacin Thia 
2009 (93) 
RCT 10 10 weeks 30%  12.5% 
Aza/6-MP Pearson 
1995 (71) 
Metaanalysis 41 - *54%  *21% 
Tacrolimus Sandborn 
2003 (91) 
RCT 42 10 weeks 10% 8% 
Infliximab Present 
1999 (73) 
RCT 
induction 
94 14 weeks 55%  13% 
Infliximab Accent II 
(74) 
RCT 
maintenance 
282 54 weeks 36%  19% 
Adalimumab CHARM 
# (105) 
RCT 
maintenance 
113 56 weeks 33%  13% 
* = remission and response included together 
# = In CHARM patients with luminal and perianal Crohn’s disease were assessed 
 
1.4.7 Other medical options 
 
Other immunomodulators including Tacrolimus, Thalidomide, Methotrexate and 
Ciclosporin have been considered.  Alternative options include GMCSF, absorptive 
carbon and hyperbaric oxygen.  
 
1.4.7.1 Tacrolimus, Thalidomide, Methotrexate, Ciclosporin  
 
1.4.7.1.1 Tacrolimus 
 
Tacrolimus was assessed in a placebo-controlled trial in which it was given orally for 
10 weeks in 42 Crohn’s anal fistula patients.  There was significant clinical 
improvement in the tacrolimus group (45%) compared with placebo (9%) but no 
significant improvement in fistula remission rates was seen (91).  Gonzalez Lama 
and colleagues in 2005 showed that longer term therapy may be required to achieve 
healing (111).  Topical tacrolimus has been used in a placebo controlled trial in which 
19 patients were stratified according to whether they had ulcerating or fistulating 
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disease (112).  There was a benefit in the ulcerating but not the fistulating group.  
There was no systemic detection of tacrolimus and side effects were not 
encountered.  This lack of systemic absorption was also noted in a case series of 
children with oral or perianal (6/8) Crohn’s and in whom the topical preparation was 
effective in improving fistulae after failure of numerous other therapies (113).  
 
1.4.7.1.2 Thalidomide 
 
Thalidomide has been used in the context of perianal Crohn’s disease.  Vasiliauskas 
and colleagues in 1999 reported an open series of 12 male patients with Crohn’s 
disease of whom six had fistulae and 5 out of 6 demonstrated significant 
improvement (114).  Ehrenpreis and colleagues in 1999 reported an open label study 
of 13 patients with fistulating Crohn’s disease (115).  Six out of 13 achieved complete 
remission of their fistulae at 12 weeks.  Plamondon and colleagues in 2007 reported 
an open label study of 11 patients with fistulating Crohn’s disease treated with 
Thalidomide (116).  Nine out of the 11 responded to the Thalidomide and 3 out of 9 
had a complete response.  The data suggest that Thalidomide can heal fistulae in 
patients naïve or refractory to anti-TNF drugs.   
 
1.4.7.1.3 Methotrexate 
 
There is little evidence to support the use of methotrexate as monotherapy to treat 
perianal Crohn’s disease. There are no randomised data, only small case series. In 
one case series, 56% of patients with Crohn's anal fistulae on methotrexate showed 
a complete or partial response to therapy (117). Schroder and colleagues used 
infliximab induction as a bridge to methotrexate (20 mg/week) in 12 consecutive 
patients of whom four (33%) had complete closure and three (25%) had partial 
response (118). 
 
1.4.7.1.4 Ciclosporin 
 
There have been small case series using intravenous ciclosporin, usually at a dose 
of 4mg/kg, to treat perianal Crohn’s disease. Although about three quarters of 
patients initially responded, the treatment was limited in that following oral transition 
or discontinuance of ciclosporin, a majority of patients relapsed (119). 
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1.4.7.2 GM-CSF 
 
Human granulocyte-macrophage colony-stimulating factor (GM-CSF) has been 
examined in luminal Crohn’s disease in a small number of studies, including a double 
blind RCT where it was used as a steroid-sparing agent in steroid dependent Crohn’s 
disease.  The primary end point was steroid free remission, which was achieved in 
18.6% of treatment patients vs. 4.9% of those taking placebo (p = 0.03) (120).  
Evidence of improvement in perianal fistulae is limited and a small case series of 
heterogeneous and complex patients published in 2010 failed to find any 
improvement in fistulae in Crohn’s disease after GM-CSF treatment (121). 
 
1.4.7.3 Hyperbaric Oxygen Therapy (HBOT) 
 
The mechanism of action of HBOT is thought to be multifactorial, including raising the 
oxygen tension in damaged tissue, improving oxygen-burst mediated phagocytosis, 
decreasing circulating LPS-stimulated pro-inflammatory cytokines such as IL-1, IL-6 
and TNFα levels, and inhibiting neutrophil-associated inflammation (122;123).  
Several studies during the 1980s and 1990s described cases or small case series of 
patients with severe perianal Crohn’s disease who partially or completely responded 
to HBOT (124-126).   
 
In these trials, side effects of HBOT included tympanic membrane perforation and 
blurred vision (which resolved after treatment finished).  Patients spent between 30 
and 130 hours in the HBOT chamber in 1.5-2 hour sessions.  It is difficult to draw firm 
conclusions from these heterogeneous studies on efficacy or side effects in the 
absence of randomised controlled data. 
 
1.4.7.4 Oral absorptive carbon 
 
Fukuda and colleagues reported a randomised controlled trial of oral absorptive 
carbon in which 57 patients received either activated absorptive carbon or a non-
absorptive carbon molecule as placebo (127).  The treatment group achieved 37% 
improvement and 30% remission of anal fistulae after 8 weeks treatment compared 
to 10% and 7%, in the placebo group.  The authors suggested that the mechanism of 
action might be a combination of firming of stool, absorption of toxins or intestinal 
 46 
stimulation factors (such as serotonin and histamine) and restoration of the normal 
luminal environment and flora. 
 
1.4.8 Monitoring response to therapy 
 
The improved medical treatment for Crohn’s perianal fistulae has prompted new 
questions: how to monitor patients, how long to treat them with drugs which have 
serious side effects and are expensive, and when or perhaps if to stop treatment.   
 
Studies have shown that although clinical healing (in the form of a closed external 
opening or cessation of drainage) has occurred in the short term, imaging modalities 
including MRI indicate that the fistula tract may remain for some time with deep and 
true healing of the fistula lagging behind clinical remission by months or with 
reactivation after cessation of treatment or during maintenance treatment (79;80).  In 
those in whom healing does take place, determining the moment of tissue healing 
using MRI and stopping treatment at this point, rather than based on clinical 
remission, ought to mean a lower risk of later recurrence.   
 
Sequential MRI scanning may also select those patients who are non-responders at 
an earlier stage, permitting an early change to another anti-TNF therapy or the 
decision to stop altogether or continue on maintenance treatment. This early 
diagnostic impact on decision making should improve treatment efficiency and 
patient safety.  
 
The prospective study of 34 patients with fistulating Crohn’s disease at St Mark’s 
Hospital, discussed above, also evaluated the impact of MRI on clinical decision 
making (80).  Patients were treated with infliximab and, if there was a lack or loss of 
response or if the patient was intolerant to infliximab, they were treated with an 
alternative agent (adalimumab or thalidomide).  Patients were assessed clinically and 
by MRI at 6, 12, 18 and 24 months, and yearly thereafter with a median follow-up of 
83 weeks (range 52 to 131 weeks). 
 
At 6 months, 58% of the infliximab treated patients and 14% of adalimumab treated 
patients were in clinical remission.  They found that deep tissue healing as assessed 
by MRI was slower to occur than clinical healing and the rate of deep tissue healing 
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varied between patients.  The presence of proctitis, but neither the complexity nor the 
duration of fistula, was associated with a lack of response.   
 
   
a          b 
  
c               
Figure 3 - T2 weighted pelvic MRI images with fat suppression showing 
improvement of anal fistula from baseline (a) at six months (b) and 21 months 
(c). 
 
 
Imaging may also be useful in guiding surgical intervention during medical treatment 
and thereby improve outcome.  A small study by Spradlin and colleagues (2008) 
showed that serial EUS during maintenance infliximab treatment, which was used to 
time seton removal and repeat abscess drainage and seton insertion, reduced fistula 
recurrence and treatment failure (128). 
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Long term treatment with expensive drugs that pose potentially serious risks to health 
is increasingly common, so an understanding of whether treatment is working and 
what the long term future holds for an individual on anti-TNF agents is crucial, but 
currently conspicuous by its absence.  This is partly because of the blunt clinical 
assessments used to monitor patients on these drugs.  The natural history of patients 
on anti-TNF agents including radiological monitoring, as well as factors predicting 
outcome, are examined in Chapter 5. 
 
1.5 Surgery for perianal Crohn’s disease 
 
The surgeon’s role has changed, management being in combination with the 
physician.  Some fistulae can be definitively cured, usually by lay open or 
advancement flap.  Other patients need a proctectomy. Others need palliation of their 
symptoms, usually employing drainage of any trapped infection and thereafter with a 
long term, comfortable loose seton (Figure 4). 
 
Examination under anaesthetic, drainage of sepsis and insertion of comfortable 
setons now forms the first stage in the truly combined surgical-medical eradication of 
anal fistulae using infliximab as described above.  If pre-treatment surgical drainage 
is inadequate, abscess formation during the infliximab course may be more likely and 
could cause the treatment to fail.  In the ACCENT II trial of maintenance infliximab in 
patients with fistulating Crohn’s disease, there was no signal that infliximab-treated 
patients were more likely to develop new perianal sepsis (129). Twenty-one (15%) 
patients in the infliximab maintenance group had at least one newly developed 
fistula-related abscess compared with 27 (19%) in the placebo maintenance group (P 
= 0.526). The number of fistula-related abscesses diagnosed over time did not differ 
between groups (Sands and colleagues 2006). Loose seton insertion seeks to 
palliate, reducing pain and discharge and in particular preventing recurrent abscess 
formation.  In addition to the described role with infliximab treatment, it remains a key 
tool in the surgeon’s arsenal for the long term management of Crohn’s perianal 
fistulae, stubbornly resistant to all attempts at eradication, and may prevent 
deterioration requiring proctectomy in some patients (130-133). 
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a.   b.  
Figure 4 - a. A bulky silastic seton and b. a low profile ethibond seton with just 
three throws and the ‘whiskers’ tied back with silk. 
 
1.5.1 Surgery and infliximab 
 
The combination of infliximab and surgery has been examined in a number of small 
trials in three ways; the application of surgery before infliximab treatment, combined 
maintenance with infliximab and seton insertion, and the application of infliximab 
before surgery.   
 
The use of pre-infusion examination under anaesthetic, drainage of trapped sepsis 
and insertion of setons improved outcome by increasing initial response rate by 
almost a fifth, lowering recurrence rate by a third and increasing time to recurrence 
by 10 months (134).   
 
Several small uncontrolled case series have reported the successful use of combined 
seton insertion and maintenance infliximab with remission rates of between 47% and 
78% (135-137).   
 
A series of 226 patients undergoing various surgical procedures for Crohn’s anal 
fistulae included 79 who received preoperative infliximab (138).  The groups in this 
study were not randomised and were heterogeneous.  For example the combined 
treatment group had a higher proportion of transsphincteric (as opposed to 
intersphincteric) fistulae, a higher proportion of seton insertions (as opposed to 
fistulotomies) and a higher proportion of patients with proctitis.    Both groups 
achieved similar healing rates of approximately 60%.  However, there were signals in 
this report which suggest there was a benefit to combined treatment.  Time to healing 
was reduced from 12.1 to 6.5 months and two subgroups, patients with 
transsphincteric fistulae or those treated with setons as their only surgical 
intervention, healed more frequently if treated with infliximab too.  Proctectomy rates 
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were similar in both groups (8-10%) and, interestingly, although proctitis was reduced 
in the combination group, this did not correlate with healing.  The above mentioned 
heterogeneity makes these results more challenging to interpret but they none-the-
less hint at the benefits which might be observed in a well-designed randomised trial 
of combined infliximab and surgical treatment.   
 
A smaller series of 17 patients in whom 7 underwent either fistulotomy (for low 
fistulae) or advancement flap (for higher fistulae) alone and 10 had preoperative 
infliximab found 100% initial healing in both arms with 2 recurrences (29%) in the 
surgery alone group and 1 (10%) in the infliximab group (139). 
 
1.5.2 Lay open 
 
Some Crohn’s fistulae can be laid open and cured.  As a general rule, surgeons are 
more cautious in Crohn’s disease and will not lay open fistulae that in the idiopathic 
setting they would be happy to treat.   Not only are there concerns regarding future 
fistula formation and problems with healing, but the increased bowel frequency and 
the tendency for this to worsen with disease activity or future resection makes 
incontinence a greater threat.   
 
1.5.3 Advancement flaps 
 
Advancement flaps can be used as a sphincter preserving technique for some higher 
fistulae in Crohn’s disease with a success rate of around 50% (140;141).  Patients 
are chosen who do not have active proctitis or extensive cavitating ulceration in the 
anal canal.  A defunctioning stoma is usually used in an attempt to improve the 
chance of success, although there is little evidence suggesting an improved success 
rate.  An adjunctive Martius flap may be helpful.  An advancement flap is easier when 
there is perineal descent or internal intussusception. 
 
Two studies from the Cleveland Clinics of Florida and Ohio, published in 2002, 
demonstrated a worse outcome for advancement flap surgery in Crohn’s anal and 
rectovaginal fistulae than those of cryptoglandular origin in more than 100 patients 
each (140;141).  Mizrahi and colleagues showed an increased recurrence rate after 
surgery from 33% in non-Crohn’s fistulae to 57% in the Crohn’s patients which was 
 51 
similar to the findings of Sonoda and colleagues with 30% recurrence rising to 50% in 
Crohn’s disease.  This latter study also demonstrated a lower success rate in 
rectovaginal than anal fistulae and found that early surgery on a well-drained fistula 
complex increased the chance of success.  Smoking has been shown to increase the 
risk of failure in cryptoglandular fistulae, although in this as well as most studies of 
advancement flap surgery, patients with Crohn’s disease were excluded (142) 
 
1.5.4 Glues and plugs 
 
Fistula infill materials, such as fibrin or collagen glues and collagen plugs, have not 
maintained the same initial enthusiasm and excellent results that their first published 
trials enjoyed.  None-the-less they remain a low risk (albeit expensive) option in the 
management of idiopathic anal fistulae.  Many of the trials of both glue (table 3) and 
plugs (table 4) have included small numbers of Crohn’s patients, although 
independent analysis of efficacy in the Crohn’s cohorts is often not possible due to 
these small numbers and the absence of MRI validation of healing. 
 
Vitton and colleagues studied 14 Crohn’s fistulae (superficial, inter- trans and 
suprasphincteric and anovaginal) and observed complete clinical healing in 8 of them 
at a median of 23 months follow-up.  The fistulae were described as refractory, 
although the complexity of the fistulae and extent of Crohn’s disease was not 
described (143). 
 
A recently published study of fibrin glue in Crohn’s perianal fistulae, an open label, 
randomised controlled trial, demonstrated initial success (clinical remission at week 
8) in 38% (13 of 34) of the fibrin glue group compared to 16% in the observation only 
group (144).  Twenty of the 37 patients in the observation only group crossed over to 
fibrin glue treatment at week 8 and 9 of these patients went into remission at week 
16.  Unfortunately, of the 54 who underwent fibrin glue treatment at some point in the 
trial, only 11 (20%) were in remission at long term follow-up (median 37 months for 
initial fibrin glue group and 17 months for cross over group).  No imaging was used to 
assess deep tissue healing in this study. 
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Table 3 - Studies of fistula glue in anal fistula including Crohn’s patients 
 
Study Year FU 
(months) 
Routine 
preop 
seton 
Total 
n 
Crohn’s 
n 
Overall 
success 
rate 
Crohn’s 
success 
rate 
Abel+ 
(145) 
1993 3-12 No 10 3 6/10 
(60%) 
1/3 
(33%) 
Venkatesh# 
(146) 
1999 12 No 30 6 18/30 
(60%) 
0/6 (0%) 
Cintron# 
(147) 
2000 12 No 79 6 48/79 
(61%) 
2/6 
(33%) 
Lindsey 
(148) 
2002 17.1 No 19 2 12/19 
(63%) 
2/2 
(100%) 
Zmora 
(149) 
2003 12.1 No 24 5 8/24 
(33%) 
2/5 
(40%) 
Sentovich 
(150) 
2003 22 Yes 48 5 33/48 
(69%) 
4/5 
(80%) 
Loungnarath 
(151) 
2004 26 No 39 13 12/39 
(31%) 
4/13 
(31%) 
Singer# 
(152) 
2005 27 No 75 3 25-44% 0/3 (0%) 
Vitton# 
(143) 
2005 23.4 No 14 14 8/14 
(57%) 
8/14 
(57%) 
Chung$ 
(153) 
2010 3 No (81) 2 23/79 
(29%) 
0/1 (0%) 
de Parades# 
(154) 
2010 11.7 Yes 30 11 15/30 
(50%) 
7/11 
(63.6%) 
Grimaud# 
(144) 
2010 2 No 34 34 13/34 
(38%) 
13/34 
(38%) 
#Includes some rectovaginal fistulae 
+The one success in the CD group had a rectovaginal fistula (RVF) which healed 
after 2 treatments 
$Idiopathic results from contemporary but separately published results by same 
authors 
 
 
The anal fistula plug has been used in trials of Crohn’s perianal disease with success 
rates between 25% and 100% (table 4) including the two largest studies (of 14 and 
20 patients) which were at opposite ends of this spectrum of success (26.6% and 
80%).   Failure occurred due to extrusion of the plug, abscess formation or ongoing 
discharge.  Long term follow-up or radiological proof of fistula healing in an 
adequately powered randomised controlled trial is required to establish efficacy of 
this expensive treatment. 
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Table 4 - Studies of the fistula plug in anal fistula including Crohn’s patients 
 
Study Year FU 
(months) 
Routine 
preop 
seton 
Total 
n 
Crohn’s 
n 
Success 
rate 
Crohn’s 
success 
rate 
O’Connor* 
(155) 
2006 10 depends 20 20 16/20 
(80%) 
16/20 
(80%) 
van Koperen 
(156) 
2007 7 No 17 1 7/17 
(41%) 
1/1 
(100%) 
Ky  
(157) 
2008 6.5 No 44 14 24/44 
(54.6%) 
4/14 
(26.6%) 
Schwandner 
(131) 
2008 9 No 18 7 12/18 
(61%) 
6/7 
(85.7%) 
Christofordis 
(158) 
2008 6.5 No 47 3 20/47 
(43%) 
NR 
Schwandner† 
(159) 
2009 9 No 9 9 7/9 
(77%) 
7/9 
(77%) 
Safar 
(160) 
2009 4 No 36 4 5/36 
(13.9) 
1/4 
(25%) 
Zubaidi 
(161) 
2009 12 No 22 2 19/22 
(86%) 
1/2 
(50%) 
Chung$ 
(153) 
2010 3 No 50 4 27/46 
(59%) 
3/4 
(75%) 
Owen 
(162) 
2010 15  35 3 13/35 
(37%) 
1/3 
(33%) 
*The O’Connor study included one pouch patient, 2 anovaginal fistulae and 4 
patients on concomitant infliximab.  Single rather than multiple tracts were 
significantly associated with successful closure.  Preoperative setons were used if 
the tract was too wide for the plug to sit snugly. 
NR – not reported or cannot be concluded form the data presented 
†In this study, 2 of the 10 patients enrolled were defunctioned and one was lost to 
follow-up. 
$Idiopathic results from contemporary but separately published results by same 
authors 
 
1.5.5 Modified infill materials 
 
The waning published efficacy of glues and plugs over time has led to the addition of 
agents designed to improve healing rates.  Preclinical work at St Mark’s has 
demonstrated that the addition of autologous fibroblasts to a collagen glue improved 
the histological appearance of the healed tract compared to glue alone and clinical 
studies are in progress (163). A single case report of autologous fibroblasts on a 
biologic scaffold (HYAFF) has been described in a Crohn’s patient with a 
transsphincteric fistula (67).  The patient had a seton inserted and three doses of 
intravenous infliximab administered before fistulectomy and then insertion of the 
scaffold with autologous fibroblasts into the tract until it was completely filled.  The 
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patient was free of recurrence throughout a 20 month follow-up period, but MRI 
validation of healing was not performed. 
 
In 2008 Garcia-Olmo and colleagues reported the administration of adipose derived 
stem cells (ASCs) in fibrin glue vs. glue alone in a randomised controlled trial of 49 
patients (14 with Crohn’s disease) and found a significant increase in healing from 
16% without ASCs to 71% with them (164).  ASCs are living adult stem cells of 
mesenchymal origin which are extracted from subdermal adipose tissue obtained 
through liposuction.  The study’s authors suggest that the ASCs may have both an 
initial anti-inflammatory effect and also aid tissue repair through differentiation into 
epithelial cells. 
 
This approach of adding constituents to correct specific aspects of the pathology in 
persisting anal fistula tracts is extremely attractive and could in the future lead to 
personally tailored treatments in both idiopathic and Crohn’s related anal fistulae, 
incorporating aspects of immunology and microbiology specific to an individual. 
 
1.5.6 Defunctioning and proctectomy 
 
Some patients have either failed medical therapy and undergone several operations 
finding nothing that helps to alleviate their symptoms and gain the quality of life they 
want, or are subdued by the systemic effects of their colorectal disease to such an 
extent that a stoma becomes a realistic option.  Proctectomy (+/- colectomy 
depending on the extent of disease) in the patient with severe rectal and/or perianal 
disease can leave patients with an improved quality of life in spite of a recurrence (of 
luminal disease) rate of around 20% and a similar risk of reoperation.  The principle 
risks of this operation include damage to the pelvic nerves and the delayed or 
unhealed perineal wound, which latter affects around 30% of patients up to 6 months 
and 10% beyond that time.  A small group of these will require further surgical 
procedures to aid healing of the wound, including curettage or (usually 
myocutaneous) flap reconstruction.   
 
Defunctioning with an ileostomy provides temporary relief of symptoms but disease 
often recurs and most of these stomas will never be reversed.  Yamamoto and 
colleagues reported their series of 31 patients who underwent defunctioning alone in 
Crohn’s disease for perianal or anovaginal disease (34).  Only 8 (26%) went into long 
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standing remission and only 3 patients (10%) had their stoma reversed. Hong and 
colleagues reported a series of 21 patients who were defunctioned for perianal 
Crohn’s disease and found the chance of having continuity restored was not 
influenced by infliximab. At median follow-up of 22 months (4-121), 4 patients (19%) 
had undergone stoma closure, 11 had had a proctocolectomy, and 6 had both a 
stoma and their rectum in situ. The effect of the procedure on severity of perianal 
disease was no effect in 4 (19%), temporary improvement in 6 (29%), initial 
improvement with a sustained benefit in 7 (33%), and healing in 4 (19%) (165). As a 
general rule, if a patient needs their large bowel Crohn’s disease excised, 
defunctioning alone will leave on-going ill-health with little or no chance of reversal in 
the longer term and should be avoided. 
 
1.6 Fistula-associated carcinoma in Crohn’s disease 
 
It is important to note that malignancies can arise in Crohn’s related perianal disease. 
Although it is uncommon, a recent literature review revealed 61 cases of carcinomas 
arising in perineal fistulae in Crohn's disease. Sixty-one percent of the patients were 
females, who were also significantly younger than males at the time of diagnosis of 
cancer, and had a shorter duration of fistulating perianal disease prior to cancer 
transformation.  Adenocarcinoma was the most common histology followed by 
squamous cell carcinoma (166). 
 
1.7 Summarising the current management of Crohn’s anal 
fistulae 
 
Anal fistulae are a common, unpleasant and treatment-resistant manifestation of 
Crohn’s disease.   
 
There is evidence for genetic, immunological and bacteriological factors in the 
aetiology of Crohn’s perianal fistulae. A combination of tackling the environmental 
milieu in the tract and the microbes may hold the key to more effective treatment of 
Crohn’s perianal fistulae. A specific focus on factors which lead to persistence of the 
tracts, including further microbiological characterisation, study of the host immune 
cells and responses to the micro-organisms present, and genetic predisposing 
factors is needed to elucidate this and guide the next steps in research and 
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management.  The pathogenesis of idiopathic fistulae is also poorly understood and 
advances in this area would improve our general understanding of perianal fistulae in 
both the idiopathic and Crohn’s disease settings. 
 
Medical treatments with antibiotics and immunomodulators have had limited success, 
but the advent of anti-TNF drugs has had a dramatic effect on the prognosis of these 
fistulae, offering the patient a realistic chance of response and indeed remission.  
However, loss of response and side effects are all too common. Local administration, 
combinations of drugs and new anti-TNFα agents all offer potential improvements.  
 
Surgery likewise can have a high rate of recurrence for most procedures and the 
risks of stomas, impairment of continence, unhealed wounds and repeated 
operations are ever present. 
 
The primary goal of treating Crohn’s anal fistulae should be eradication without 
recurrence.  This may sometimes be achieved by surgery in the form of laying open 
in low fistulae, or alternatives such as advancement flaps or fistula plugs (although 
the evidence for these latter is scant and contradictory).  Healing is more likely to 
occur using anti-TNF treatments.  Surgery and imaging remain absolutely crucial to 
this mode of management with EUAs with drainage of trapped sepsis and insertion of 
setons before and sometimes during treatment, and high quality radiological 
monitoring of response so that appropriate decisions on interventions such as 
surgery, cessation of medical treatment or dose or drug change can be made.   
 
1.8 Idiopathic anal fistulae 
1.8.1 Background 
 
Idiopathic anal fistulae most often occur in patients aged between 30 and 60 with an 
incidence of around 1-2 per 10,000 people (167), far less commonly than in Crohn’s 
disease, however they pose a very significant problem both to the sufferers and to 
colorectal surgeons.  The symptoms of pain or discomfort, recurrent abscess 
formation, persistent discharge and limitations to sexual and other activities of daily 
living can be very debilitating.   
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1.8.2 Aetiology 
 
As discussed above, idiopathic fistulae are also known as cryptoglandular based on 
the aetiological theory proposed by Parks in which he described an intersphincteric 
anal gland becoming infected and this infection becoming chronic with a fistula tract 
forming as a result (81).  Parks noted dilated anal glands in 8 of 30 patients 
described in his aetiological paper and suggested that this might represent a 
congenital abnormality, making some people more susceptible to the formation of a 
granulation lined tract fed and kept open by the abscess around this gland in the 
intersphincteric space.   
 
However, deeper examination of the cryptoglandular hypothesis has taken place only 
rarely since Parks’ original work.  Goligher and colleagues found evidence of 
intersphincteric sepsis in less than half the anal fistulae they examined for his 1967 
paper (168).  Also, this theory implies a bacteriological aetiology with organisms 
feeding the infection from the internal opening and it is for this reason that surgical 
treatments focus upon draining sepsis, obliterating the internal opening or 
disconnecting it from the rest of the fistula tract.  However, a consistent culprit 
organism has never been found (1.2.5) and indeed Lunniss and colleagues 
surprisingly found an enrichment medium was necessary to culture organisms from 
what one might expect to be a floridly infected wound, given this aetiological 
explanation (52). 
 
As mentioned above, epithelialisation has been suggested as a potential factor in the 
persistence of anal fistulae and epithelialisation has been found to occur from one 
end of the tract or the other more commonly than evidence of an infected anal gland 
(84).  
 
In fact, as with Crohn’s disease, the histological, immunological and microbiological 
nature of idiopathic anal fistula tracts remains obscure and an examination of these 
factors is reported in Chapter 2. 
 
1.8.3 Classification 
 
The surgical basis for management of idiopathic anal fistulae demands a more 
rigorous classification system than that employed for the majority of Crohn’s anal 
fistulae.  Parks described anal fistula according to their primary tract and secondary 
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extensions with the external sphincter as the ‘keystone’ (169).  The primary tract is 
either intersphincteric (comprising 45% of his initial cohort), trans-sphincteric (30%), 
suprasphincteric (20%) or extrasphincteric (5%) (Figure 5).  This latter group is 
aetiologically distinct from true anal fistulae and will not be discussed further here. 
 
 
 
Figure 5 - Parks' classification of anal fistulae, (169) by kind permission of 
John Wiley and Sons. 
 
In addition to the primary tract, secondary extensions can occur in the 
intersphincteric plane, the ischioanal fossae or the pararectal space and may form 
linear extensions leading to abscesses or horseshoe extensions which curl around 
the anorectum on one or both sides. 
 
 a b 
 
Figure 6 - a. trans-sphincteric fistulae with extensions into the ischioanal 
fossae and pararectal space and b. the three planes in which horseshoeing can 
occur (intersphincteric, ischioanal fossa and pararectal) (169) by kind 
permission of John Wiley and Sons. 
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1.8.4 Clinical assessment 
 
The assessment of a patient with an anal fistula is based on a sound history and a 
focused clinical examination.  Aetiological factors, like the presence of diagnosed or 
occult inflammatory bowel disease, nicorandil use, and anal digitation will potentially 
change the planned management.  The consistency of stool and any likelihood of 
sphincter deficiency, such as obstetric injury or previous sphincterotomy for fissure, 
are relevant when considering surgical options. 
 
Some patients may have cultural or religious difficulties with treatment-induced minor 
discharge or soiling which will inform their decision, and a long suffering patient may 
well have a higher tolerance of risk than a younger patient with a short history.   
 
Although there is no standard or evidence base to the techniques employed for 
clinical assessment of anal fistulae, one approach, previously described, is outlined 
below (170).  Examining the patient in the left lateral position, the surgeon performs 
rigid sigmoidoscopy to identify proctitis after a detailed digital rectal examination.  
Any external opening (open or healed) should be described and palpated for 
tenderness and induration.  The area between the external opening (EO) and the 
anal verge should then be palpated with a lubricated finger and any tract felt will of 
necessity be superficial.  The absence of induration implies a deeper course.   
 
Within the anal canal, the internal opening may be palpable and is likely to be lower 
than assumed, even in higher fistulae.  It may be felt as a grain of sand, more tender 
than surrounding tissues.  Induration, a feeling like bone rather than fillet steak, 
should then be sought within the anal canal, at the anorectal junction and within the 
rectum itself (170).  This gives a clue to the passage of the primary tract or to the 
presence of any secondary extensions. 
 
The length of good quality contracting external sphincter above the internal opening 
must be assessed as incontinence of greater magnitude than flatus incontinence and 
minor anal seepage depends not on how much muscle is cut, but on how much 
muscle is left behind.  Minor incontinence (flatus incontinence and < 1 teaspoon of 
mucus leakage in a 24 hour period) is probably related to internal sphincter division 
alone (171-174). 
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1.8.5 Investigations 
 
The majority of patients can be fully assessed clinically and investigations are not 
usually necessary.  In the case of complex disease, however, or fistulae which 
cannot be characterised clinically, it is sometimes valuable to undertake pelvic 
imaging to elucidate the fistula tract’s course.  Endoanal ultrasound and pelvic MRI 
are the most commonly used and their various merits have been discussed above 
(page 34). 
 
Briefly, although EUS is useful for assessing the sphincter complex and gives an 
excellent description of the internal opening and any tract close to the anal canal, it 
cannot assess the ischioanal fossae well due to rapidly declining resolution with 
distance from the probe, it is operator dependent and it can be uncomfortable in the 
presence of acute sepsis.  Generally speaking, clinicians find the images difficult to 
interpret and rely on the report from their radiology colleague. 
 
MRI, using a T2 weighted fat suppressed sequence (e.g. STIR), gives excellent 
images without the need for a radiologist to be present at the time of the scan.  The 
images are more easily interpreted by clinicians who can often identify the important 
anatomical structures more clearly and can use the images in the clinic or theatre 
setting.  Although the position of the internal opening is often inferred rather than 
actually seen, any tract can be visualised regardless of how far from the anus it 
travels. 
1.8.6 Surgical treatment 
 
Based on the aetiological and anatomical findings from clinical assessment and any 
investigation, patient preference and surgical expertise, the most appropriate form of 
treatment can be determined. 
1.8.6.1 Addressing the compromise 
 
All currently available operations for anal fistula represent a compromise.  The 
patient needs to decide whether he or she prefers a higher risk of recurrence or a 
higher risk of (usually minor) impairment of continence.  The word incontinence is 
both emotive and ambiguous, embracing as it does all situations between full faecal 
incontinence to formed stool alongside the slightest occasional inadvertent escape of 
flatus or slight staining of the underwear.  Some patients have recurrent problems 
 61 
with abscess formation and copious discharge, repeated operations and significant 
interference with their daily lives over many years and are willing to risk a high rate of 
minor inadvertent escape of gas or slight marking of the underwear to gain a good 
chance of cure.  Each individual’s approach to this compromise is a crucial element 
of the management plan. 
 
Importantly, not all patients who develop incontinence after fistula surgery are 
dissatisfied by their outcome (175) and a study published in 2000 by Garcia-Aguilar 
and colleagues found that the risk of dissatisfaction was greater in patients suffering 
recurrence (61%) than those who developed impairment of continence (24%) after 
fistulotomy (176).   
 
1.8.6.2 Fistulotomy 
 
Laying open a fistula and allowing healing to take place by secondary intention 
remains the treatment of choice for many surgeons encountering low intersphincteric 
or trans-sphincteric fistulae and has been shown in large series to have a high 
success rate (177).  High transsphincteric fistulae, too, may be laid open in some 
circumstances.  The risk of impairment of continence is the principle concern 
regarding this procedure and, although the rate of incontinence following this 
procedure in expert hands is between 1/4 and 1/3, the impairment produced is 
usually minor with only the inadvertent loss of flatus or mild mucus leakage (171).  
This is often acceptable to patients if a reasonable chance of cure offsets the risk.   
 
It is reasonable to postulate, given that the impairment is similar in intersphincteric 
and trans-sphincteric fistulae (171), that internal sphincter division is responsible for 
this incontinence, which can also be seen after lateral anal sphincterotomy for anal 
fissure (178;179).  Moreover, a policy of leaving behind usually 2cm but at least 1cm 
of contracting muscle cephalad to the fistulotomy resulted in minimal incontinence in 
a recently published cohort (171). 
 
Nevertheless, when deciding to offer lay open of a high fistula, factors such as those 
discussed above including the patient’s usual bowel habit, tendency towards IBS, the 
presence of IBD, a history of sphincter injury or traumatic vaginal delivery, the quality 
of the residual sphincter and the presence of extensions which will be hard to drain 
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adequately, need all to be considered in order to offer a reasonable assessment of 
the risk of recurrence and ‘incontinence’. 
 
Marsupialisation can be used to reduce the size of the wound (which usually heals 
well despite florid bacterial contamination) and may decrease time to healing (180).  
The addition of immediate reconstruction of the divided sphincter has been described 
in low fistulae and is successful in terms of rapid healing and postoperative pain as 
well as avoiding recurrence and incontinence (181) (see below).  Open excision of 
the fistula tract delays healing (182), and core out fistulectomy, whilst less destructive 
and advocated by some (183), remains a less popular technique than fistulotomy. 
 
1.8.6.3 Fistulotomy or core out fistulectomy and primary 
sphincter repair (FSR) 
 
Fistulotomy or core out fistulectomy and immediate sphincter repair offers the chance 
to cure fistulae deemed too high to lay open without risking major incontinence. 
Suitable patients include those with recurrent fistulae, contraindications to 
advancement flap, or a pre-existing sphincter deficit amenable to surgical repair. 
 
Advocates suggest that post-operative healing is faster than in fistulotomy alone but 
with comparable recurrence rates (181), and that continence is improved in patients 
with a preoperative deficit with only a minor risk to those who are fully continent 
(184). 
 
Large series were reported in 1968 and 1985 with over 100 patients with low fistulae. 
Parkash and colleagues found that 88% of wounds healed within 2 weeks of surgery 
and recurrence occurred in 4% of patients with general satisfaction with functional 
outcome (181). 
 
More recently, 4 case series have been published with cohorts of 14 to 75 patients 
with high fistulae. Recurrence and post-operative (mostly minor) incontinence rates 
ranged from 0 to 14% and 0 and 21% with the worst outcomes seen in a report of 
recurrent fistulae (185;186).  High quality studies are lacking and this technique does 
not enjoy the support of many colorectal surgeons.  Randomised controlled data are 
required to prove its worth. 
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1.8.6.4 Advancement flaps 
 
Through disconnection of the tract from the bowel and eradication of the internal 
opening, advancement flaps have been a valuable tool in the fistula surgeon’s 
armoury for a century.  Different techniques of flap repair have been proposed, 
including full and partial thickness flaps from the rectum cephalad of the internal 
opening to rhomboid flaps and anodermal flaps from below.  The internal sphincter is 
often taken, at least in part, supposedly to preserve the flap’s blood supply. 
 
Causes of failure are thought to be either technical through flap ischaemia or 
anastomotic breakdown, or due to underlying disease.  In a large (albeit 
heterogeneous) consecutive series of 96 patients treated with endorectal 
advancement flap, Mizrahi and colleagues identified the presence of Crohn’s disease 
but not gender, number of previous repairs, transsphincteric vs. rectovaginal fistulae 
or the presence of a diverting stoma to be associated with failure (140).  In a similar 
sized series of idiopathic anal fistulae, smoking was found to predict failure of 
transanal flap repair, reducing success from 79% to 60% with a greater impact the 
more cigarettes the patient smoked per day (142).  The overall success rates in 
these two studies, in line with larger studies in the literature, were 60% and 69% 
respectively. 
 
Randomised controlled trial data of fistulotomy (with immediate sphincter repair in the 
Perez trial) vs. two different advancement flap techniques (island flap anoplasty [from 
below upwards] and transanal endorectal advancement flap [from above 
downwards]) suggest parity in terms of incontinence and recurrence (187;188).  
Those fistulae too high to contemplate fistulotomy obviously cannot be included in a 
randomised trial, so success in the treatment of these very high anal fistulae 
managed by advancement flap should not be directly compared with fistulotomy 
outcomes. 
 
1.8.6.5 Infill materials 
 
The ongoing search for fistula treatments that avoid the compromise between 
recurrence and incontinence led to the advent of first fistula glues and subsequently 
fistula plugs.  These infill materials also disconnect the tract from the bowel along 
with filling the lumen of the tract.  Most trials of either glue or plug have utilised 
preoperative seton insertion, antibiotic cover, bowel preparation or a combination of 
 64 
these to try to reduce the septic load and acute inflammation in the perioperative 
period. 
 
Fibrin glues use fibrinogen and thrombin in separate barrels of a double-barrelled 
syringe which come together at the point of instillation in the tract.  The resulting fibrin 
plugs the void and allows collagen to be laid down across the scaffold.  
Unfortunately, the fibrin is absorbed within 7-10 days which may not be long enough 
for tissue repair to take place (189).  The external opening often heals over, however, 
with epithelialisation occurring rapidly but ultimately breaking down when sepsis 
recurs within the tract itself, which explains the early healing and later recurrence 
pattern of failure seen with fibrin glues. 
 
Initial success rates of around 80% have gradually fallen away to around 30-40% 
seen in some of the more recent trials (Figure 7) with the exception of studies which 
have examined modifications to the fibrin glue, including the addition of antibiotics 
(152), using a more concentrated glue (149), and the addition of porcine collagen 
fibres (190) which are postulated to reduce the bacterial load within the fistula and 
improve the action of the glue as a scaffold respectively.   
 
Failure adequately to drain sepsis and remove granulation tissue and epithelialisation 
from the primary tract and secondary extensions will inevitably lead to failure.  Early 
absorption or leakage of glue from the tract will also promote recurrence.  However, 
the great advantage of fibrin glue instillation is that it is repeatable and the sphincter 
is not damaged, so it may be attempted a number of times before an operation, 
which latter may offer a higher chance of success but also has a risk of incontinence. 
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Figure 7 - Graphs of published healing rates over time in studies of fibrin glue 
in anal fistulae. # = only high transsphincteric fistulae studied.  * = enhanced 
glue. 
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The collagen plug appears to be following in the footsteps of fibrin glue with initial 
success rates over 80% decreasing over time (Figure 8).   
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Figure 8 - Graphs of published healing rates over time in studies of fistula plug 
in anal fistulae. 
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Rather than gradually decreasing in published efficacy, it is probably fairer to say that 
the efficacy of the fistula plug is extremely variable with the large variation in reported 
success rates maintained each year from 2006 to 2009 (Figure 9) (191).   
 
Perhaps this variability is due to poor patient selection and/or poor placement 
technique, including failure adequately to prepare the tract or secure the plug.  Poor 
technique often results in extrusion of the plug and later reports contain fewer 
extrusions as the cause for failure.  The variable nature of the research 
methodologies and follow-up used may also play a part and randomised controlled 
trials of the fistula plug are required to demonstrate its efficacy.  One RCT of fistula 
plug vs. advancement flap in high transsphincteric idiopathic fistulae was stopped 
early due to an unacceptably high failure rate in the fistula plug group of 80% 
compared to 12.5% in the advancement flap group (192). 
 
 
Figure 9 - Fistula healing rates with the anal fistula plug as reported in articles 
found in PubMed over the past 4 years. Each triangle represents a publication. 
The horizontal bars represent median and range of values (191).  By kind 
permission of Wolters Kluwer Health. 
 
Interestingly, a recent report indicated that tracts >4cm in length were almost 3 times 
as likely to heal as their shorter counterparts which the authors suggested was due to 
the presence of a greater surface area of tissue into which the plug could be 
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incorporated (193).  Importantly, one of the authors of this report was an experienced 
fistula plug surgeon and it must be assumed that placement and technique were 
optimal in this series – the overall success rate of 43% is therefore particularly 
disappointing. 
 
In order to reduce the variability in technique and outcome, consensus statements 
describing optimal patient selection, surgical technique and follow-up were published 
in 2008 (194). Failure often occurs due to plug extrusion, which is related to surgical 
technique or tract diameter and should occur less frequently in more experienced 
hands, where a success rate of 50-60% is expected. 
 
On long term follow-up or through the use of MRI scanning a true healing rate lower 
than that quoted in some studies of AFP may be found. One study found the success 
rate fell from 84% at 2 months to 54% at 12 months (157).  Ellis and colleagues 
found a quarter of patients clinically healed for a year had evidence of residual fistula 
tract at MRI scan (195). 
 
As with fibrin glue, even a modest success rate (if true), given its repeatability and 
the lack of sphincter damage, would be valuable. The plug is expensive compared to 
fistulotomy, yet one cost effectiveness study reported AFP (at $2100) to be cheaper 
per success than endoanal advancement flap for high fistula (196). 
 
1.8.6.6 Intersphincteric approaches and the LIFT procedure 
 
Another method of disconnecting the fistula from the bowel and encouraging healing 
via an intersphincteric approach was first described at St Mark’s in 1993 by Matos 
and colleagues (197).  The technique involved an intersphincteric approach to the 
area of intersphincteric sepsis which was eradicated, closure of the internal opening 
and IAS defect, excision of the external element of the tract, repair of the EAS defect 
and primary wound repair Figure 10. 
 
The primary outcome in this study was the preservation of both sphincters which was 
achieved in 7 of 13 patients with a further 2 having preservation of the external 
sphincter only.  Five of the patients experienced primary healing following the 
procedure. 
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Figure 10 - Intersphincteric sphincter conserving approach in high anal fistula 
(197). 
 
In 2009 the LIFT (ligation of inter sphincteric fistula tract) procedure was described 
and is different in two regards: ligation and division of the intersphincteric tract rather 
than closure of the internal sphincteric defect and IO is performed and curettage 
rather than excision and primary repair of the external component (198).  The authors 
suggest that ligation is more secure and curettage faster and suggest that their 
improved results (recurrence of 5.6%) are due to the IS ligation, although the cohort 
consisted of mainly low fistulae by comparison with the suprasphincteric, rectovaginal 
and IBD-related fistulae in the St Mark’s cohort. 
 
Further series have been published.  A Malaysian group has reported a study of 45 
patients with predominantly low trans-sphincteric fistulae (3/4) with primary healing in 
82.2% of patients with no deterioration in continence (199).  Another study of 39 
patients with mostly recurrent fistulae has reported a success rate of 57% and also 
found no subjective deterioration with regards incontinence (200). 
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1.8.6.7 Setons 
 
Setons are surgical sutures or wires placed through the lumen of the fistula tract and 
tied externally with the loose ends external to the external opening and the anus.  
The role of the seton can be for anatomical assessment, for curative treatment as 
part of a staged approach or through recurrent tightening, or palliative. 
 
The decision about whether or not it is safe to lay open an anal fistula should be 
based on the length of good quality contracting sphincter above the internal opening.  
Clearly, this assessment can only be made when the IO can be felt.  At EUA, the 
placement of a seton in the patient who has not undergone spinal or epidural 
anaesthesia (which relaxes the sphincter to such an extent that accurate estimation 
may be impossible) may permit determination of this distance before lay open.  
Alternatively, further clinical assessment can be carried out in a subsequent clinic 
appointment and further counselling on the risks of fistulotomy can be undertaken. 
 
Tight or cutting setons are methods of gradual fistulotomy with fibrosis of the 
sphincter taking place behind, theoretically lowering the risk of impairment of 
continence.  A seton is placed through the fistula and, when the acute sepsis is 
drained, it is tightened either once (tight) or on a regular basis until it has cut through 
(cutting).  Some patients find the tightening painful (201).  Low fistulae as well as 
higher tracts, including horseshoe fistulae, have been treated with this approach 
(202;203); the more complex fistulae suffer from similar continence disturbance and 
recurrence rates as those treated with fistulotomy. Lunniss has favoured what he 
terms a ‘snug’ seton which he claims cuts through more slowly (204). 
 
A recent systematic review comparing tight or cutting seton placement either with 
(SIAS) or without (PIAS) surgical division of the internal anal sphincter up to the level 
of the fistula, found that dividing the IAS at operation reduced recurrence from 5% to 
3% but increased incontinence from 5.6% to 25.2% (205).  The overall rates of 
recurrence and faecal incontinence in the 18 studies of tight or cutting seton reported 
ranged from 0 to 16% and 0 to 75% respectively.  
 
These rates of incontinence are not dissimilar to those seen in single stage 
fistulotomy which has prompted some to question the value of the tight or cutting 
seton.  Unfortunately this cannot be tested experimentally; in a fistula low enough to 
undergo fistulotomy, there is no advantage to the cutting seton, whereas in higher 
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fistulae one cannot randomise patients to a fistulotomy arm in the knowledge of a 
high rate of faecal incontinence, even to prove that the rate in tight setons is similar. 
 
Loose setons can be placed as part of a staged surgical approach, for example with 
an advancement flap (206), or as a permanent palliative treatment.  Setons initially 
provide consistent drainage which reduces acute sepsis and encourages healing of 
accessory tracts and extensions.  A well-drained system can then have the seton 
drain removed to allow healing to take place with or without further surgery.  This is a 
long process and it is not clear that the nature of the final continence outcome is 
different to that which would have been offered by fistulotomy. 
 
A comfortable, soft, low profile seton can be placed to provide palliation of symptoms 
of pain and recurrent abscess when the risk of incontinence is too great for the 
patient to countenance.  Sharp, stiff or bulky setons, especially those with multiple 
knots, can be uncomfortable and may not provide the respite from symptoms which 
patients desire in order to obtain an adequate quality of life.  Even the most 
comfortable setons may break from time to time and require replacement. 
 
1.8.7 Optimal treatment of high anal fistulae 
 
The presence of so many options for the treatment of high anal fistulae implies the 
lack of a definitive solution.  In Chapter 3 the outcomes of a cohort of mainly high, 
tertiary referred anal fistula patients treated with fistulotomy is explored with the 
specific aim of identifying the level of compromise found in this group of patients with 
experience of prior failure and often a degree of impairment of continence from 
earlier attempts at cure.  The risk of recurrence and the additional risk of 
incontinence from further surgery are key to deciding whether to offer further 
attempts at radical treatment or whether palliation may be preferable.  Associations 
between aspects of anatomy and natural history with recurrence or incontinence are 
also explored in Chapter 3. 
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1.9 Rectovaginal fistulae 
1.9.1 Background 
 
Rectovaginal fistulae are not well tolerated and patient pressure to resolve even the 
more minor ones is frequently intense.  They usually occur following obstetric injury, 
perianal sepsis or in the presence of Crohn’s disease, although radiation, malignancy 
and iatrogenic injury are other known causes. 
 
Symptoms include the passage of air, discharge and faeces from the vagina, 
recurrent urinary tract or genital infections, perianal and vaginal pain and discomfort, 
including dyspareunia. 
 
The commonest cause of rectovaginal fistula is obstetric injury.  The fistula usually 
occurs following a third or fourth degree tear which is sustained during approximately 
5% of labours.  One to two percent of these will go on to suffer a rectovaginal fistula 
(207).  A large study of women undergoing vaginal delivery found 0.1% developed a 
rectovaginal fistula (208). 
 
In a population based survey of Crohn’s disease patients, 35% were found to have 
fistulae and of these 9% had a rectovaginal fistula (3) which appeared at a mean age 
of 34 years (209).  A larger study of 886 patients revealed that rectovaginal fistulae 
may occur in up to 10% of those with Crohn’s disease (209).  RVF is more common 
in association with colonic (23%) than small bowel (3.5%) Crohn’s disease (210;211).   
 
1.9.2 Clinical assessment 
 
A detailed history considering symptoms of inflammatory bowel disease or irritable 
bowel syndrome, stool consistency and frequency and continence is required.  The 
obstetric history is also important, along with a description of any perianal 
procedures, including previous repairs. 
 
The severity of symptoms is important since surgery may not cure and could involve 
multiple procedures and possibly a stoma, so a balance of the risks and benefits in 
each case, and particularly recurrent cases, must be made. 
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Clinical examination must consider the presence of proctitis, the position of the 
anorectal opening and the position of the vaginal opening.  These may be assessed 
digitally or with a proctoscope or sigmoidoscope in the vagina.  The presence of 
extensions is clearly relevant, although many tracts will be straight and unbranching. 
 
Internal intussusception within the rectum will make an advancement flap easier and 
can be assessed with the patient awake by asking them to bear down with a 
proctoscope in place.   
 
The quality of the anal sphincters and rectovaginal septum can be assessed digitally 
although anal ultrasound may be required to fully identify any defects.   
 
1.9.3 Imaging 
 
Clinical assessment is sometimes augmented with imaging to determine the relations 
and extent of the fistula disease.  Secondary extensions, abscess and the 
relationship of the fistula tract to the anal sphincter are of particular importance.  
Transperineal and endoluminal ultrasound, magnetic resonance imaging and 
fistulography have all been used to identify and delineate fistula tracts.   
 
1.9.3.1 Fistulography  
 
Fistulography relies on the ability of the clinician to identify and cannulate the vaginal 
opening of the tract, which is rarely possible.  It also gives no information on the 
relation of the fistula to the anal sphincters and is noted to have a low accuracy in 
delineating the tracts.  False positives can follow iatrogenic injury through falsely 
directed probing (212).  Despite these shortcomings, fistulography does have its 
advocates (213). 
 
1.9.3.2 Ultrasonography  
 
Endoanal ultrasound can be used to identify anal and anovaginal fistulae.  Some 
reports suggest a high sensitivity, others disagree (214-216).  This is perhaps 
explained by differences in the study methodology or the operator dependent nature 
of the technique. Most reports do agree, however, that ultrasonography offers an 
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excellent interpretation of the anal sphincters, including revealing any occult 
sphincter defect before surgery.  Trans perineal ultrasound (TPUS) has been shown 
to have a similar accuracy to endoluminal ultrasound with the added advantages of 
being a quicker, cheaper, simpler technique requiring less specific training, although 
some subtle tracts can be missed using this technique (214).  Endoluminal 
ultrasonography is more widespread and is considered, along with MRI, to represent 
the gold standard in perianal fistula imaging, and is sometimes enhanced with 
hydrogen peroxide (217). 
 
1.9.3.3 MR techniques 
 
Body coil and surface coil MR imaging have a spatial resolution too low accurately to 
detect small diameter tracts between the anorectum and the vagina consistently in 
contrast with the gold standard use of body coil imaging in anorectal fistulating 
disease (218;219).  In addition, fistulae to the vagina are frequently epithelialised, 
which means they will not show an enhanced signal on MRI.   Endoluminal MRI coils 
improve the spatial resolution at the potential risk of not appreciating more complex 
tracts extending beyond the field of view of the scan, however a supplementary 
phased array or body coil scan can be used to provide this information (220;221). 
 
 
1.9.3.4 Agreement in MRI 
 
Endoluminal MRI is an effective imaging method for anovaginal fistulae, but 
availability has become more or less non-existent.  A study of 20 consecutive 
patients with proven anovaginal fistulae was undertaken by Dwarkasing et al in 2003 
(221).  Two radiologists independently reviewed the MRI scans of each patient 
looking for the presence, course and relation of the tract, secondary extension, 
abscess or oedema, the openings of the tract and the state of the anal sphincters.  
T2 weighted images using an endoanal coil had been taken and were retrospectively 
reviewed.  The radiologists had a minimum of 1 year of experience in MR imaging of 
the abdomen and pelvic floor.  The anal opening was identified in all cases and the 
vaginal opening in 19 (95%) and there was 100% agreement between the two 
radiologists on all factors, except for the presence of secondary extensions (90%).  
Anal fistulae, abscesses and oedema of the septum were found in 6 of 10 patients 
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with an underlying diagnosis of Crohn’s disease or obstetric or iatrogenic injury 
compared to 1 of 10 patients without a known underlying condition. 
 
1.9.3.5 Endoluminal MRI vs. EUS 
 
The debate regarding the optimal imaging method for rectovaginal fistulae continues.  
Hussain et al. in 1996 found that classification of fistulae was possible in 17 of 28 
patients (61%) with EUS, 25 (89%) with endoanal MR imaging and 26 (93%) with 
surgery (222).  Maier et al. examined Crohn’s related and recurrent fistulae, of which 
5 were anovaginal, comparing EUS and MRI with surgery (223).  In this small group 
there was no difference between the two techniques.  Stoker and colleagues also 
found similar accuracy in the two techniques in a slightly larger group of patients (13) 
with positive predictive values for EUS and endoluminal MRI of 100% and 92%, 
respectively (215). 
 
1.9.4 Treatment 
 
RVF are notoriously difficult to treat, with surgical success of around 50% rising to 
80% with repeated procedures (224-228).  Defunctioning stomas and, in the case of 
Crohn’s disease, bowel resection are sometimes required for healing, with 
proctectomy rates between 20% and 30% - which is probably lower than in the past, 
when between a third to a half of patients with RVF underwent proctectomy, 
sometimes for rectal rather than the fistulous disease itself (131;133;229;230).  This 
reduced rate is probably due to improved control with anti-TNF drugs. 
  
1.9.5 Medical treatment of Crohn’s rectovaginal fistulae 
 
Medical treatments for Crohn’s RVFs have, until recently, centred on improving 
luminal disease control.  Antibiotics, thiopurines, parenteral nutrition and 
immunosuppressants, such as cyclosporine and methotrexate, have all been used.  
As with anal fistulae, the anti-TNF drugs have altered the potential of medical 
treatment, offering the possibility of true healing of the fistula itself.  The majority of 
studies are of Crohn’s disease or perianal Crohn’s disease more generally and 
contain only a few rectovaginal fistulae, the outcome of which is not always clear. 
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Antibiotics remain a mainstay of treatment of perianal sepsis in Crohn’s disease as 
discussed above (1.4.2) and ciprofloxacin and metronidazole are most commonly 
selected.  Short term relief is sometimes achieved but remission is rare.  Thiopurines 
are used for disease control and two small studies have reported a benefit of 6-
mercaptopurine over placebo, one finding improvement or remission in 3 of 6 
patients (90;94).  Present and Lichtiger found that intravenous cyclosporine healed 1 
and improved 1 (of 2) rectovaginal fistulae but unfortunately they relapsed on oral 
maintenance (231).  Methotrexate in three patients led to remission in one and 
improvement in two but unfortunately two of the patients relapsed between 2 and 4 
years later and suffered side effects such as alopecia and respiratory infections in the 
meantime (117). 
 
1.9.5.1 Infliximab 
  
Several studies of infliximab in Crohn’s disease have included RVF patients.  In most 
of these studies, partial response is not the reduction in baseline draining fistulae of 
at least 50% used for anal fistulae, since RVF are often single in number, so a 
reduction in drainage, perceived by the patient, is used instead. 
 
A small cohort of RVF patients was assessed by Parsi and colleagues who reported 
a low remission rate (compared to anal fistulae) of 2 of 12 patients (14%), although 9 
of the patients achieved a partial response (104).  Luna-Chadid published slightly 
better results, finding 1/3 improved and 1/2 in remission in their small cohort.  
Multivariate analysis found no factors predicting success (232).  The RVF data from 
ACCENT II were analysed post hoc by Sands in 2004 (233).  Of 28 RVFs, 60% were 
closed after the 3 dose induction.  By week 54, 46% of those on maintenance 
therapy and 43% on placebo remained in response. 
 
Gaertner and colleagues published an interesting report in 2010 in which they 
considered combined medical and surgical therapy (234); 51 patients undergoing 
staged or definitive surgery for Crohn’s rectovaginal fistulae were analysed.  All were 
on some form of medical therapy (ranging from 73% on metronidazole to 5% on 
methotrexate) and 26 of them had also received infliximab induction.  The study 
considered the impact of infliximab on surgical outcome. 
 
 77 
They found that preoperative infliximab decreased proctitis at the time of surgery but 
that proctitis did not correlate with fistula healing.  Eleven of twenty-five (44%) 
surgery only patients healed compared to 16 of 26 (62%) who had infliximab before 
surgery, although the difference was not statistically significant.  Time to healing was 
significantly reduced in the infliximab group, however, from 8.1 to 2.9 months, from 
which it is reasonable to infer that perhaps a larger group might have demonstrated 
improved healing with infliximab.  Interestingly, all patients who underwent seton 
insertion before definitive surgery healed.  Faecal diversion did not improve 
remission rates.  Proctectomy was undertaken in 36% of the surgery only group and 
19% of the infliximab plus surgery group, although again the difference was not 
significant (p=0.25).  A larger study is needed to answer the questions raised by this 
study; whether reducing proctitis preoperatively improves surgical outcome and 
whether doing so using infliximab, setons, faecal diversion or a combination improves 
the long term remission rate. 
 
The value of medical treatment of Crohn’s rectovaginal fistulae in the era of anti-TNF 
agents is unclear.  Whether a significant number are healed by medication alone, 
whether surgery represents the main chance of success, and whether the risk of 
permanent diversion or proctectomy has changed in the last decade will be examined 
in Chapter 4. 
 
1.9.6 Surgery 
 
Surgery for rectovaginal fistula is difficult and success rates are lower than with other 
proctological procedures, particularly in Crohn’s disease.  An assessment of faecal 
incontinence and the state of the sphincters must be made to determine whether 
sphincter repair is indicated at the same time as fistula repair.  The patient and 
surgeon must also decide whether to defunction and which approach to take to offer 
the patient the best chance of the best result. 
 
Recurrence is the major complication but stomas, sexual dysfunction and impairment 
of continence are also all too common and distressing for patients. 
 
Advancement flap repair is generally accepted to be the current gold standard 
operation but multiple approaches and adjuncts are possible as part of this operation.  
Several other approaches, conservative through to radical, are also used.  Surgery is 
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generally avoided in the presence of proctitis and medical treatment, seton drainage 
or defunctioning are often used before definitive surgery. 
 
1.9.6.1 Mixed surgical series 
 
Several series of both Crohn’s and mixed aetiology cohorts have been reported.  
Some earlier reports suggest success rates of around 50% at primary repair rising to 
80% or more after multiple attempts (224-228;235).  Defunctioning stomas were 
often used and transanal rectal advancement flaps, perineoproctotomy, transvaginal 
and transperineal approaches were used. 
 
More recent series report similar results.  In 2007 Athanasiadis and colleagues 
published data on 37 women with Crohn’s disease and RVFs in whom they 
performed 56 procedures (226).  Their overall recurrence rate was 30% with failure 
being significantly more common in rectal advancement flaps than direct closure of 
the fistula and anocutaneous advancement, which latter also protected continence 
more completely.  Proctectomy was performed in 13.5% of women.  In 2009 Loefler 
and colleagues performed an average of 2.1 operations on 45 Crohn’s disease 
patients with RVF with long term success in 53% of cases and 10 proctectomies 
(228). 
 
El Gazzaz and colleagues reported a series of non-CD RVF patients in 2010 (227).  
Sixty had obstetric injuries and 40 had a cryptoglandular aetiology.  The final success 
rate was 68% with both a high BMI and repeated repairs increasing the risk of failure 
on multivariate analysis.  They also considered quality of life and found no 
differences between the healed and non-healed groups.  Only 47 were sexually 
active at follow-up and of these 25% suffered from dyspareunia. 
 
1.9.6.2 Advancement flaps  
 
Several different flap techniques and adjuncts are currently used for rectovaginal 
fistula repair.  Depending on the pliability of the perineal, vaginal and rectal tissues, 
some approaches can be impossible and others made easier.  The choice of 
approach is based partly on the particular expertise of the operating surgeon and the 
majority of series of flap repairs are of one or two types. 
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The commonest advancement flap is the transanal rectal advancement flap which 
was used in several series with success rates ranging from 43% to 92% 
(141;225;228;236;237).  The technique involves raising a flap with a broad base and 
the rectal opening in the apex.  The opening is excised and the flap pulled down to fill 
the defect and sutured in place.  The vaginal opening is left to allow drainage.  The 
lack of a perineal wound means less pain and fewer problems with healing.  
Concomitant sphincter repair is possible and the risk of sphincter injury is minimal 
(238). 
 
In a study of transanal advancement flap repair of anal fistulae (in which RVFs and 
Crohn’s patients were excluded), smoking was found to increase the risk of failure 
and the number of cigarettes smoked per day was also found to correlate with the 
healing rate (239). 
 
Rectal sleeve advancement requires a circumferential flap to be raised cephalad 
from the dentate line.  The flap is full thickness and after it has been raised a core out 
fistulectomy is performed.  The diseased cylinder of the flap is then excised and the 
remaining tissue brought down and anastomosed back onto the dentate line.  
Success rates in two small series suggest success in 60-75% after multiple 
operations (240;241). 
 
The anocutaneous flap was first reported in 10 Crohn’s RVF patients in 1993 by 
Hesterberg and colleagues (242).  They reported excising the tract, repairing the 
sphincteric defects from anal (IAS) and vaginal (EAS) ends and then raising and 
securing a cutaneous flap up inside the anus to cover the anal opening.  Primary 
success was achieved in 7 of 10 cases.  More recent series also describe successful 
use of this technique (226).  Pliable and healthy perianal skin is not always present in 
Crohn’s disease or radiation, which may preclude this technique.  The house 
advancement flap is another technique of anocutaneous advancement which raises a 
robust flap based on a dissection down to ischiorectal fat, thereby maintaining 
vascularity from the perforating vessels that pass through the fat layer (243). 
 
The modified Martius graft uses the fat pad of the labia majora as an interposition to 
bolster the rectovaginal septum.  Small series in the literature have reported success 
rates between 50% and 94% with impairment of continence and dyspareunia as 
significant complications (244-247). 
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Most advancement flaps are placed on the high pressure side of any fistula repair but 
some surgeons opt for a transvaginal approach.  This may be because there is more 
lax and pliable tissue to raise flaps with or because of the lower likelihood of 
inflammation, particularly in Crohn’s disease.  A systematic review has found that 
there is no difference in healing rates between rectal and vaginal advancement flaps 
(248). 
 
1.9.6.3 Glue and plugs 
 
As with anal fistulae, a surgical technique offering success without anal sphincter 
damage is extremely attractive.  The use of fibrin glues, collagen plugs and the 
interposition of bioprosthetic sheets to repair the rectovaginal septum have all been 
employed. 
 
The evidence for these techniques, however, comprises several small, uncontrolled 
trials with mixed fistula types, aetiologies and surgical techniques.  For example, 
some studies included only defunctioned patients whereas others did not, and there 
are varying proportions of patients with Crohn’s disease from 0-100%.  Most of the 
studies are of various perianal fistulae and include a few rectovaginal fistulae within 
them; few were specific to anovaginal or rectovaginal fistulae.   
 
Studies of fistula glue, fistula plugs and bioprosthetic meshes including Crohn’s and 
non-Crohn‘s rectovaginal fistulae are listed in Table 5 below. 
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Table 5 - Studies of fistula glue, fistula plugs and bioprosthetic meshes 
including Crohn’s and non-Crohn’s rectovaginal fistulae 
 
Technique Study Year Success rate in RVF 
Fistula glue Venkatesh 
(146) 
1999 6/8 
 Cintron (147)  2000 1/3 
 Loungnarath 
(151) 
2004 1/3 
 Singer (152) 2005 0/1 
 Vitton (143) 2005 3/4 
 Grimaud (144) 2010 0/3 
 de Parades 
(154) 
2010 0/5 
Fistula plug Ellis (249) 2008 6/7 
 Thekkankattil 
(250) 
2008 1/7 
 Gonsalves 
(251) 
2009 3/5 
Bioprosthetic interposition Ellis (249) 2008 22/27 
 Schwandner 
(252) 
2009 19/21 
 
It is difficult to determine the efficacy of any of these techniques based on these 
studies. 
 
1.9.6.4 Gracilis muscle interposition 
 
The Gracilis muscle has two distinct advantages over other thigh and buttock 
muscles for use in perineal transposition, filling defects in the perineum with the 
potential to improve continence.  Firstly, it has only a vestigial function, unlike gluteus 
maximus, for example, and secondly its single pedicle lies proximally, meaning that it 
is both versatile and robust.  After mobilisation of the muscle from distal to proximal it 
is passed into the perineum and can fill a large perineal defect.  Technical 
considerations, such as too short a muscle, inadequate vascularity and rotation or 
malposition of the muscle, are key intra-operatively.  Complications include infection, 
wound breakdown and venous thromboembolism.  Good results have been reported 
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using this technique which is used in rectovaginal, rectourethral and rectovesical 
fistulae (253). 
 
Wexner and colleagues reported success in 5 of 6 non-Crohn’s RVFs treated with 
gracilis muscle interposition which fell to just 3 of 9 in Crohn’s disease. Complications 
included pain and infections at both the thigh and perineal wounds (254).  Further 
small series in the last 2 years have reported similar findings, often in recurrent 
fistulae (255-257), although Furst and colleagues reported a high success rate in 
their series of Crohn’s patients.  Larger series are required to determine the efficacy 
of this technique. 
 
1.9.6.5 Setons 
 
Permanent loose setons are used in rectovaginal fistulae to palliate, reducing 
symptoms and the occurrence of new fistulae.  Several studies have been shown to 
improve symptom control and thereby avoid the need for permanent diversion or 
proctectomy (131-133).  This is not a successful strategy in all patients and it may be 
that sufficient time to achieve symptom control is necessary, but even then some 
patients will not do so (131).  Thornton and colleagues found that age, reduction in 
anal wall thickness after seton insertion and length of follow-up were significant 
predictors of long term symptom control.  It has been previously demonstrated that 
anal wall thickness correlates with disease activity (258) and a combination of 
medical disease control with seton drainage may avoid radical surgery in patients 
who have failed other treatment options. 
 
 
1.9.6.6 Diversion 
 
The difficult course of the recurrent rectovaginal fistula will sometimes lead to 
permanent diversion or proctectomy.  The presence of proctitis increases the chance 
of a patient with perianal Crohn’s disease requiring proctectomy, as does anal 
stenosis, and diversion rates in rectovaginal fistula vary from 20% to 60% 
(209;229;230;234;259), although in recent years the rate of proctectomy has 
decreased, perhaps in response to improved medical management.   
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As well as higher rates of permanent diversion, a temporary defunctioning stoma is 
often used in the surgical treatment of rectovaginal fistula, with the attendant risk of 
the stoma becoming permanent following failed treatments (230).  In one study, 
univariate analysis identified rectovaginal fistula, as well as temporary diversion, as a 
factor increasing the need for permanent diversion, and although in multivariate 
analysis rectovaginal fistula was not significant on its own, complex fistula (including 
RVF and anal fistulae with multiple openings) was a significant factor (230). 
 
In the majority of cases, temporary diversion is used to increase the chance of 
healing from other medical or surgical interventions.  Indeed diversion alone is of 
limited value in perianal Crohn’s disease, including rectovaginal fistulae.  A small 
study discussed above by Yamamoto and colleagues reported 6 cases of RVF in 
which early improvement in 4 led to relapse within three years and proctectomy was 
undertaken in all 6 cases (34). 
 
1.9.6.7 Predicting failure 
 
Attempts to ascertain risk factors for failure have produced varied results.  One 
centre has produced two reports on this subject, in 2001 and 2009, the former 
incorporating a review of the literature as well as an analysis of 32 of their own 
patients, comprising a previously published group with 24 consecutive additions 
(259;260).  They found a healing rate of 56% after the first procedure rising to 81% 
overall with no differences between the various techniques (rectal, cutaneous or 
vaginal advancement flaps or perineoproctotomy).  The initial report suggested that 
failure was associated with more sites of Crohn’s disease, the presence of 
extraintestinal disease and proctitis, although only the number of sites was significant 
on multivariate analysis.  In the larger series, duration of disease and a previous 
extensive colonic resection were associated with failure. 
 
El-Gazzaz and colleagues  published a series of 65 patients with a median follow-up 
of 44 months and healing in 46% (261).  Twenty-eight of these women (43%) were 
sexually active at follow-up, of whom 9 (all with unhealed fistulae) had ongoing 
dyspareunia.  Multivariate analysis revealed that immunomodulators were associated 
with healing and smoking and steroids with failure. 
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Different RVF injury complexes require different surgical approaches and the level of 
success seen with the different injuries and approaches is important.  There is also 
value in identifying factors which increase or reduce the chance of successful 
healing, particularly in redo repairs or in tertiary patients in whom options may be 
limited and more radical procedures contemplated.  These issues will be further 
examined in Chapter 4. 
 
1.10  Summary 
 
Despite much research in the aetiology of Crohn’s disease, anal fistulae remain 
mysterious in their creation and persistence.  Many basic aspects of fistula pathology 
in both Crohn’s and idiopathic tracts remain obscure.  Similarly, the optimal medical 
management of Crohn’s perianal fistulae, and surgical options for any fistula tract but 
particularly high tracts or those associated with Crohn’s disease, are the subject of 
debate rather than consensus.  Rectovaginal fistulae are also difficult to treat and 
their management has changed in the last decade following the introduction of the 
anti-TNF drugs.  The use of MRI to monitor and assess the efficacy of these drugs in 
the various perianal fistulae associated with Crohn’s disease has revealed a flaw in 
clinical assessment of these tracts which is often used alone to justify ongoing use or 
cessation of treatment.  The studies which follow aim to answer some of the following 
questions: 
1. How are idiopathic and anal fistula tracts similar and how do they differ at a 
microbiological and immunological level? 
2. Do bacteria populate the luminal surface of fistula tracts and if so which 
bacteria are present? 
3. Is there an inflammatory infiltrate in the wall of the fistula tract and if so what  
are the constituent immune cells? 
4. What is the additional burden of impairment of continence in the complex, 
tertiary anal fistula tract managed by fistulotomy? 
5. Which patients are likely to recur or lose continence? 
6. What are the current options for medical management and the efficacy of 
drugs in Crohn’s rectovaginal fistulae in the anti-TNF era? 
7. What factors influence success in the surgical management of rectovaginal 
fistula, which operations are currently employed for the various injury 
complexes seen and what is the risk of permanent diversion or proctectomy? 
 85 
8. When treating Crohn’s perianal fistulae with anti-TNF agents, does 
radiological monitoring describe a different natural history to clinical 
monitoring alone? 
9. Which factors influence clinical and radiological outcome on anti-TNF agents? 
10. What happens to patients who stop maintenance treatment after healing has 
occurred? 
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2 The aetiology of anal fistulae 
2.1 Abstract 
 
Introduction 
 
The aetiology of Crohn’s anal fistula remains obscure.  Microbiological, genetic and 
immunological factors are thought to play a role but are not well understood.  We 
aimed to characterise bacterial and immunological components of Crohn’s and 
idiopathic anal fistula tracts. 
 
Methods 
 
Crohn’s and idiopathic anal fistula tracts were sampled and analysed using 
Fluorescent in situ hybridisation, flow cytometry and immunohistochemistry to identify 
and compare luminal bacteria and immune cells present. 
 
Results 
 
Bacteria were not found in association with the luminal surface of the anal fistula 
tracts although inflammation was found to be on the peri-luminal surface of the fistula 
tract.  Crohn’s tracts contained more CD3 positive cells in the luminal and deep 
layers than idiopathic tracts, but fewer CD65 positive cells.  Crohn’s anal fistula tracts 
had lower numbers of immune cells expressing gut and skin homing molecules.  
TNFα levels were similar in both Crohn’s and non-Crohn’s tracts but IL-17a levels 
were lower in Crohn’s anal fistula tracts.   
 
Conclusions 
 
Crohn’s anal fistula tracts lack bacteria but inflammation is more pronounced in the 
peri-luminal zone of the tract wall implying an alternative luminal factor driving the 
inflammation.  Specific differences in cytokine milieu and immune cell composition 
between Crohn’s and idiopathic fistulae represent potential targets for diagnostic 
tests, therapy and future research. 
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2.2 Introduction 
 
Anal fistulae are a common (2) and unpleasant complication of Crohn’s disease (CD) 
and also occur, less commonly, in patients without Crohn’s or other predisposing 
disease when they are called idiopathic or cryptoglandular fistulae.  Cryptoglandular 
fistulae are thought to follow infection of an intersphincteric anal gland and are most 
commonly low, simple fistulae although higher, more complex tracts can occur.  
Crohn’s anal fistulae, by contrast, are more commonly complex (262) and multiple 
(13) and are thought to arise from deep penetrating ulcers or fissures in the anal 
canal (24). 
 
Aetiological factors leading to the formation of fistulae or their persistence remain 
obscure.  As with luminal Crohn’s disease, a combination of genetic, microbiological 
and immunological factors is thought to play a role.  In genetically susceptible 
individuals, the interaction of normal commensal bacteria with host immunity leads to 
an aberrant inflammatory response causing persistent inflammation and sometimes 
ulceration, stricturing and fistulation.  The most common site of fistulation is the anus 
(3). 
2.2.1 Microbiology 
 
The temporary improvement seen in perianal disease after faecal diversion (34) and 
the partial efficacy of antibiotics (56) (57) support the concept of a microbiological 
element in the aetiology of anal fistulae.  Several animal models of inflammatory 
bowel disease support this concept, since inflammation is dependent on the 
presence of microbiota and in its absence there is no disease.  Single causative 
organisms and dysbiosis have been suggested as mechanisms by which bacteria 
might cause inflammation.  Adherent invasive strains of Escherichia coli have been 
found in patients with CD (38;39) and are known to persist inside macrophages and 
epithelial cells producing large amounts of TNF, selectively colonising the terminal 
ileum of Crohn’s patients (263).  A reduction in biodiversity in mucosa-associated 
microbiota and a loss of normal anaerobic components, a decrease in bifidobacteria 
and Faecalibacterium prausnitzii, and an increase in the number of mucosal adherent 
bacteria have all been noted in Crohn’s disease (44) (264;265) (48) (49).   
 
Different bacteria exert different immune effects on the host tissue.  Some groups 
(such as Bacteroides and E Coli) are known to be pro-inflammatory within the gut, 
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whereas others are known to be anti-inflammatory (bifidobacteria, Faecalibacterium 
prausnitzii (266)). Dysbiosis is a change in the proportions of bacteria normally 
present in the gut and several studies have examined the flora in CD and found a 
reduced diversity with a change in the ratio of pro- and anti-inflammatory bacteria in 
active disease (reviewed in (263)).   
 
As discussed in chapter 1, the microbial content of fistula tracts in CD is less well 
understood.  Studies examining cultured pus or curettings from Crohn’s and 
cryptoglandular fistula tracts have demonstrated different organisms in 
crypotoglandular than Crohn’s fistulae (51) (52;53) and enrichment media required 
due to a paucity of organisms.  However, bacterial culture techniques are unable to 
detect the majority of gastrointestinal organisms (54). Molecular techniques, which 
can identify not only the presence but in some cases the number and location of 
bacteria, allow closer examination of the microbiota. Moreover, in situ techniques 
allow an assessment of the clinical relevance of bacteria found by contrast with both 
culture and qPCR techniques. 
 
2.2.2 Immunology 
 
Histologically, Crohn’s anal fistulae have a central fissure which penetrates the 
lamina propria and muscularis mucosae to reach the underlying tissues.  Previous 
studies have indicated that most fistula tracts contain some epithelium but it often 
occurs in small islands, is rarely circumferential and most often occurs near the 
internal opening (59;84;267).  Bataille and colleagues examined 97 fistula tracts 
from various sites in Crohn’s and non-Crohn’s patients, including 8 Crohn’s and 6 
non-Crohn’s anal fistula tracts (59).  The remaining fistula tracts were non-anal.  
Clear differences were reported across the 97 patients, including T cells lying closer 
to the luminal surface of the Crohn’s fistula tracts and in deeper layers in non-Crohn’s 
tracts, and macrophages intensely infiltrating the whole wall of non-Crohn’s tracts but 
lying in only a small band in Crohn’s tracts.  Only results describing the entire cohort 
were presented and it is not clear whether these findings were representative of anal 
fistula tracts. 
 
Dendritic cells (DC) are antigen presenting cells which sample mucosa-associated 
bacteria and migrate to lymph nodes to stimulate immune response via T cells. They 
imprint homing of T cells to organs e.g. skin (cutaneous lymphocyte-associated 
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antigen, CLA) and gut (α4β7 integrin).  DC have been shown to play a key role in the 
aberrant immune response in Crohn’s disease (268), where they express more Toll-
like receptors which recognise microbes and increase inflammatory cytokine levels. 
The presence, phenotype, homing characteristics and function of DC have not 
previously been examined in Crohn’s and cryptoglandular anal fistulae. 
 
Serum and rectal mucosal cytokines have been analysed in Crohn’s anal fistula 
patients in whom higher levels of rectal mucosal IL-1β and IL-6, and raised serum IL-
6 and TNFα were found compared with both healthy controls and Crohn’s patients 
with disease limited to the small bowel (77).  In this study correlations were also 
found between some cytokines and the activity or severity of disease and no 
influence on cytokines was found from infliximab, azathioprine or steroids.  Cytokines 
from the wall of the fistula tract were not considered.  Mucosal cytokines from 
idiopathic anal fistulae were examined by Kiehne in 2007 who found elevated levels 
of IL-8 and IL-1β but normal levels of TNFα, IL-10 and IL-6 (68). 
 
Infliximab and other anti-TNFα agents have been found rapidly and, in some cases 
completely, to heal anal fistula tracts in Crohn’s disease, underlining the importance 
of cytokines in fistula tract pathology. However, the cytokine milieu of Crohn’s anal 
fistula tracts themselves is not known. 
 
2.3 Hypothesis and Aims 
2.3.1 Hypothesis 
 
We hypothesised that Crohn’s and idiopathic fistula tracts differ with regard to 
microbiological and immunological factors which drive their formation and 
persistence. 
2.3.2 Aims 
 
We aimed:  
a. to identify the specific bacteria or dysbiosis present in Crohn’s and idiopathic anal 
fistula tracts themselves and additionally to identify the rectal microbiota in Crohn’s 
patients with and without anal fistulae; and 
b. to characterise the inflammatory cell population and cytokine profile in Crohn’s and 
idiopathic anal fistula tracts. 
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2.4 Methods 
2.4.1 Patient selection 
 
Four groups of patients were approached to take part in this study: 
 patients with cryptoglandular, or idiopathic, anal fistulae (IPD), 
 patients with Crohn’s anal fistulae (CPD), 
 patients with Crohn’s disease but no past or present anal fistulae (CD), 
 patients without inflammatory or malignant bowel disease. 
 
Demographic and disease related data were noted including duration and extent of 
disease, smoking status and previous medical and surgical therapy. 
 
Baseline characteristics of all patients are shown in Table 13. 
 
2.4.2 Sample collection 
 
All patients were recruited prior to clinically indicated surgery or colonoscopy.  
Surgical procedures included fistulotomy, seton insertion and proctectomy.  The 
specific technique for sample collection for each of the three modalities studied, 
microbiology, immunology and immunohistochemistry, is described in detail in the 
relevant section below.  Some factors were specific to the type of procedure 
undertaken and these are addressed here. 
 
2.4.3 Surgery 
2.4.3.1 Lay open 
 
Patients undergoing lay open of a perianal fistula were placed in the lithotomy 
position.  After washing the perineum with antibacterial skin prep but before any 
manipulation of the fistula, the fistula tract and anorectal biopsies (taken at the 
internal opening in the anus) for microbiological assessment were obtained using 
colonoscopy biopsy forceps (see below).  The operation then proceeded and when 
the fistula tract had been laid open, forceps and scalpel were used to retrieve the 
tract biopsies for immunology and immunohistochemistry. 
 
 91 
2.4.3.2 Proctectomy 
 
Patients undergoing proctectomy also had the perianal portion of their operation 
carried out in the lithotomy position with antiseptic preparation of the perineum.  After 
the anorectum had been excised with the surrounding perineal tissues, the specimen 
was quickly dissected on a sterile surface.  The fistula tract was identified and laid 
open using a scalpel or excised intact.  All biopsies were then taken from this 
exposed bed. 
2.4.3.3 Seton 
 
Patients undergoing seton insertion or change sometimes underwent a small lay 
open at the outer end of the fistula tract in which case they were treated as in lay 
open above.  If not, the same process of antiseptic preparation of the perineum 
followed by fistula tract and anorectal biopsies was undertaken.  Tru-cut biopsies 
were then taken of the wall of the fistula tract, gaining tissue for immunology and 
immunohistochemistry, although if only very small scraps of tissue were obtained, 
histological specimens were not processed. 
2.4.4 Colonoscopy 
 
Since no internal opening was present in the patients undergoing colonoscopy and 
anal biopsy would have been difficult to obtain and would have caused discomfort to 
the patient, rectal biopsies were taken in these patients from low in the rectum.  
Biopsies for microbiological analysis were obtained in Crohn’s patients without 
perianal disease.  Tissue for cytokine analysis was taken from patients without 
inflammatory or malignant bowel disease. 
 
2.4.5 Proctitis 
 
At surgery, along with biopsies for microbiological analysis, a further anorectal biopsy 
was taken and sent for histological assessment in the hospital histopathology 
department as per normal care.  This biopsy was used to assess whether proctitis 
was present. 
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2.5 Microbiology methods - Quantification of Fistula Tract 
and Anal/Rectal Mucosa-Associated Microbiota using 
Fluorescent In Situ Hybridisation 
 
2.5.1 Patients 
Patients with idiopathic or Crohn’s related anal fistulae, or Crohn’s disease but no 
perianal disease were recruited as described above. Fistula patients underwent a 
planned operation, usually examination under anaesthetic (EUA) with seton insertion 
or laying open of fistula although a small number underwent proctectomy.  At surgery 
biopsies were taken and snap frozen in liquid nitrogen as described below.  Non-
fistula patients underwent a planned colonoscopy and had biopsies taken in the 
same way. 
2.5.2 Anal/rectal and fistula tract sample processing 
2.5.2.1 Sample processing and storage 
 
Rectal and fistula tract biopsies were taken using Radial Jaw 3 (Boston Scientific, 
France) biopsy forceps whether at colonoscopy or surgery. Samples taken at 
colonoscopy were obtained during the procedure from as low in the rectum as 
possible.  The samples were retrieved on the biopsy forceps, dipped briefly in sterile 
phosphate buffered saline (PBS) and then placed into dry, sterile, irradiated, 1.2 ml 
cryovials (VWR international Ltd, Lutterworth, UK) using a sterile hypodermic needle. 
The cryovials were snap frozen in liquid nitrogen and stored at -80oC. 
 
At surgery, both gut and fistula tract samples were obtained.  To obtain fistula tract 
samples, careful precautions were undertaken.  The patient was placed in the 
lithotomy position for the purposes of the operation and the entire buttock and 
perianal region was cleaned with antibacterial skin prep.  The protective outer sheath 
from an 18G cannula was inserted into the EO (Figure 11) to prevent the biopsy 
forceps from picking up bacteria form the surrounding skin (Figure 12).   
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Figure 11 - The protective outer sheath from an 18G cannula is inserted into the EO to prevent 
contamination of the biopsy forceps 
 
 
Figure 12 - The biopsy forceps are passed down the sheath 
 
If the EO was too small to admit the cannula sheath then the forceps were inserted 
into the internal opening without it.  The biopsy forceps were then fed into the tract as 
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far as possible until resistance was met (Figure 13) at which point the biopsies were 
taken in the normal way and removed using a sterile needle (Figure 14). 
 
 
Figure 13 - The biopsy forceps are passed until resistance is met when a biopsy is taken. 
 
 
Figure 14 - The biopsy is retrieved using a sterile needle, before washing in sterile PBS and 
placement in a sterile cryovial for snap freezing. 
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If visible, biopsies were taken from the anal canal at the internal opening (Figure 15).  
If this was not possible because the IO could not be found, a random anal or low 
rectal biopsy was taken. 
 
Figure 15 - An internal opening biopsy taken in theatre. The silastic seton marks the IO in the 
anal canal. 
 
Both anal/rectal and tract biopsies were then washed in sterile PBS, placed into a 
cryovial using sterile forceps and snap frozen in liquid nitrogen before transfer to a 
freezer where they were stored at -80oC. 
 
The samples were transferred from the freezer in containers of dry-ice, orientated so 
that the luminal surface of the anal/rectal or fistula tract biopsy was facing up, 
mounted in OCP (Bright Instrument Company, UK) and placed back into the dry-ice. 
The frozen, mounted tissue was transferred into a cryostat (Bright Instrument 
Company, UK) and secured. Sections were cut at 6μm thickness and mounted onto 
plain 4 well slides (Hendley, UK) ( 
 
 
 
 
Figure 16). Each slide was marked with the patient identifier, the site of the sample 
(R = rectum or T = tract) and the level of the section (each time the sample was 
sectioned the slices were taken off in order and labelled so we could identifiy a 
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deeper or more superficial section if appropriate) (figure 2.1).  The sections were 
then frozen and stored at -20oC until the hybridisation step.  
 
The orientation of the sample was confirmed by performing a haematoxylin and eosin 
stain (although in the case of fistula tract samples, if no epithelium was present, 
orientation could not be confirmed microscopically). Briefly, haematoxylin is added for 
two minutes and then washed in tap water for five minutes, then slides are 
counterstained in eosin for a further five minutes before being briefly dipped in tap 
water and then dehydrated through 70%, 95% and 100% ethanol/distilled water 
washes for a minute each and placed in xylene before mounting with DPX 
(Surgipath, UK) and a 22x64mm cover slip.  
 
 
 
 
 
 
 
Figure 16 - An example 4 well slide 
 
2.5.2.2 Fixation 
 
Slides were taken from the freezer and allowed to thaw at room temperature for 10 
minutes. They were fixed using filtered 4% paraformaldehyde solution (appendix 1) 
for 10 minutes. Excess paraformaldehyde was removed and the slides washed in 
Diethyl pyrocarbonate (DePC) Water (Sigma, USA) (appendix 1), twice, for five 
minutes each. 
2.5.2.3 Pre-hybridisation 
 
  M4R-6 
    EUB 
6μm section 
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Each slide was then pre-incubated at the hybridisation temperature (HT) with 20µl of 
hybridisation buffer (appendix 1) per well for 30 minutes in sealed hybridisation trays.  
The optimal hybridisation temperatures for each probe are described below (see 
Table 7).  In order to prevent the slides drying out tissue paper saturated in de-
ionised water was placed in the tray. The Pre-incubation step reduces non-specific 
binding and, by raising the temperature of the slides, improves specific binding of the 
probe in the hybridisation step. 
2.5.2.4 Oligonucleotide probes 
 
Each probe used was manufactured and supplied by Microsynth, Switzerland. They 
were supplied as a lyophilised powder of 0.2μmol per probe at room temperature. 
The probes we used had previously been successfully used in published research. 
Table 6 lists each probe and its sequence. 
 
The probes were made up to a stock concentration of 50ng/μl or 1000ng/μl in sterile 
10mMol Tris-HCl (Trizma, Sigma, UK) buffered to pH 6.5. Once diluted the probe 
was stored at -20oC in 5 and 50μl aliquots. All the probes were conjugated with Cy3 
fluorophore which has an absorption spectrum of 550nm and an emission spectrum 
of 570nm. 
 
Table 6 - Oligonucleotide probe sequences 
 
Target bacterial group Clone Sequence 
   
Panbacteria (269) EUB 338 5’-GCT GCC TCC CGT AGG AGT-3’ 
Bifidobacteria (270) Bif 164 5’-CAT CCG GCA TTA CCA CCC-3’ 
Clostridium coccoides – 
Eubacterium rectale 
cluster (271) 
EREC 482 5’-GCT TCT TAG TCA RGT ACC G-3’ 
Bacteroides – Prevotella 
cluster (272) 
Bac 303 5’-CCA ATG TGG GGG ACC TT-3’ 
Faecalibacterium 
prausnitzii (273) 
Fprau 645 5’-CCT CTG CAC TAC TCA AGA AAA AC-3’ 
Escherichia coli (274) Ecoli 1531 5’-CAC CGT AGT GCC TCG TCA TCA-3’ 
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2.5.2.5 Hybridisation 
 
During pre-hybridisation, the appropriate amount of each probe was diluted to a 
concentration of 5ng/μl with hybridisation buffer warmed to the hybridisation 
temperature. A final volume of 18μl of probe was placed on each well under a 13mm 
diameter cover slip used to protect the wells during hybridisation, in order to prevent 
evaporation of hybridisation fluid and drying out of the sections. The trays were then 
resealed with cling film with the paper wick still in place, and placed back into the 
blacked out hybridisation oven set at the appropriate HT for the probe concerned 
overnight. 
    
As the hybridisation temperatures for some probes were within 2 °C of each other, a 
compromise temperature in between the two was used so that multiple probes could 
be hybridised at the same time (Table 7). 
 
A positive control sample, known to contain the bacteria for which we were probing, 
was used in each experiment. 
 
Table 7 - Hybridisation temperatures 
 
Oligonucleotide 
Probe/Clone 
Optimal Hybridisation 
Temperature (+/- 2°C) 
Hybridisation 
Temperature used 
EUB 338 48 49 
Bif 164 50 49 
EREC 482 50 49 
Bac 303 45 45 
Fprau 645 35 36 
E. coli 1531 37 36 
 
2.5.2.6 Stringent washes 
 
After overnight incubation, the slides were removed from the oven and the cover slips 
gently tapped off. The slides were then placed into either DePC water for 5 minutes 
or washed using Hybridisation wash for 20 minutes on a gentle agitator and then 
placed in De PC water for 5 minutes (appendix 1, 7.2) (Table 8). During the washing 
 99 
phase the slides were protected from exposure to light using aluminium foil wrapped 
around the Coplin jars.   
 
The slides were removed from the wash, excess water tapped off and a fluorescent 
mountant (Vectashield, Vector Laboratories, USA) was added and then covered with 
a 22x64mm coverslip. 
 
Table 8 - Post-hybridisation washes 
 
Oligonucleotide 
Probe/Clone 
20 minutes hybridisation 
wash and agitation 
5 minutes DePC water 
EUB 338 No Yes 
Bif 164 Yes Yes 
EREC 482 No Yes 
Bac 303 Yes Yes 
Fprau 645 No Yes 
E. coli 1531 No Yes 
 
 
2.5.2.7 Microscopy 
 
All slides were reviewed using a Zeiss Axioskop 2 epifluorescent microscope with a 
mercury vapour lamp. Each anal/rectal section was reviewed to identify the epithelial 
border, mucus lying next to it and fluorescing bacteria within it. The best field 
containing the most bacteria in any of the wells was used and all bacteria lying within 
mucus associated with the epithelium in this high power field were counted by two 
researchers and their scores were averaged.   
 
If the positive control samples within an experiment had detected bacteria and at 
least two sections of a sample appeared morphologically intact with a clear run of 
epithelium and mucus lying off it but no bacteria were seen, we counted the sample 
as having no bacteria of the type probed for present.   
 
If there were no positive samples within an experiment then no sample was 
determined as a zero and the experiment was repeated with new slides from each 
sample. 
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If the positive control or any other sample did detect bacteria but a given sample did 
not have at least two sections containing a run of epithelium with mucus lying off it, it 
was considered inadequate and the experiment was repeated with new slides from 
the sample. 
 
Fistula tract samples were viewed in the same way but since there is no consistent 
mucosal or epithelial surface, all aspects of each sample were considered possible 
luminal surfaces of the fistula tract and examined for the presence of bacteria.   
 
Good examples of bacteria or samples with good morphology, epithelium and mucus 
but no bacteria were photographed using a fluorescent Leica DMIRE2® confocal 
microscope or the Zeiss Axioskop described above. 
2.5.2.8 Gram stain 
 
Slides were allowed to air dry and thaw at room temperature for 10 minutes.  After 
warming for 10 minutes at 37°C they were allowed to cool before flooding with 
Crystal Violet (Pro-Lab diagnostics, Richmond) for 70 seconds and rinsing with 
water.  The slides were then flooded with Gram’s iodine for 60 seconds before rinsing 
with water and differentiating with Gram’s Differentiator and immediately rinsing.  
Safranin counterstain was applied for 20 seconds before rinsing and mounting with 
DPX. 
 
2.5.2.9 Scanning electron microscopy 
 
On three occasions specimens were taken for scanning electron microscopic (SEM) 
analysis.  Full thickness fistula tract specimens were dissected and placed in cell 
culture wells. Cotton wool soaked in 2.5% phosphate buffered glutaraldehyde was 
placed in adjacent wells in order that the specimens were exposed to glutaraldehyde 
vapour during transport.  
 
Vapour fixation with 1% osmium tetroxide in phosphate buffer was performed 
overnight.  The osmium tetroxide was then removed and the specimens allowed to 
air dry over 36 hours.      
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The specimens were removed from the wells and mounted on SEM stubs using silver 
dag, and gold coated using a Polaron E5100 SEM coating unit (Quorum 
Technologies).  The specimens were viewed in a “Quanta” field emission gun SEM 
(FEI UK Ltd) at 5 Kv accelerating voltage in secondary electron mode. 
 
 
2.6 Histology and Immunohistology methods 
 
2.6.1 Patients 
 
Patients with idiopathic or Crohn’s related anal fistulae were recruited as described 
above and underwent a planned operation, usually examination under anaesthetic 
(EUA) with seton insertion or laying open of fistula although a small number 
underwent proctectomy.  
 
2.6.2 Histology sample processing 
 
Samples were taken from the fistula tract using a scalpel and forceps (Figure 17) 
after the tract had been examined with a fistula probe and, in the case of fistulotomy, 
after the laying open had taken place.   
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Figure 17 - Full thickness fistula tract wall sample retrieved after fistulotomy using scalpel and 
forceps. 
 
In the case of seton operations, a Tru-cut biopsy needle was used to obtain a sample 
of the wall of the fistula tract.  This was performed by placing the needle as far into 
the tract as possible and then firing it with the sampling surface pressed up against 
the wall of the tract.  Where a proctectomy was performed, the tract was not 
disturbed until after resection of the anorectum whereupon the tract was excised 
intact from the surrounding tissues. 
 
Samples were orientated, if possible, at the time of retrieval.  They were placed in 
sterile saline and on ice for transfer to the laboratory which took place soon 
afterwards.   
 
Samples were then cut into smaller pieces, if large enough, demonstrating the full 
thickness of the fistula tract wall across the cut surface and placed into cassettes with 
this face uppermost. The cassettes were placed into 10% neutral buffered formalin 
solution for at least 48 hours to fix the tissues. The tissue was then processed to wax 
using an automated processor (7.1.2.1) and embedded into wax blocks with the full 
thickness face of the fistula tract wall at the cutting surface.  A rotary microtome was 
used to cut 5µm sections which were then mounted onto APTS (3-
aminopropyltriethoxysilane) (Sigma Aldrich, UK) coated (to improve adhesion) glass 
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microscope slides (Surgipath, UK)  using a warm water bath and left to dry overnight 
at 60ºC, cooled and stored at room temperature.  
 
2.6.3 Histological staining 
 
Haematoxylin and Eosin (H&E) staining, according to a standard protocol (appendix 
1, 7.1.2.2), was performed to assess basic tissue and cellular morphology. Picro-
Sirius Red and Miller’s Elastin (PM) staining (appendix 1, 7.1.2.3) was also used to 
identify and assess collagen and elastin within the samples.  
 
2.6.4 Histological assessment 
 
An expert histologist (Prof Paul Sibbons) performed a blinded assessment of the 
histology and morphology of fistula tract specimens using an Olympus BX40 
microscope equipped with an Olympus DP70 digital camera. 
2.6.4.1 Orientation and morphology 
 
Confirmation (and in some cases primary assessment since orientation at operation 
had not been possible) of the orientation of the section was sought microscopically 
with the presence of a non-skin epithelial border taken to indicate the luminal surface 
of the fistula tract.  If orientation was possible, the luminal aspect of the section was 
marked. 
 
If distinct layers of tissue throughout the section were visible, they were named 
according to their predominant feature and their size relative to the section was 
estimated. 
2.6.4.2 Inflammation 
 
Inflammation was described as chronic or acute and assigned a severity score on a 
scale from 0-5 where 0 = no inflammation and 5 = severe inflammation based on the 
presence of immune cells and tissue responses.  
2.6.4.3 Epithelialisation 
 
Epithelialisation was sought in each section. 
2.6.4.4 Collagen 
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The presence, quantity and quality (healthy or denatured) of collagen were assessed 
using PM stain with polarised light. 
2.6.5 Immunohistochemistry sample processing 
 
Immunohistochemistry was performed on all samples.  CD3 primary antibodies, 
staining for T lymphocytes, and Ab-1 primary antibodies, staining for macrophages, 
were used (Table 9).  Protocols (appendix 1, 7.1.2.4 & 7.1.2.5) were developed 
specifically for the antibodies used on fistula tract tissue in order to provide adequate 
antibody staining without excessive non-specific staining.  Antigen retrieval with 
Target Retrieval Solution (DAKO, UK) at 98°C for 30 minutes was necessary for the 
CD3 protocol but not for Ab-1.   
 
 
 
 
 
 
 
 
Table 9 - Antibody data 
 
Antibody name Clone Company Type Isotype Cells stained 
      
Calprotectin-
Monocyte/Macrophage/L1 
Protein Ab-1 
MAC 
387 
Thermo 
Scientific 
Mouse 
monoclonal 
antibody 
IgG1 
Neutrophils, 
Monocytes, 
macrophages, 
squamous 
epithelia 
CD3 F7.2.38 
Dako 
Cytomation 
Mouse 
monoclonal 
antibody 
IgG1, 
Kappa 
T cells 
 
 
Briefly, sections were rinsed in distilled water and treated with 3% hydrogen peroxide 
in methanol to block endogenous peroxidase activity and then washed with PBS 
alone (CD3) or both distilled water and PBS (Ab-1) before treatment with normal 
horse serum (Impress Kit, Vector Laboratories, UK) to prevent non-specific staining 
before being incubated with the primary antibody either overnight at 5°C (Ab-1) or for 
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1 hour at room temperature (CD3). Sections were then washed in PBS again and 
anti-mouse secondary antibody (ImmPRESS Reagent, Vector Laboratories, UK) was 
applied at room temperature. After further PBS washing, diaminobenzidine 
(ImmPACT DAB) peroxidase substrate (Vector Laboratories, UK) was added to allow 
visualisation of the target cells with a light microscope.  Finally, sections were 
counterstained with Harris haematoxylin for 15 (Ab-1) or 30 (CD3) seconds, 
dehydrated, cleared in xylene and mounted using DPX mountant (Surgipath, UK) and 
cover slips.  
 
The samples were viewed on a light microscope (Olympus BH2) to confirm 
appropriate staining and a negative control sample was used with each experiment to 
ensure the absence of non-specific binding.   
 
2.6.6 Two dimensional stereology 
 
Each sample then underwent a 2 dimensional stereological count using a microscope 
with accurate stage movement measurement and computer software with unbiased 
sampling frames.  The dimensions of the tissue were established using the stage 
movement measurement device and then the distance between fields of view to 
achieve approximately 20 different fields was noted.  A count for these fields of view 
was obtained and the coefficient of error (CE) was noted (Figure 18).  If it was noted 
to be above 10%, the number of fields of view was increased to try to reduce the CE 
by counting a field of view between each of the fields of view already counted and 
then the CE was noted once again.  This process continued until the CE reached the 
acceptable level of 10% or it plateaued and would not reduce any further.  The 
magnification was kept constant between samples. 
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Figure 18 - Example tessellation 
 
Some samples could be orientated according to their appearance on H&E staining 
and showed zones with different densities of the examined cell types closer to and 
further from the luminal aspect of the tract (Figure 19, 
 
Figure 21).  These samples underwent separate counts in the two zones.  If the 
zones were small, a perfect tessellation was performed to try to produce as accurate 
a result as possible (Figure 20). 
 
 
 
Figure 19 - Separate tessellations across zones 
 
 
 
Figure 20 - Perfect tessellation 
 
Tissue Counting frame 
Zone 1 
Zone 2 
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Figure 21 - Separate tessellations across two zones in full cross section 
specimen 
 
Some samples which could not be orientated showed clustering of the examined 
cells.  A note was made of these clusters and counting was performed within them if 
they were large enough ( 
Figure 22). 
 
 
 
 
Figure 22 - Separate tessellations across a cluster and the remaining tissue 
 
 
 
 
 
2.7 Immunology methods 
 
2.7.1 Patients 
 
Patients with idiopathic or Crohn’s related anal fistulae were recruited as described 
above and underwent a planned operation, usually examination under anaesthetic 
Cluster 1 
Fistula lumen Zone 2 
Zone 1 
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(EUA) with seton insertion or laying open of fistula although a small number 
underwent proctectomy.  Control patients in the cytokine experiments had no history 
or evidence of malignancy or colitis on colonoscopy and had been referred with 
symptoms of rectal bleeding or a change in bowel habit, or for colonic polyp follow-up 
or family history screening colonoscopy.   
 
2.7.2 FACS sample processing 
2.7.2.1 Tissue collection and transport 
 
One to two biopsies were obtained from the luminal surface of the fistula tract at 
operation.  Tissues were placed in complete medium (appendix 1), placed on ice and 
transported immediately for processing.  
 
2.7.2.2 ‘Walk out’ 
 
Samples were removed from the transport medium using sterile forceps and 
processed within a level 1 fume hood.  The samples were washed in complete 
medium to remove blood and cut into pieces approximately 2mm3 using a scalpel 
blade.  One or two of these pieces were then placed in a test tube for subsequent 
freezing and multiplex analysis (see below).  The other samples were placed in a 
single well of a 24 well plate (VWR international Ltd, Lutterworth, UK) and incubated 
overnight at 37°C with 5% CO2 in air in 1ml of complete medium. After incubation, 
the samples for cell analysis were removed from the incubator and the supernatant 
removed from the 24 well plate into a test tube.  The well was then washed with 1ml 
of FACS buffer (appendix 1, 7.3.1) three times and the wash placed into the test tube 
to obtain as many cells as possible.  This test tube was then centrifuged at 1500 pm 
for 5 minutes and the fluid was discarded.  Walk out cells remain at the bottom of the 
test tube. 
 
 
2.7.2.3 Cell surface labelling 
 
The cells were agitated by flicking the bottom of the tube and the resulting volume 
measured.  This volume was made up to 150μl per tube plus 50μl with FACS buffer 
and antibodies and their isotype controls were added (Table 10).  The tubes were 
then placed in the refrigerator at 4C for 20 minutes.  The cells were washed by 
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centrifugation in FACS buffer (1500 rpm, 5minutes), and re-suspended in 200µ/L of 
paraformaldehyde (appendix 3).  The samples were stored at 4C until acquisition on 
the flow cytometer within 72 hours.  
 
Table 10 - An example labelling grid with antibodies and isotype controls 
 
Tube number FitC PE PC5 APC 
     
1 CLA β7 - CD3 
2 CLA β7 Lineage cocktail HLA-DR 
3 rIgM rγ2a Lineage cocktail HLA-DR 
4 CD65 CD19 - γ1 
5 mIgM - -  
 
 
2.7.2.4 Peripheral blood mononuclear cells (PBMCs) for 
compensation in flow cytometry 
 
Human whole blood was obtained by venepuncture and placed into sodium-heparin 
Vacutainers (Beckton-Dickinson).  It was diluted with an equal volume of RPMI-1640 
Dutch modification. The whole blood was centrifuged over the same volume again of 
Ficoll-paque density gradient at 2000 rpm for 25 minutes at room temperature. 
PBMCs were collected from the interface that resulted and washed twice in FACS 
buffer at 1500 rpm for 5 minutes.  They were then re-suspended in 500μl and 
labelled (Table 11).  After 20 minutes at 4°C a further FACS buffer wash was 
performed and 1% paraformaldehyde was added to 500μl.  
 
 
 
 
 
Table 11 - Antibody labelling of compensation tubes 
 
Tube number FitC PE PC5 APC 
     
Compensation 1 CD8 - - - 
C2 - CD8 - - 
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C3 - - CD3 - 
C4 - - - CD8 
C5 - - - - 
 
 
2.7.2.5 Flow cytometry 
 
Multi-colour flow cytometry allows characterisation of individual cells in suspension 
by measuring size and granularity as well as identifying the wavelength of light given 
off by a fluorophore (FitC, PE, PC5 or APC) attached to cells as they pass through 
one or more focused laser beams. 
 
Twenty microlitres of flow-count fluorospheres (Beckman Coulter, High Wycombe, 
UK) at a known concentration was added to each tube to enable absolute cell 
number assessment. Samples were acquired for approximately 5 minutes at high 
flow rate until all cells had been analysed.  Compensation samples were acquired 
until between 20000 and 50000 events had occurred. All data were then saved as 
list-mode data files, stored and transferred to a computer for subsequent analysis. 
 
2.7.2.6 FACS analysis 
 
Data were acquired using a FACS Calibur flow cytometer (Becton Dickinson, 
England) and CellQuest software. Further compensation and analysis of list-mode 
data were carried out subsequently using WinList software (Verity Software House, 
Maine). To enable compensation, a region was made around lymphocytes, identified 
by their size and granularity on the side scatter (SSC) versus forward scatter (FSC) 
plot and, in each channel, the CD8 (or CD3 in the PC5 tube) marker was evaluated 
and compensation applied with the compensation tool on Winlist. Live cells (again, 
based on size and granularity) were analysed on a plot of HLA-DR+ versus lineage 
cocktail- staining which identifies DCs. Lineage cocktail comprised specific 
monoclonal antibody labels for T cells (CD3), monocytes (CD14, CD16), B cells 
(CD19), and stem cells (CD34).  Using multi-colour analysis, CD11c+ and CD11c- 
populations within the DC population were assessed for proportion and expression of 
homing markers. T cells, macrophages, B cells and monocytes were also identified 
by gating on viable cells and then determining the proportion of cells within this 
region positive for the fluorophore corresponding to the cell marker in that tube.  Both 
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Region Gating and Enhanced Normalised Subtraction (ENS) were used to analyse 
the flow cytometry data. 
 
2.7.3 Multiplex sample processing 
2.7.3.1 ‘Walk out’ 
 
The one to two samples set aside for cytokine analysis were incubated overnight 
(37°C in humidified 5% C02 in air) in complete medium.  The supernatant was then 
removed into a 1.2ml cryovial and stored at -80°C until multiplex analysis was 
undertaken on all samples examining for the presence of Th1/Th2/Th17 cytokines 
(IL-2, IL-4, IL-6, IL-10, TNF, IFN-γ, IL-17A). 
2.7.3.2 Multiplex methods 
 
Cryovials containing supernatant were thawed at room temperature and vortexed.  
Fifty microlitres of supernatant was placed into labelled sample tubes containing 50μl 
of vortexed human Th1/Th2/Th17 cytokine capture beads (BD Biosciences, UK).  
Fifty microlitres of human Th1/Th2/Th17 PE Detection Reagent (BD Biosciences, 
UK) was added to each tube and incubation at room temperature occurred for 3 
hours, with the tubes protected from light.  One millilitre of wash buffer (BD 
Biosciences, UK) was then added to each tube before 5 minutes of centrifugation at 
200g.  The supernatant was discarded and 300μl of wash buffer was added to 
resuspend the precipitate. 
 
Samples were acquired using a FACS Calibur flow cytometer as described above 
until all events had been captured.  The resultant data were analysed using FCAP 
Array software (BD Biosciences, UK). 
 
 
 
 
2.7.4 Statistical methods 
 
The Stata software package - version 9.2 (StataCorp LP, College Station, Texas, 
USA) was used for performing all appropriate statistical analyses. Continuous 
variables were summarised by the medians and inter-quartile range (IQR) due to the 
skewed distribution of some variables. The number and percentage of subjects in 
each category were used for categorical variables.  
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The Chi-square test was used to compare categorical outcomes between groups. 
Additionally, logistic regression was used to jointly examine the effect of several 
factors upon the binary categorical outcomes. The size of effects of these analyses 
was given in the form of odds ratios.  
 
Differences in continuous outcomes between independent groups were evaluated 
using the Mann-Whitney U test to compare between two groups, or the Kruskal-
Wallis test to compare between more than two groups. These non-parametric tests 
were used due to non-normal distribution of most outcomes. For differences between 
paired groups the Wilcoxon signed rank test was used.  A P value of 0.05, or where 
multiple testing was used 0.01, was considered significant. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.8 Results 
 
A summary of our findings can be found in Table 12.  
 
Table 12 - Summary of aetiological findings. 
 
Pathological feature Crohn’s anal fistula Idiopathic anal fistula 
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Fistula tract 
bacteria 
Panbacteria, 
Bifidobacteria, 
Bacteroides, 
Faecalibacterium 
Prausnitzii, Clostridia, 
Escherichia Coli 
None None* 
Rectal 
bacteria 
Bifidobacteria Fewer (P=0.02) More 
 Bacteroides Fewer (P=0.05) More 
 
Faecalibacterium 
Prausnitzii, Clostridia, 
Escherichia Coli 
Similar Similar 
    
Immune cells 
Acute/Chronic 
inflammation 
Similar Similar 
 Macrophage position Luminal Luminal 
 Macrophage number Similar Similar 
 T-lymphocyte position Luminal Luminal 
 T-lymphocyte number 
More luminal (P=0.05) 
and deep (P=0.04) 
Fewer 
 DC homing 
Less gut (α4β7) and 
skin (CLA) homing 
More (P=0.03) 
 CD65 +ve cells Fewer More (P=0.04) 
    
Cytokines IL-17a levels Lower Higher (P=0.04) 
 TNFα Similar Similar 
 Other Th1/2/17 Similar Similar 
 
2.8.1 Patient demographics 
 
Sixty-one patients were recruited to the study including 18 with cryptoglandular anal 
fistulae (IPD), 20 with Crohn’s anal fistulae (CPD), 13 with Crohn’s disease but no 
previous or current anal fistulae (CD) and 10 normal controls.  The demographic 
details of the 4 groups are shown below (Table 13).  
 
Table 13 - Patient demographics and baseline disease data. 
 
 Crohn’s anal 
fistula (CPD) 
n= 20 
Luminal 
Crohn’s 
disease (CD) 
n= 13 
Idiopathic anal 
fistula (IPD) 
n=18 
Controls 
(n=10) 
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Age (median, 
years) 
 
31.5 32 46.5 56.5 
Gender (M:F) 
 
9:11 5:8 12:6 5:5 
Smokers 
 
6 (30%) 2 (15%) 6 (33%) 2 (20%) 
Disease location* 
 
 
 
 
4 L1p (20%) 
7 L2p (35%) 
6 L3p (30%) 
3 p (15%) 
5 L1 (38%) 
1 L2 (8%) 
7 L3 (54%) 
N/A N/A 
Duration of 
luminal disease 
(median, years) 
 
12 11 N/A N/A 
Duration of 
perianal disease 
(median, years) 
 
4 N/A 3 N/A 
Stoma 
 
3 (15%) 3 (23%) 0 0 
Seton 
 
8 (40%) N/A 8 (44%) N/A 
Immunomodulator 
(Steroid, 
Thiopurine, 
Methotrexate) 
7 4 N/A N/A 
* Montreal classification of Crohn’s disease. L1 = Terminal ileum, L2 = Colon, L3 = 
Ileocolon, L4 = Upper GI, p = perianal disease modifier (275). 
 
The demographics of the patients used for each experiment were compared to 
determine any differences.  In all experiments, the median age of patients with 
idiopathic anal fistulae was significantly greater than those with Crohn’s fistulae.  In 
the cohorts undergoing FISH and flow cytometry, patients with idiopathic fistulae had 
undergone more previous operations than those with Crohn’s fistulae.  There was no 
difference in disease duration or fistula duration between the groups in any 
experiment. 
 
 
2.8.2 Reduced bacteria in anal fistula tracts 
 
Fistula tract specimens from 32 patients (18 IPD, 14 CPD) were examined using 
fluorescent in situ hybridisation.  No bacteria were identified in 31 patient samples 
including all 14 Crohn’s anal fistula tracts.  Only 1 patient’s fistula tract (a patient with 
an idiopathic fistula) was found to contain any bacteria associated with the wall of the 
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tract (Figure 24).  These initial 32 specimens were processed as described above 
with a wash stage in theatre straight after collection.   
 
Figure 23 - Fluorescent in situ hybridisation using eubacterial probe showing mucus devoid of 
bacteria alongside epithelium (EUB x630) 
 
Luminal surface of 
fistula tract 
Luminal mucus, 
devoid of bacteria 
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Figure 24 - Fluorescent in situ hybridisation using eubacterial probe showing bacteria within 
mucus layer alongside epithelium (EUB x630) 
 
 
To control for a technical cause to explain this lack of bacteria, i.e. the washing of 
bacteria from the sample during processing, a further 4 patient samples (all Crohn’s) 
were retrieved and placed into cryovials without a washing stage. Three of these 
were paired samples where washed samples were also processed.  In all 4 cases no 
bacteria were seen. 
 
A Gram stain was performed on 14 patient samples including 3 paired samples 
(washed and unwashed) and also the sample positive for bacteria in the patient with 
an idiopathic fistula from the FISH experiments; once again the positive sample was 
strongly positive but the remaining samples showed no bacteria. 
 
Scanning electron microscopy was performed on 3 patient samples all with no wash 
stage at any point.  One sample (IPD) showed a small cluster of cocci in a very small 
area on its surface. The rest of its surface and FISH examination of this specimen, as 
well as SEM assessment of both of the other samples (CPD) found no bacteria. 
Tract wall 
Lumen 
Luminal mucus 
containing 
bacteria 
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Figure 25 - Scanning electron microscopy image of tract surface showing a small cluster of cocci 
(x10000) 
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Figure 26 - Scanning electron microscopy image of fistula tract surface devoid of bacteria 
(x10000) 
 
2.8.3 Reduced rectal bifidobacteria and Bacteroides in Crohn’s 
patients 
 
Crohn’s anal fistula patients had fewer rectal bifidobacteria (median 0 bacteria per 
high powered field, IQR 0-8, vs. median 32, IQR 0-88, P=0.02) and Bacteroides 
(median 0 bacteria per high powered field, IQR 0-0, vs. median 15, IQR 17-72, 
P=0.05) than patients with IPD.  Crohn’s patients without anal fistula also had fewer 
bifidobacteria than IPD patients.  The numbers of Faecalibacterium Prausnitzii, 
Escherichia Coli and Clostridia examined using the probes were similar across all 
three groups. 
 
A longer duration of Crohn’s disease (with fistula and non-fistula patients grouped) 
was associated with more Bacteroides (correlation coefficient 0.45, P=0.02). 
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There was no association found between gender, smoking status, site of luminal 
disease, presence of a stoma, presence of a seton, or the use of antibiotics, 
immunomodulators or anti TNF agents and rectal bacteria. 
 
Full results are found in appendix 1 (7.4.2). 
 
2.8.4 Histopathological features of anal fistula tracts  
 
Fistula tract specimens analysed in our study varied with regards to the cells present 
and their location in the wall of the fistula tract.  Some of the Crohn’s fistula tracts 
contained a keratinised squamous epithelium on their luminal surface with 
granulation tissue also found on this surface and deeper into the wall of the tract.  
Ulceration was sometimes seen. 
 
Deeper in the fistula tract wall and surrounding the lumen there was fibrosis with a 
mostly chronic inflammatory infiltrate composed predominantly of lymphocytes and 
plasma cells with a few eosinophils and occasional neutrophils also seen.  
Inflammation was often moderate, chronic and perivascular.  Granulomas were rarely 
seen in the Crohn’s fistula tracts. 
 
The inflammation and fibrosis continued into the deeper layers of the wall of the tract 
and into the adipose tissue that surrounded the tract. 
 
2.8.5 Similar levels of acute and chronic inflammation in Crohn’s 
and idiopathic fistulae 
 
Acute inflammation in the fistula tract wall was examined histologically.  The median 
acute inflammation score (based on the types and numbers of cells present, 
measured on a scale of 0-5) was higher in patients with a seton in situ at the time of 
surgery (1.5 vs. 0, P = 0.03).  There was a trend towards smokers having a higher 
level of acute inflammation than non-smokers, although this result was not 
statistically significant (P = 0.08). 
 
A strong positive correlation was found between a longer duration of luminal Crohn’s 
disease and a higher level of acute tract inflammation in the Crohn’s anal fistula 
group (Correlation Coefficient = 0.91, P = 0.005).  The presence of a seton was also 
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associated with a higher level of acute tract inflammation (median acute inflammation 
score = 1.5 vs. 0, P = 0.03).   
 
Chronic inflammation was also assessed (0-5).  Although not statistically significant, 
trends were seen suggesting patients with a stoma had lower and smokers had 
higher levels of chronic inflammation. Patients with a stoma had a mean chronic 
inflammation score of 1.0, compared to 2.7 for those with no stoma (P = 0.07).  
Patients who smoked had a higher level of inflammation, with a mean of 3.1 
compared to a mean of 2.1 for those who did not smoke (P = 0.07). 
 
There was no difference in either acute or chronic inflammation between the Crohn’s 
and idiopathic fistula tracts. 
 
Full results are found in appendix 1 (7.4.1.1). 
 
2.8.6 Inflammation is greatest near the luminal surface in Crohn’s 
and idiopathic fistula tracts 
 
Fistula tract specimens were examined histologically across the full thickness of the 
fistula tract wall. A clear demarcation between zone 1 (luminal) and zone 2 (deep) 
was visible microscopically.   
 
In Crohn’s and idiopathic anal fistula tracts, both Ab-1 (macrophage) and CD3 (T 
lymphocyte) counts showed significant differences in median number per unit area 
between zone 1 and zone 2 (10.8 x 10-5μm2 vs. 2.5 x 10-5 μm2, P=0.02 and 16.6 x 10-
5 μm2 vs. 5 x 10-5 μm2, P=0.002 respectively) indicating that the luminal layer of the 
fistula tracts contain more macrophages and T lymphocytes than the deep layers 
(Figure 27). 
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Figure 27 - Increased macrophages and T lymphocytes at luminal surface of fistula tract 
compared to deeper layers 
 
 
Figure 28 - H&E x 20 of fistula tract with lumen in lower left corner and full thickness of tract 
wall up to fat.  Inflammatory zone seen near lumen of tract. 
 
Figure 25 
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Figure 29 - Close up of figure 24 (x100) showing epithelium of tract lumen in lower left corner 
with peri-luminal T lymphocytes 
 
Full results are found in appendix 1 (7.4.1.2). 
 
2.8.7 Higher T lymphocytes in Crohn’s than idiopathic anal fistula 
tracts 
 
When the number of cells seen in Crohn’s and idiopathic fistula tracts was compared, 
more CD3 +ve T lymphocytes were seen in both the luminal (Figure 30) and deep 
(Figure 31) layers of Crohn’s fistula tracts compared to idiopathic tracts (21.7x10-5 
μm2 vs. 14.4x10-5 μm2, P=0.05 and 9.1x10-5 μm2 vs. 4.5x10-5 μm2, P=0.04 
respectively). 
 
No difference in Ab-1 positive cells (macrophages) between Crohn’s and idiopathic 
patients overall, or in zone 1 or zone 2 counts was found. 
 
T 
epithelium 
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Figure 30 - Increased T lymphocytes in luminal layer of Crohn's compared to idiopathic fistula 
tracts 
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Figure 31 - Increased T lymphocytes in deep layer of Crohn's compared to idiopathic fistula 
tracts 
 
Full results found in appendix 1 (7.4.1.3). 
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2.8.8 Dendritic cells lack homing markers in Crohn’s anal fistula 
tracts 
 
DC in Crohn’s fistula tracts had significantly reduced levels of both the gut (α4β7, 
median 0% cells positive, range 0-0, vs. median 16%, range 0-96%, P=0.03) and 
skin (CLA, median 0%, range 0-0, vs. median 78%, range 0-99%, P=0.03) homing 
markers compared with idiopathic fistula tracts.  Crohn’s fistula tracts showed lower 
levels of CD65 than idiopathic fistula tracts (median positive control intensity ratio 6, 
range 1-93, vs. median 77, range 0-743, P=0.04).  There was no significant 
difference in proportions of either myeloid or plasmacytoid DC, or of monocytes 
(CD14, CD16), B lymphocytes (CD19) or T lymphocytes (CD3), or HLA DR positivity 
between Crohn’s anal fistulae and idiopathic anal fistulae found by flow cytometry.  
 
Full results are found in appendix 1 (7.4.3). 
 
2.8.9 Crohn’s and idiopathic anal fistula contain similar levels of 
TNF but IL-17a is reduced in Crohn’s compared to idiopathic 
anal fistulae 
There was no significant difference in levels of Tumour necrosis Factor (TNFα) 
between Crohn’s and idiopathic anal fistula tracts (1.61 pg/ml vs. 2.81 pg/ml, P = 
0.48). 
 
IL-17a levels were lower in Crohn’s anal fistula tracts (2.63 pg/ml) than normal 
rectum (3.01 pg/ml) and idiopathic anal fistula (3.38 pg/ml) (P=0.04). 
 
Levels of IL-2, IL-4, IL-6, IL-10 and IFN-γ were also similar in Crohn’s and idiopathic 
anal fistula tracts.   
 
The full results are found in appendix 1 (7.4.4). 
 
2.8.10 Associations between bacteria and immunity 
 
When examined across all patients, some rectal bacteria were found to be 
associated with tract immune cells.  This analysis utilised multiple testing and as 
such a lower level of significance (P=0.01) was used. 
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Higher levels of Faecalibacterium Prausnitzii tended towards association with fewer 
CD3+ve T cells in the deeper layer of the fistula tract (cc=-0.58, P=0.0367). 
 
Higher levels of Bacteroides were associated with higher levels of CLA (cc=0.78, 
P=0.014) and β7 (cc=0.92, P=0.0004) in tract tissue generally and higher levels of 
CLA on DC (cc=0.90, P=0.0009). 
  
Rectal and tract cytokines also showed some association with some bacteria.   
 
Higher levels of EREC tended towards association with higher levels of IL-2 
(cc=0.64, P=0.024) and IFNγ (cc=0.65, P=0.021). 
Higher levels of Bacteroides tended towards association with lower levels of IL-10 
(cc=-0.62, P=0.025). 
 
2.9 Discussion 
 
We aimed to characterise and compare the fistula tract microbiota using a molecular 
technique.  Like standard culture, quantitative polymerase chain reaction amplifies 
the bacteria present so that contamination can confuse the results achieved.  
Fluorescent in situ hybridisation identifies bacteria where they are fixed so that it is 
possible to assess the nature and number of mucosal-associated bacteria, those 
thought to interact with the host immune cells and drive inflammation, whilst 
discounting those that sit well away from the tissue or on top of it which are likely 
contaminants or at least unlikely to be clinically relevant. 
 
Our fistula tract findings suggest that very few if any bacteria occupy a clinically 
relevant position in anal fistula tracts.  A reduced number of bacteria in the 
established fistula tracts seen in our study may suggest that there is limited bacterial 
colonisation of the luminal surface of anal fistula tracts which would imply limited 
interaction with host immune cells and a less significant role for bacteria in the 
persistence of anal fistula than previously thought.   
 
This finding could be due to a sampling error since only two small biopsies were 
retrieved for each tract although several levels within these biopsies were examined.  
The biopsies were taken as far cephalad in the tract as possible but rarely next to the 
internal opening where most bacteria might be postulated to be found. 
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Another explanation may be that after the initial infective insult with abscess and 
ultimately fistula formation, fistula tract immune activity is able to prevent colonisation 
of the luminal surface of the tract by bacteria, and analysis of this ‘stand off’ reveals 
active innate immunity and few if any live bacteria (as seen here): an effective host 
defence. The tract may subsequently fail to fully heal due to a separate pathology or 
abnormality in tissue repair, for example.   
 
Previous assessment of mucosa-associated bacteria in the rectum by Swidsinski and 
colleagues using molecular techniques (49) suggests that a. bacteria do not invade 
denuded mucosal areas but colonise the intact mucosal surface; b. are held in 
position, despite washing, by a thick bacterial film in which the bacteria sit; c. the 
bacterial film is only present in specimens with concentrations of 10,000cfu/μ/; and d. 
below this concentration few if any scattered bacteria are seen.  
 
Our fistula tract specimens examined contained little or no epithelium and rarely a 
mucus layer.  An absence of mucus leaves cells open to adherence and invasion by 
bacteria but also denies them an immediate home and it may be that by washing, 
either in theatre after collection of the specimen, or during the FISH or Gram 
experiments, any bacteria present in vivo were simply washed away. 
 
Electron microscopy in 3 patients also revealed sterile tracts, in spite of quite large 
sections of tissue, in 2 of the 3 cases.  The small, isolated cluster of cocci seen in the 
third sample may represent contamination, or possibly a precursor to fistula re-
activation. 
 
Our fistula tract findings may be relevant to persistence of established fistula tracts 
rather than the initial insult which leads to fistula formation, and the role of bacteria 
within this aetiopathogenesis.   
 
The rectal microbiota may be a more likely element in the initiation of fistulation.  We 
found reduced bifidobacteria in Crohn’s patients both with and without anal fistulae, 
compared to patients with idiopathic anal fistulae.  This finding is consistent with 
previous reports of reduced bifidobacteria in Crohn’s disease (48) which suggests 
our experimental technique and patient population are consistent with those 
published elsewhere, however a dysbiosis or single causative organism responsible 
for anal fistulation in Crohn’s disease or across aetiologies was not seen. 
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However, both idiopathic and Crohn’s fistula tracts showed evidence of acute and 
chronic inflammation and, significantly, both groups of patients had more CD3 
positive and Ab-1 positive (monocytes, macrophages, neutrophils) cells in the luminal 
zone than the deep zone, suggesting inflammation arising from the luminal surface of 
the tract.   
 
If the inflammation is peri-luminal and therefore driven by luminal factors, but these 
factors are not live bacteria, what can be causing this inflammatory reaction?  
Endotoxin, remnants of bacterial cell walls following lysis or other proteins recognised 
as foreign may be present.  Non-bacterial infective agents were not sought in our 
experiments and nor were degraded bacterial remnants which, in the absence of 
RNA, would not have been detected by our FISH probes. 
 
Although, since we cannot find them, we cannot differentiate between luminal agents 
driving the immune response in Crohn’s and idiopathic fistulae, we can examine the 
responses themselves. 
 
Dendritic cells direct the immune response to invasion by migrating from the site at 
which they have encountered an antigen to the lymph node where they imprint T 
cells with a migration marker which sends them to the site of invasion to mount a 
local defence.  We found a reduced tendency for DC to express both gut and skin 
homing markers in Crohn’s anal fistulae compared to idiopathic fistulae.  This implies 
a less ordered immune response which might lead to ineffective bacterial killing.  If 
this finding were related to maturity of the tract alone then we would expect a similar 
low level of homing in idiopathic fistulae. 
 
Crohn’s anal fistula tracts expressed less CD65 than idiopathic anal fistula tracts.   
CD65 is a cell surface antigen found on monocytes in the blood and macrophages in 
the tissues, as well as other myeloid cells, including neutrophils and cells of the 
innate immune system.       
 
Although the proportions of CD3 positive T lymphocytes in Crohn’s and idiopathic 
anal fistula tract tissue were similar when examined with flow cytometry, 
immunohistochemistry revealed a difference between the two groups.  In samples 
with a clear luminal surface, Crohn’s patients had higher numbers of CD3 positive 
cells than idiopathic patients in both the luminal and deep zones of the fistula tract 
wall.   
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Similarities in the remaining immune cell composition of fistula tract specimens from 
both idiopathic and Crohn’s fistula patients suggest that similar persistence factors 
may be in play in both groups regardless of initial aetiology. 
 
Cytokines, including TNF, were also similar across idiopathic and Crohn’s anal fistula 
specimens with the exception of IL-17a.  Crohn’s fistula tracts expressed less IL-17a 
than both idiopathic fistula tracts and normal rectum.  The potential for IL-17a as a 
diagnostic or therapeutic target should be explored.  IL-17a is generally considered a 
pro-inflammatory cytokine and levels of both IL-17a itself and IL-17a producing cells 
are higher in the GI mucosa of Crohn’s patients than healthy controls (reviewed in 
(276)).  However, some recent evidence suggests that IL-17a may have a protective 
role in T cell mediated intestinal inflammation in vitro (277) and that IL-17 expressing 
cells can be inflammatory or protective depending on co-expression with other 
cytokines (276;278).  
 
Since there is no normal control for a fistula tract it is not clear whether the similar 
TNF levels are depressed, normal, or raised to the same degree in both Idiopathic 
and Crohn’s anal fistula.  Samples of rectal mucosa from patients undergoing 
colonoscopy to investigate fresh rectal bleeding or in colorectal cancer family history 
screening and found to have neither IBD nor CRC, showed similar cytokine levels to 
fistula tract patients but the validity of this as a normal control is unknown.  
Therapeutic strategies directed towards TNF in Crohn’s anal fistulae are often very 
successful (73) and raised TNF levels have been found in the serum of patients with 
Crohn’s anal fistulae compared to Crohn’s patients with only luminal disease (77).  
However, given that tract TNF levels are similar, and if local treatment with anti-TNF 
agents were successful, there may be value in trials of similar treatments in complex, 
inoperable or refractory idiopathic anal fistulae. 
 
We should interpret our findings on the association between rectal bacteria and tract 
immunity with caution given the multiple statistical testing used to identify them.  
Nevertheless, we found higher levels of Bacteroides were associated with higher 
levels of CLA and β7 in tract tissue generally and higher levels of CLA on DC in 
particular with great statistical confidence.  The impact of rectal bacteria on fistula 
tract immune cells and cytokines, and of luminal bacteria on luminal immune cells 
and cytokines in Crohn’s disease and Ulcerative Colitis, may represent a fruitful 
avenue of future research. 
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2.10  Summary 
 
Inflammation in anal fistula tracts is more pronounced in the peri-luminal zone of the 
tract wall, implying a luminal factor is driving the inflammatory process.  The absence 
of live bacteria associated with the luminal surface of the tract suggests that bacteria 
may not be that factor.   
 
The broad similarities in the immune cell composition of Crohn’s and idiopathic anal 
fistula tracts suggest that, at least in mature tracts, a similar process permits 
persistence.  Further, medical treatments advantageous in one group may also prove 
useful in the other, particularly where, as with anti-TNF agents, levels of the target 
molecule are similar in the two types of tract. 
 
Specific differences between Crohn’s and idiopathic fistulae such as lower levels of 
IL-17a, greater numbers of peri-luminal and deep CD3 positive T cells and impaired 
(skin and gut) homing in the tracts themselves, and an altered rectal microbiota, in 
Crohn’s disease, represent potential targets for diagnostic tests, therapy and future 
research. 
 
2.11 Limitations 
 
This study was carefully designed with several control groups and as large a study 
population as possible given the relatively specialist nature of the patient group.  
Nevertheless, several factors limit its usefulness and findings. 
 
Patient selection was limited to St Mark’s which allowed for a large throughput of 
fistula and in particular Crohn’s fistula patients, but meant that most were tertiary 
referrals with a relatively long duration of Crohn’s and/or anal fistulating disease.  
This meant that we were examining a group of well-established fistulae rather than 
newly created tracts which might be postulated to express more of the factors which 
lead to formation of the tract. 
 
The collection of samples was formalised to limit sampling error but on some 
occasions the tract diameter did not allow passage of the cannula sheath to protect 
the forceps as they entered the tract and once inside, we were only able to blindly 
pass the forceps rather than specify the location of the biopsies or their quality. It 
might be the case that influential bacteria reside in a particular part of the tract which 
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we did not sample, for example near the internal opening.  Orientation of the samples 
was also difficult. 
 
The microbiology samples demonstrated the rather surprising finding of a lack of 
clinically relevant ‘mucosa-associated’ bacteria.  Several factors have been 
discussed above which may mean this is an erroneous finding due to technical 
problems.  The washing stages of sample collection and processing may have 
cleared bacteria which were influential in vivo and although techniques were used to 
eradicate this as a factor, the most powerful of these, SEM, was only used in three 
cases and does not rule out washing as the culprit.   
 
It may also be the case that fistula tract tissue is simply not amenable to the FISH 
technique.  Although the tissue stained appropriately, FISH in the gut demonstrates 
bacteria held fast in a biofilm alongside intact mucosa and the lack of these 
structures in the tract may make it a less useful technique here; FISH has not been 
undertaken in fistula tracts before, to my knowledge. 
 
Our immunological findings are also derived from tissue which was heterogeneous in 
size, shape and depth of penetration through the wall of the tract, all of which may 
influence the number and proportions of particular cells seen. 
 
The patient groups were consecutive and although some significant differences were 
seen, the size of the groups (particularly when one considers that not all patients 
were used in all experiments) means that the study may have been under powered to 
detect more subtle differences.  In addition to this, the very large number of analyses 
including subgroup analyses performed, means the risk of type 1 error due to 
multiple testing is significant. 
 
The lack of a true control tissue for fistula also limits the immunology and particularly 
cytokine data obtained.  It is only possible to infer from our results whether one or 
other group of patients demonstrates a higher or lower level of a given factor than the 
other.  This is adequate in some circumstances, particularly given the multiple control 
groups used, but care must be taken in others, for example with TNF where, as 
discussed above, similar levels may mean high in both Crohn’s and idiopathic 
fistulae, low in both, unremarkable in both or, indeed, that our sample size was too 
small to detect the true difference. 
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3 An audit of the surgical management of anal 
fistulae: Fistulotomy in the tertiary setting can 
achieve high rates of fistula cure with an 
acceptable risk of deterioration in continence 
 
3.1 Abstract 
 
Introduction 
 
Surgery is the mainstay of treatment of anal fistulae.  Low fistulae are often laid open 
but higher fistulae present a more difficult problem.  Patient choice centres on a 
compromise between risk of recurrence and risk of impairment of continence.  We 
aimed to determine the efficacy and safety of fistulotomy at a tertiary referral centre, 
in particular the additional risk of impairment of continence following fistulotomy of 
the often recurrent, multiply-operated patients seen. 
 
 
Methods 
 
Patients undergoing surgery under one Consultant Surgeon (Professor Phillips) for 
an anal fistula during the study period (2005-2006) were identified and a thorough 
review of the patients’ clinical records was undertaken. Demographic, fistula 
anatomy, treatment and follow up data were obtained.   
 
Results 
 
Eighty-four patients underwent either fistulotomy (50) or insertion of a permanent 
loose seton.  The mean length of follow up was 11 months (SD 14.22).  In the 
fistulotomy group there was an overall ‘success rate’ of 93%. Secondary extensions 
were associated with failure to achieve cure (P=0.008).  Nine patients (20%) suffered 
a deterioration in continence after surgery. A longer time to referral was associated 
with a greater degree of impairment of final continence. 
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Conclusions 
 
It is safe and reasonable to offer fistulotomy to appropriate patients despite previous 
surgery and within the tertiary setting.  By so doing, a very high rate of healing can be 
achieved in patients who have previously failed to heal.  The additional risk of 
impairment of continence is around 1 in 5 and in the majority will represent only 
minor incontinence. 
 
3.2 Introduction 
 
Anal fistulae are common and usually occur following infection of an intersphincteric 
anal gland (81).  They lead to pain and discharge and patients often suffer recurrent 
abscesses which undergo surgical or spontaneous drainage before a period of 
quiescence and then further eruption.   
 
In the absence of Crohn’s disease, surgery is the mainstay of treatment and for low 
fistulae, fistulotomy (also known as laying open) is the standard treatment.  When a 
higher fistula is seen, sphincter-preserving operations such as ligation of the 
intersphincteric fistula tract (LIFT) (198;199), advancement flap surgery (188;192) or 
the placement of an infill material such as fibrin glue (279) or collagen plug (191) is 
often considered but the risk of recurrence is high.  Fistulotomy will cure a high fistula 
but impairment of continence may occur. Cutting setons probably produce a similar 
level of impairment of continence to fistulotomy (205) and can be uncomfortable for 
the patient. 
 
Careful anatomical and bowel function assessment can allow fistulotomy in high 
fistulae with a low rate of recurrence and an acceptable level of impairment of 
continence – similar to that seen in lower fistulae (171).  Given an appropriate length 
(1-2 cm) of preserved external sphincter, internal sphincter division leads to the 
majority of continence impairment seen after fistulotomy (171-173;178). 
 
Patient choice centres on a compromise between risk of recurrence and risk of 
impairment of continence.  The approach to this compromise of patients with a new, 
primary fistula may differ to that of a patient with multiply recurrent fistulae of a longer 
duration, who may also have suffered complications or impairment of continence at 
previous operations.  
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This study seeks to determine the efficacy and safety of fistulotomy at a tertiary 
referral centre, in particular the additional risk of impairment of continence following 
fistulotomy of the often recurrent, multiply-operated patients seen. 
 
3.3 Hypothesis and Aims 
3.3.1 Hypotheses 
 
 The anatomy, duration and aetiology of anal fistulae as well as age and 
smoking status influence surgical outcome; 
 The presence of a defunctioning stoma influences outcome; 
 Incontinence following laying open of fistulae is usually minor and, in the 
tertiary setting, additional laying open procedures add little impairment of 
continence or other morbidity. 
3.3.2 Aims 
 
The efficacy and safety of fistulotomy at a tertiary referral centre has been 
determined, in particular the additional risk of impairment of continence following 
fistulotomy of the often recurrent, multiply-operated patients seen. 
3.4 Methods 
 
3.4.1 Patient identification 
 
Patients were identified from the operation booking diary and surgical log.  Any 
patient undergoing surgery for an anal fistula under Professor Phillips during the 
study period (2005-2006) was noted and their clinical notes retrieved.  If an operation 
note for a procedure carried out on an anal fistula within this period was available, 
the records were then reviewed. 
3.4.2 Review of records 
 
A thorough review of the patients’ clinical notes was undertaken with examination of 
the clinical notes, clinic correspondence, operation records and examination results.  
Computer records of imaging tests or other investigations were also accessed where 
relevant.  Demographic, fistula anatomy, treatment and follow up data were obtained.  
A low fistula was defined as involving no more than the most caudad 1cm of 
sphincter. 
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3.4.3 Database and statistics 
 
Data were entered into a database on Microsoft Excel 2003™. The Stata software 
package - version 9.2 (StataCorp LP, College Station, Texas, USA) was used for 
performing all appropriate statistical analyses. Data were compared using Fisher's 
exact test, the unpaired t-test and the Mann-Whitney test as appropriate. 
 
3.4.4 Surgical procedures 
 
The two surgical procedures studied were fistulotomy and seton insertion.  All 
patients deemed suitable for a fistulotomy were counselled regarding the risks of 
minor incontinence (≤ flatus incontinence and 1 teaspoon of mucus leakage in 24 
hours) occurring in a quarter to a third of patients, recurrence occurring in 2-3% and 
delayed wound healing.  Patients for seton insertion were fully informed regarding the 
permanent nature of the loose seton, the occasional need for replacement and the 
small risk of ongoing symptoms requiring further drainage and/or seton insertion. 
 
Both procedures take place in the lithotomy position with the hips and knees flexed to 
around 110°.  A monopolar diathermy pad is placed on the patient’s thigh if any 
fistulotomy is to take place.  After skin preparation with antibacterial skin prep the 
patient is draped and a digital rectal examination is undertaken to gain an 
appreciation of the anatomy of the internal opening(s) and the course of the primary 
tract and any extensions.  A probe is then passed through the fistula from external to 
internal opening.  If the internal opening cannot be found using the probe or felt 
digitally, dilute hydrogen peroxide is instilled into the external opening through a 23G 
cannula and then the external opening is occluded.  A view of the anorectum is 
maintained throughout this procedure using an Eisenhammer retractor and bubbles 
entering the anal canal through the internal opening identify its position. 
 
The probe is placed carefully through the fistula tract without any pressure to avoid 
iatrogenic injury.  If the tract traverses the roof of the ischiorectal fossa it is 
sometimes necessary to apply gentle traction to the probe once the tip is at the apex 
of the tract in order for it to follow the inner aspect of the tract through the sphincters.  
An hourglass deformity of the fistula tract sometimes precludes passage of the 
Lockhart-Mummery probe and under these circumstances lachrymal probes are 
used.   
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Once the probe is successfully placed through the fistula tract, a further assessment 
of the quantity of external sphincter cephalad of the internal opening is made.  The 
amount of muscle and any distal keyhole deformity can be assessed under general 
anaesthetic but the contractile quality of the muscle can only be assessed in the 
awake patient, usually in the outpatient clinic. 
 
If adequate muscle to maintain continence to stool will remain after fistulotomy (taken 
to be 1cm in the presence of a normal bowel habit by the senior surgeon) and the 
patient consents to it, a full laying open of the fistula can take place.  If there is 
insufficient muscle or the patient does not consent to fistulotomy, a comfortable, low 
profile seton is inserted. 
 
The senior surgeon uses a 1-0 Ethibond tied with a single surgeon’s knot over two 
fingers placed on the buttock.  The loose ends of this suture are then tied back using 
a 2/0 silk suture with a single surgeon’s knot (Figure 4b).  This leaves a low, soft 
seton with small knots which is unlikely to cause problems for the patient. 
 
 
3.5 Results 
 
3.5.1 Demographic and baseline disease data 
 
Eighty-four patients underwent either fistulotomy (n=50) or insertion of permanent 
loose seton.  Results for the fistulotomy group are presented below. Mean (SD) 
length of follow up was 11 (14) months. 
 
In the fistulotomy group, 41 (82%) were tertiary referrals with a mean 1.3 (SD 1.1) 
operations prior to referral.  Fourteen (28%) had a seton in situ.  Median age was 48 
years (range 18-79) and 9 were women.  Six patients had inflammatory bowel 
disease (5 Crohn’s disease, 1 indeterminate colitis), 7 had diabetes and 1 
hidradenitis suppurativa.  Sixteen were smokers.  MRI scanning was performed in 27 
patients, endoanal ultrasound in 1 patient and both in 3.  Nineteen had no imaging 
investigations performed. 
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3.5.2 Fistula anatomy 
 
The median number of both internal and external openings was 1 (range 1-2 and 0-5 
respectively).  The positions of the primary internal openings are shown in Figure 32. 
The internal opening was palpable in 41 patients and located at the dentate line in 
33, below it in 7 and above it in 10.  Goodsall’s rule was obeyed in 76% of cases 
including 80% of external openings behind the transverse anal line.  Tract height is 
shown in Figure 33. 
 
 
Figure 32 - Position of internal openings 
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Figure 33 - Height of fistula tracts in fistulotomy patients 
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3.5.3 Impairment of continence 
 
A continence deficit was found in 13 (26%) patients at referral and included 9 
patients with minor incontinence (flatus +/- < 1 teaspoon of mucus leakage in a 24 
hour period), 3 with a greater degree of leakage and 1 with urgency. 
 
Six patients did not attend follow up or were referred for local follow up.  Following 
fistulotomy, 34% of patients (15/44) had some degree of continence deficit, of whom 
12 had minor incontinence (Figure 34).  Nine patients (20%) suffered a deterioration 
in continence after surgery (7 previously normal patients developed minor 
incontinence, 1 with minor incontinence at referral developed more significant 
leakage leading to the use of a pad and 1 developed urgency).   
 
Deterioration in continence following fistulotomy
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Figure 34 - Deterioration in continence seen post fistulotomy 
 
In the fistulotomy group, time to referral was associated with final continence.  Only 
7% of patients referred within one year suffered a decrease in continence, whilst this 
increased to 38% for patients who were referred after two years (P = 0.05).  When all 
84 patients (the fistulotomy and loose seton groups combined) were examined 
together, continence at referral was the only factor significantly associated with final 
continence; 84% of those continent at referral were continent at discharge compared 
to 27% of those incontinent at referral (P<0.001).  Fistulotomy rather than seton 
insertion (P = 0.07) and tertiary rather than secondary referral (P = 0.09) had a 
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borderline association with incontinence at discharge but after multiple logistic 
regression only continence at referral remained significant. 
 
3.5.4 Recurrence 
 
Recurrence occurred in 5 patients.  Two of these required a second fistulotomy 
following early bridging of the fistula wound and were cured following the second 
procedure giving an overall success rate of 93% (41/44).  Of the remaining 3 patients 
one had an underlying osteomyelitis of the pubis, one had Crohn’s disease and 
developed recurrence more than a year later and one developed an apparently new 
fistula after 4 years. 
 
Secondary extensions were associated with failure to achieve cure.  Ninety-seven 
percent of patients (31 of 32) without secondary extensions at fistulotomy were cured 
compared to only 60% (6 of 10) of those with them (P=0.008).  There was a trend 
towards a longer time to referral being associated with failure to heal, although this 
did not quite reach statistical significance in our cohort (P=0.09).  No other 
anatomical features were associated with healing in the fistulotomy group. 
 
 
3.5.5 Complications 
 
Six patients experienced complications other than recurrence and impairment of 
continence.  These included anal pain with no evidence of recurrence in 2 patients, 
post-operative bleeding at 2 weeks in 1, an anal fissure and pruritus ani in 1, 
overgrowth of granulation requiring cautery in the outpatient department in 1 and a 
wound infection in another.  None of these 6 patients required further surgery.  
 
One patient with a high transsphincteric idiopathic fistula with internal opening at 6 
o’clock and external opening at 4 o’clock had a stoma created at the time of 
fistulotomy and reversed 7 months later.  He had incontinence to stool at referral and 
this persisted after restoration of continuity which took place at his request. 
 
Of 9 women treated with fistulotomy, 3 had anterior internal openings, 1 a 
subcutaneous tract, 1 patient with Crohn’s disease had a high transsphincteric tract 
and 1 a low transsphincteric tract.  This latter patient had minor incontinence at 
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referral which worsened after surgery.  The other two remained fully continent 
following fistulotomy.  None developed recurrence. 
 
3.6 Tertiary referral patients 
 
Of 50 fistulotomy patients, 41 of whom were tertiary referrals, 37 were referred by 
another colorectal surgeon having undergone a mean of 1.7 previous operations (SD 
1.9).  After a mean follow up of 10 months (SD 14), 5 patients were lost to follow up 
and 4 patients suffered recurrence of fistula including 1 with early bridging who 
underwent a successful second lay open giving an overall success rate in this group 
of 29 of 32 patients (91%).  The remaining three recurrences were those patients 
with underlying osteomyelitis and delayed recurrence detailed above.   
 
At referral, 12 of 37 (32%) patients had some degree of continence impairment (9 
minor, 2 with greater leakage and 1 with urgency).  Following fistulotomy, 13 of 32 
(40%) patients had some degree of continence impairment (11 minor, 2 with greater 
leakage).  Six patients (19%) suffered deterioration in their continence following 
surgery, all to minor incontinence only. 
 
3.7 Complex fistulae 
 
Twenty seven patients (54%) who underwent fistulotomy had complex fistulae (high 
tracts, secondary extensions, inflammatory bowel disease).  In this group, one third 
of patients had impairment of continence at referral (6 minor incontinence, 1 with 
greater leakage and 1 urgency).  Following fistulotomy 3 were lost to follow up.  
Recurrence occurred in 4 patients in this group (16%) and 5 patients (20%) 
developed new or worse impairment of continence including 4 with minor 
incontinence and 1 patient with urgency.  Overall final continence impairment in this 
group was 41%, four fifths of which was minor incontinence. 
3.8 Inflammatory bowel disease 
 
Six patients (3 female) with inflammatory bowel disease underwent fistulotomy (5 
Crohn’s disease, 1 indeterminate colitis).  The patients had undergone a median of 1 
(range 0-4) operation prior to referral.  Tracts were intersphincteric in 1, low 
transsphincteric in 2 and mid or high transsphincteric in 3.  Three had minor 
incontinence at referral and one of these improved following surgery.  One patient, 
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with a low transsphincteric tract, developed recurrence over a year after successful 
fistulotomy. 
 
3.9 Setons 
 
Permanent loose seton insertion was undertaken in 28 patients deemed unsuitable 
for fistulotomy (21) or who declined fistulotomy when offered it (7).  A low profile, soft 
seton fashioned from 1 ethibond tied in a single surgeons knot with the ‘whiskers’ tied 
back with silk was placed in all cases.  Ten seton patients were women, 20 were 
tertiary referrals, 3 had inflammatory bowel disease, 3 had diabetes, 11 had 
secondary extensions and 10 had setons in situ at referral.  Two presented with 
continence impairment (1 urgency, 1 minor) and after surgery no new continence 
impairment was noted.  Median follow up was 20 months. 
 
 
3.10  Conclusions 
 
High or complex anal fistulae, including fistulae in patients with inflammatory bowel 
disease or other co-morbidities, can be successfully treated even after previous failed 
surgery and in the presence of impairment of continence.   
 
More than 80% of the present cohort had been seen in another hospital and 
undergone previous surgery which had been unsuccessful.  Patients face a decision 
when offered fistula surgery: do they opt for a modality offering a higher rate of 
success but with it a higher risk of impairment of continence, or do they opt for a 
safer but less successful method of treatment?  Previous failed surgery and a longer 
duration of symptoms may influence this decision.  In order correctly to inform 
patients, the risk of deterioration of continence following fistulotomy must be known.  
An earlier study showed that a quarter to a third of patients will develop impairment of 
continence following laying open of a tract traversing the anal sphincter and that 
internal sphincter division is responsible for the greater part of that impairment (171).   
 
In this group of mostly complex, tertiary referred, previously operated patients, the 
proportion with continence impairment at referral was 26% which rose to 34% at 
discharge.  Although this change is only 12%, some patients improved following 
surgery and 1 in 5 patients suffered deterioration in their continence following 
fistulotomy, the majority from full continence to minor incontinence. 
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As in an earlier study, lay-language has been used to describe impairment of 
continence.  This is because the utility of these data is in advising patients of their 
likely outcome whilst obtaining informed consent. The Vaizey (280) and Wexner 
(281) scores, which add different aspects of incontinence to produce an overall score 
and which value flatus and solid incontinence with an equal weight, may be less 
useful in the clinical setting. 
 
Although 5 patients developed fistula recurrence, two were cured following a second 
fistulotomy and of the remaining three, two developed a new fistula more than a year 
after treatment, one in the presence of Crohn’s disease. The third had an underlying 
osteomyelitis.  The final healing rate was 93%.  A previous study  demonstrated 
healing following fistulotomy in 97-98% of patients in a  large cohort of 
cryptoglandular fistulae using the same principles of treatment (171).  In the present 
study, patients with more complex tracts in the form of secondary extensions were 
more likely to recur. 
 
It is not true to say that all patients should undergo fistulotomy.  The decision making 
process employed in this study has been previously described (171).  Briefly, an 
assessment is made, usually in Outpatients, of the likely residual sphincter following 
a planned fistulotomy in order to ensure that at least 1-2cm of good quality contractile 
muscle will remain, along with an assessment of the current and likely future bowel 
habit (IBD, IBS, chronic diarrhoea).  This requires a thorough physical examination, 
sometimes aided by high quality imaging with MRI or endoanal ultrasound (rarely), to 
identify the position of internal and external openings as well as assessment of any 
extensions or collections. 
 
Alternative techniques in those wishing to avoid any impairment of continence 
including permanent loose seton insertion, tight setons, infill materials such as fistula 
plugs and glues, the LIFT procedure and advancement flaps offer alternatives to 
fistulotomy but risk failure and therefore further abscesses, fistula recurrence and 
future procedures.  LIFT has been most extensively reported in low anal fistulae with 
success rates of around 80% (198) which falls to 60% (200) in recurrent tracts.  Infill 
materials have suffered a waning success rate down to around 30% with fistula glues 
(279) and 50% with plugs (191).  Nevertheless, all three techniques are repeatable 
and none precludes future surgery in any form.   
 
 142 
A longer time to referral seems to be associated with a higher risk of both recurrence 
and deterioration in continence.  This may be because later referral implies more 
previous operations or selects those patients with more complex fistula anatomy or 
biology. 
 
3.11 Summary 
 
It is safe and reasonable to offer fistulotomy to appropriate patients despite previous 
surgery and within the tertiary setting.  By so doing, a very high rate of healing can be 
achieved in patients who have previously failed.  The additional risk of impairment of 
continence is around 1 in 5 and in the majority will represent only minor incontinence. 
 
3.12 Future work: a prospective database 
 
The aspects of outcome in fistula surgery which are crucial to the patient are long 
term recurrence, continence impairment and quality of life.  There are few data on 
these subjects beyond a year or so in the literature and care must be taken when 
comparing the outcome from different procedures since a. there is often significant 
selection bias; higher fistulae are less likely to be laid open, more complex fistulae 
are rarely treated with infill materials etc., and b. heterogeneity in technique between 
surgeons, for example in long term loose seton material choice, may limit the value of 
results found. 
 
We have begun prospective data collection on all fistula patients seen in the 
outpatient department.  Simple tick box sheets (Appendix 3, page 213) are filled in at 
the initial outpatient appointment, in theatre immediately after surgery, and at each 
subsequent follow-up appointment. 
 
The demographics and comorbidities of the patient, anatomy of the fistula, 
investigations, details of surgery and outcomes in terms of recurrence, continence, 
wound healing and overall satisfaction are monitored throughout the patient journey. 
 
As well as monitoring recurrence and continence impairment rates, the overall 
satisfaction gained from early long term seton use, laying open, (often repeated) 
advancement flap surgery and newer techniques in the management of high fistulae 
can be determined.   
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Prognostic factors will be sought that might help determine that seton placement, for 
example, is likely to fail to produce a satisfactory outcome, perhaps because of the 
presence of a high extension of the fistula which might act as a ‘sump’, pouring pus 
down into the drained fistula tract and preventing the palliation hoped for.  Another 
example might be factors that improve the chance of success in advancement flap 
surgery, or predict failure early to prevent fruitless repeated operations. 
 
3.13 Limitations 
 
This retrospective study represents the practice of a single surgeon and examines 
only two of the techniques he uses in the management of anal fistulae.  The anatomy 
of the fistulae has been defined by the same surgeon undertaking surgery and 
deciding on the procedure to be offered to the patient.   
 
Assessment of healing and recurrence may be imperfect since long term follow up 
may be undertaken back at the secondary care institution in some cases although 
our median follow up was comparable with the published literature. 
 
Assessment of incontinence did not utilise a standardised tool as discussed above 
and although the reasoning behind this is, in my view, sound, this limits comparison 
with other studies in which such tools are used. 
 
The group of patients is small and heterogeneous.  Subgroup analysis and 
conclusions based thereon must be considered carefully and a largely tertiary group 
of patients is not the same as a group of patients with complex fistulae hence the 
analysis of these smaller groups. 
 
The exact process for determining which procedure to offer a patient, whilst clearly 
described, remains to some extent subjective albeit in the hands of the senior 
surgeon alone, and may not be applicable directly in other contexts.  It is likely that 
patients arrive at St Mark’s with different expectations and tolerance of impairment of 
continence to those of a patient with a new fistula which informs the surgeon’s 
discussion with the patient and selection of the appropriate procedure. 
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4 An audit of the medical and surgical management 
of Crohn’s and non-Crohn’s rectovaginal fistulae 
4.1 Surgical management of rectovaginal fistulae in a tertiary 
referral centre: many techniques are needed 
4.1.1 Abstract 
 
Introduction 
 
The mainstay of treatment for rectovaginal fistulae (RVF) is surgery.  Published 
success rates vary; initial success being around 50% rising to 80% with repeated 
surgery.  Crohn’s fistulae are more likely to recur.  
 
Methods 
 
A retrospective study of rectovaginal fistula repair between 2003 and 2008 was 
performed in a tertiary referral centre.  Patients undergoing surgery for a rectovaginal 
fistula under the senior author during the study period were identified and their 
clinical notes reviewed.   
 
Results 
 
Thirty-five patients underwent 50 operations.  Their median age was 42 years and 
83% were tertiary referrals. Two patients were lost to follow-up and 19 of 33 patients 
were ultimately healed (58%) after a mean of 1.4 operations.  Median time to 
success was 11 months (range 2.5 – 48).  The ‘curative’ group had an overall 
success of 73% (19 of 26).  Seventy-five percent of non-IBD patients and 67% of 
those with Crohn’s disease had successful treatment of their RVF.   
 
Twenty-four of thirty-five patients (67%) underwent creation of a stoma.  Sixteen of 
twenty-four (67%) were deemed fit for restoration of continuity. No demographic or 
disease related factors were found to influence healing. 
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Discussion 
  
Rectovaginal fistulae require a range of surgical approaches, both abdominal and 
anal.  A variety of different anal techniques is necessary, depending on the integrity 
of the anal sphincter and the presence or absence of perineal descent/internal 
intussusception.  There remains significant scope for improvement.  
 
4.1.2 Introduction 
 
Fistulae to the vagina from the anus or low rectum are variously called ano-vaginal or 
rectovaginal fistulae (RVF).  The latter term has been employed in this article.  They 
are uncommon.  RVF may arise in the vaginal midline following obstetric injury, 
perianal sepsis or in patients with Crohn’s disease, as well as following radiation, 
malignancy or iatrogenic injury.  Low anastomoses after anterior resection or ileoanal 
pouch formation may fistulate to the vagina.   
 
There are also abdominal sources, such as appendicitis, terminal ileal Crohn’s 
disease and diverticular disease, where the fistula, rather than being in the posterior 
midline, usually is to one of the vaginal fornices.  These can best be inspected using 
a rigid sigmoidoscope in the vagina. 
 
The predominant symptom is of passage of stool or flatus vaginally.  Whereas it is 
usually wise to accept the likely presence of a RVF based on the history, women can 
sometimes be mistaken, particularly when an anterior internal sphincter injury results 
in flatus blowing across the vaginal introitus causing an abnormal sensation often 
interpreted as a fistula. 
 
The commonest cause of rectovaginal fistula is obstetric injury.  The fistula usually 
occurs secondary to a third or fourth degree tear which latter is sustained during 
approximately 5% of labours.  One to two percent of these will go on to suffer a 
rectovaginal fistula (207).  A large study of women undergoing vaginal delivery found 
0.1% developed a rectovaginal fistula (208).  Injury to the rectovaginal septum in its 
lowest part is synonymous with an anal sphincter injury, in its upper part with a 
rectocele, and to both parts with perforation of the central portion with a rectovaginal 
fistula.   
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Another frequent cause of RVF is Crohn’s disease.  In a population based-survey of 
Crohn’s disease patients, 35% were found to have fistulae, 9% of whom had a 
rectovaginal fistula (3), which appeared at a mean age of 34 years (209).  A larger 
study of 886 patients revealed that rectovaginal fistulae may occur in up to 10% of 
patients with Crohn’s disease (209).  RVF is more common in association with 
colonic (23%) than small bowel (3.5%) Crohn’s disease (210;211).   
 
Surgery for rectovaginal fistula is difficult and success rates are modest, particularly 
in Crohn’s disease.  Recurrence, a permanent stoma, dyspareunia, anal stenosis and 
incontinence may all ensue. 
 
The outcome of repair is uncertain.  Some reports have suggested success in 50% 
after one operation rising to 80% after many (224;225).  Others report similar results 
in Crohn’s disease (226;228) and non-CD patients (227).  In one recent Crohn’s 
disease series advancement flaps fared badly; proctectomy was required in 14-22% 
of patients.  Success rates were slightly higher in non-CD patients.  A high body 
mass index (BMI) and multiple repairs were associated with failure.  Perhaps 
surprisingly, quality of life was no different whether the RVF was successfully 
repaired or not.  Less than half the patients were sexually active at follow-up and of 
these a quarter suffered from dyspareunia. 
 
Studies of various types of transanal rectal advancement flaps (TRAF) have been 
published, usually containing few patients with varied aetiology.  Success rates  
range from 43% to 92% for ‘above down’ flaps (141;225;228;236;237), around 70% 
for ‘from below up’ (sliding skin) flaps (242), and 60% to 75% for sleeve 
advancement (240;241).  Pliable tissues are required, so Crohn’s disease or 
extensive scarring from sepsis or previous radiation may preclude these techniques. 
Adjuncts such as levatorplasty or Martius flaps may be used to bolster repairs.  One 
study reported a 75% success rate with Martius flaps in 8 women with RVF or 
suprasphincteric anal fistulae (246).  Similar rates have been reported by others 
(244;245;247). 
 
Many surgeons advocate closure approached from the high pressure, rectal side, but 
there are advocates for a transvaginal approach, access being easier.  A systematic 
review has found little difference in healing rate between either approach (260).  
Several studies have shown no advantage to defunctioning (235;259;261;282). 
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As with high anal fistulae, glues, plugs and bioprosthetic sheets are intuitively 
attractive to some, but numbers are few and experience limited (Table 14).  
 
Table 14 - Studies of sphincter saving infill materials in RVF repair 
 
Technique Study Year Success rate in RVF 
Fistula glue Venkatesh 
(146)  
1999 6/8 (75%) 
 Cintron (147) 2000 1/3 (33%) 
 Loungnarath 
(151) 
2004 1/3 (33%) 
 Singer (152) 2005 0/1 (0%) 
 Vitton (143) 2005 3/4 (75%) 
 Grimaud (144) 2010 0/3 (0%) 
 de Parades 
(154) 
2010 0/5 (0%) 
Fistula plug Ellis(249) 2008 6/7 (86%) 
 Thekkankattil 
(283) 
2008 1/7 (14%) 
 Gonsalves 
(251) 
2009 3/5 (40%) 
Bioprosthetic interposition Ellis (249) 2008 22/27 (81%) 
 Schwandner 
(159) 
2009 19/21 (90%) 
 
Muscle transposition might seem like using a sledgehammer to crack a walnut, but 
RVF surgery is difficult and recurrence is frequent.  Gracilis, having only a vestigial 
function and a convenient axial blood supply, has been favoured over other thigh and 
buttock muscles.  Wexner and colleagues (2008) reported success in 5 of 6 non-
Crohn’s RVFs treated with gracilis muscle interposition but just 3 of 9 with Crohn’s 
disease (254).  Further small series in the last 2 years have reported similar findings, 
often in recurrent fistulae (255-257), although Furst and colleagues reported a high 
success rate in their series of Crohn’s patients. 
 
In Crohn’s patients, diversion and proctectomy are sometimes required.  Proctitis 
increases the chance of a patient with perianal Crohn’s disease requiring 
proctectomy, as does anal stenosis.  Proctectomy rates in patients with rectovaginal 
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fistula vary from 20% to 60% (131;133;229;230), with some decline in recent years, 
perhaps in response to improved medical management.   
 
Besides use for permanent diversion, a stoma may be used to defunction the 
perineal area with the hope that future reversal might become possible.  A small 
study by Yamamoto and colleagues reported 6 cases of RVF where early 
improvement in 4 was followed by relapse within three years and ultimately 
proctectomy in all 6 cases (34). 
 
A large study from the Cleveland Clinic published in 2010 retrospectively examined 
125 patients treated for RVF of various aetiologies.  Over a 10 year period, 184 
operations were performed with an initial success rate of 57% that rose to 87% of 
patients after a mean of 1.5 operations (235).  Smoking and the presence of Crohn’s 
disease were associated with a higher chance of failure.  Only 34% underwent 
temporary faecal diversion and this conferred no benefit.  Gracilis interposition was 
their most successful procedure.   
 
Variable responses to medical therapies for rectovaginal fistulae in patients with 
Crohn’s disease have been reported. There is only limited evidence of response of 
rectovaginal fistulae to cyclosporine, azathioprine or 6-mercaptopurine 
(94;231;284;285) and the response is not maintained in most patients.  The anti-TNF 
therapy, infliximab, allowed closure of 61% of rectovaginal fistulae when infliximab 
was given at weeks 0, 2 and 6 in the Accent II trial (A Crohn’s Disease Clinical Trial 
Evaluating Infliximab in New Long-term Treatment Regimen in Patients with 
Fistulising Crohn’s Disease) and infliximab provided a longer duration of closure than 
placebo when assessed by history of symptoms typical of draining rectovaginal 
fistulae or where possible physical examination (233). 
 
One surgeon’s referral practice and outcomes over a 6 year period are reported 
below.   
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4.1.3 Hypothesis and Aims 
4.1.3.1 Hypotheses 
 
 The anatomy, duration and aetiology of rectovaginal fistulae as well as age 
and smoking status influence surgical outcome; 
 The type of surgery carried out on rectovaginal fistulae influences outcome; 
 The presence of a defunctioning stoma influences outcome; 
4.1.3.2 Aims 
 
 To describe the surgery on patients with rectovaginal fistulae under a single 
surgeon at a tertiary referral centre over a five year period; 
 To describe the factors influencing surgical outcome in these patients; 
4.1.4 Methods 
4.1.4.1 Patient identification 
 
Patients were identified from the operation booking diary and surgical logs, clinic 
letters (available from 2006 onwards), the CIS system and the ‘medsecs’ system 
drive containing available data from before that point.  Any patient undergoing 
surgery for a rectovaginal fistula by Professor RKS Phillips during the study period 
(2003-2008) was identified and their clinical notes drawn. 
4.1.4.2 Review of records 
 
A thorough review of the patients’ clinical notes was undertaken with examination of 
the clinical notes, clinic correspondence, operation records and examination results 
performed.  Computer records of imaging tests or other investigations were also 
accessed where relevant. 
 
4.1.4.3 Database and statistics 
 
Data were entered into a database on Microsoft Excel 2003™. The Stata software 
package - version 9.2 (StataCorp LP, College Station, Texas, USA) was used for 
performing all appropriate statistical analyses. Data were compared using Fisher's 
exact test, the unpaired t-test and the Mann-Whitney test as appropriate. 
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4.1.4.4 Surgical approach 
 
In outpatients, the mainstay of diagnosis was clinical.  Examination of the vagina with 
a rigid sigmoidoscope, permitted fistulae to the fornices or the posterior midline to be 
seen (they are rarely present anywhere else), the latter aided by using a bevelled 
proctoscope in the vagina, such as a Graham-Anderson.  Anal ultrasound was 
performed in all patients to assess the state of the anal sphincters.  MRI was not 
found to be useful as the tracks, being usually epithelialised, show no enhanced 
signal.  Clinical assessment of perineal descent and internal intussusception 
completed the examination. 
 
Perineal descent can be checked by placing the thumb on the ischial tuberosity with 
the patient in the left lateral position and observing descent below the imaginary line 
joining both tuberosities.  Internal intussusception can be determined clinically by 
observing with a rigid sigmoidoscope a tongue of anterior wall descending on 
straining at rigid sigmoidoscopy, or on proctography, or in theatre using Babcock 
forceps. 
 
Patients with Crohn’s disease were assessed for their overall level of sickness 
(unlikely to be related to any fistula and guiding any discussion towards ablative 
surgery) and in those otherwise well, the state of the rectum. 
 
Selection of the appropriate surgical approach is summarised in Figure 35. 
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Figure 35 - Flowchart for selection of surgical procedure 
 
 
In essence, almost all patients with an intact anal sphincter on ultrasound and an 
anastomosis resulting in a potential 2cm+ distal cuff underwent an abdominal 
procedure with mucosectomy and colon/pouch pull-through.  Patients without an 
anastomosis but with a sufficiently high rectovaginal fistula to make perineal access 
difficult also underwent some form of pull-through procedure. 
 
The remaining fistulae were treated using an anal, perineal or vaginal approach.  The 
determining questions were: 
 
a) Lower Injury, sphincter broken.  Did the anal ultrasound show an intact or a 
broken anal sphincter?  If broken, then the approach was by a sphincter 
repair with the dissection cephalad beyond the fistula to the pouch of Douglas 
and both pelvic sidewalls.  The fistula was divided and the rectal, high 
pressure part repaired from within the rectovaginal septum.  An adjunct of 
either a levatorplasty (when the adjacent tissues were supple and easily 
opposable) or a Martius flap (when more rigid) was used. 
b) Lower injury, sphincter intact, perineal descent.  If the anal ultrasound showed 
an intact anal sphincter, then the key question was whether there was clinical 
 152 
evidence of internal intussusception or perineal descent.  If there was, then a 
transanal, ‘Delorme’s-style’ advancement flap was used, usually without a 
stoma being constructed at St Mark’s. 
c) Lower injury, sphincter intact, no perineal descent.  If the anal sphincter was 
intact and if there was also no perineal descent/internal intussusception, a ‘U’ 
shaped incision was made at the posterior introitus and the rectovaginal 
septum was entered above the anal sphincter.  The dissection proceeded as 
for (a) above but without the perineal incision or need for sphincter repair. 
 
The ‘Delorme’s-style’ advancement flap may be circumferential or hemi-
circumferential and is akin to a Sarles’ operation for rectocele.  The submucosal 
plane is developed almost to mid-rectal level.  The fistula is divided, any epithelium is 
removed, and the first level, a direct repair, made.  The intussuscepting circular 
smooth muscle wall is then drawn down and sutured caudad as the second level 
repair, re-enforcing the first.  Tension free mucosa is then sutured caudad still, 
sometimes accepting a small amount of anal ectropion, as the third level of repair. 
 
Consent for a stoma (except for ‘Delorme’s-style’ flap surgery) was usually sought 
and almost always given. 
 
4.1.4.5 Crohn’s patient data collection 
 
Demographic and disease specific data were collected on patients with Crohn’s 
disease including smoking status, family history of inflammatory bowel disease, site 
and duration of luminal and perianal disease and drugs used during the study period.  
Various Crohn’s medications were used including anti-TNF agents, steroids, 
antibiotics (metronidazole and ciprofloxacin), thiopurines, 5 ASAs and methotrexate. 
 
 
4.1.5 Results 
 
4.1.5.1 Demographic and baseline disease data 
 
Thirty-five patients underwent 50 operations over 5 years, being on average 7 
cases/year.  Their median age was 42 years and 83% were tertiary referrals (Figure 
36) having undergone a median of 2 (range 0-6) operations before referral to St 
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Mark’s.  The aetiology was Crohn’s disease in 10 cases, obstetric in 10, anorectal 
sepsis in 6, iatrogenic in 4, Bartholin’s sepsis in 3, UC in 2 and pemphigus, 
radiotherapy and chemotherapy in 1 patient each (Figure 37).  Thirteen patients were 
smokers and one had peripheral vascular disease.  
 
Referral pattern of rectovaginal fistula study patients
83%
17%
Tertiary
Secondary
 
Figure 36 - Referral pattern of rectovaginal fistula study patients 
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Figure 37 - Aetiology of rectovaginal fistula study patients 
 
4.1.5.2 Overall success 
 
Two patients were lost to follow up and 19 of 33 patients were ultimately healed 
(58%) after a mean of 1.4 operations.  This represented a success rate of 68% in 
non-IBD patients and a 40% rate in those with Crohn’s disease.  The median time to 
success was 11 months (range 2.5 – 48).  When loose seton patients were excluded 
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(as with a seton in place they cannot heal), the overall success for ‘curative’ cases 
was 19 of 26 (73%), being 75% of non-IBD patients and 67% of Crohn’s cases. 
 
4.1.5.3 Abdominal operations 
 
Eight patients including 1 with Crohn’s disease underwent abdominal operations, two 
with an intended permanent stoma (proctocolectomy and end ileostomy [CD], pouch 
excision), and 6 restorative (colonic pouch, rectal advancement, pouch 
advancement, Soave x 3).  Two patients developed recurrence following Soave 
procedures, One of these underwent successful perineal repair, re-utilising a 
previously placed adjunctive omental flap, while the other underwent a repeat Soave 
that left a pinhole fistula, for which she declined further treatment. The final success 
rate in the whole group was 88% after a mean of 1.25 operations.  Five of the 6 
patients with restorative procedures had reversal of their stomas after a mean of 4 
months.  Complications included delayed healing in 1 perineal wound, an incisional 
hernia in 1 laparotomy wound, dyspareunia in one woman (present at referral), and 
impaired continence in a patient who arrived at St Mark’s already with a stoma. 
 
4.1.5.4 Lower Injury, sphincter broken.   
 
Anal ultrasound showed a significant sphincter defect and a sphincter repair with an 
adjunct was undertaken. 
 
Six patients underwent nine perineal operations involving an overlapping sphincter 
repair, direct repair of the fistula, and an adjunct (levatorplasty 2 operations, Martius 
flap 5).  There were 5 tertiary referrals, 3 smokers, 1 Crohn’s patient and all had a 
degree of tissue loss.  Four had obstetric injuries and a stoma was used in all 6. 
 
Only 2 of 6 patients (33%) healed.  No redo procedures were successful.  Of the 4 
failures, 1 went on to successful lay open, 1 had a seton inserted, 1 was satisfied 
with a colostomy and 1 declined further surgery.  Four stomas were later closed.  No 
dyspareunia or anal stenosis was reported. 
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4.1.5.5 Lower injury, sphincter intact, perineal descent.  
 
Anal ultrasound showed an intact anal sphincter and perineal descent/internal 
intussusception was present on clinical examination so a ‘Delorme’s-style’ 
advancement flap was undertaken. 
 
Twelve patients underwent 13 Delorme’s-style advancement flap repairs.  Ten were 
tertiary referrals, 4 had obstetric injuries, 3 had Crohn’s disease and 1 was of 
Bartholin’s sepsis origin.  Six were smokers and one had peripheral vascular 
disease.  The median length of stay was 2 days.  Five patients (already) had stomas. 
 
One patient was lost to follow-up and of the remaining 11, the initial procedure was 
successful in 6 (55%).  One patient had a successful redo Delorme’s-style procedure, 
one went on to successful lay open, one had only a pinhole recurrence and wanted 
no further intervention, one was offered further surgery but declined a defunctioning 
stoma and therefore further attempts at repair, and one had a permanent seton 
inserted following recurrence.  Overall ‘success’ in this group was 73% (8 of 11 
patients) with 82% of patients satisfied with their outcome.  There were three 
complications in the group. Difficulty in evacuation occurred in 1 patient and two 
patients required a short period of Hagar dilatation for temporary anal stenosis. 
 
4.1.5.6 Lower injury, sphincter intact, no perineal 
descent  
 
Anal ultrasound showed an intact anal sphincter and perineal descent/internal 
intussusception was absent so a ‘U’ shaped incision at the introitus with direct repair 
with an adjunct was undertaken. 
 
Six patients underwent seven procedures utilising a ‘U’ shaped incision at the 
posterior introitus.  Dissection was in the rectovaginal septum to the pouch of 
Douglas and both pelvic sidewalls with direct repair of the fistula and an adjunct.  All 
were tertiary referrals; 3 had obstetric injuries, 1 had Crohn’s disease, 2 were 
smokers, all had stomas.  Adjuncts were levatorplasty in 2, Martius flap in 3 and 
omentoplasty (mobilised during earlier Soave procedure) in 1.   
 
After the initial procedure, 3 of 6 patients healed and 2 recurred with much smaller 
tracts, one having few symptoms and being satisfied, the other continuing to be 
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symptomatic but without wishing to undergo further surgery.  The final patient had a 
second attempt via this approach, which failed, a Delorme’s-style advancement flap, 
that also failed, and finally successful lay open with no deterioration in continence.  
Five of the six patients in the group were therefore satisfied with their final outcome 
(83%).  The stoma was reversed in all 6 at a median of 4 months (range 3-23 
months).  Two women later suffered dyspareunia; they had altogether undergone 4 
and 6 perineal operations respectively by the end of the study period.  There was no 
anal stenosis. 
 
4.1.5.7 Miscellaneous operations 
 
Seven patients underwent seton insertion.  Four were Crohn’s patients on medical 
therapy and one patient had UC and a seton on arrival at St Mark’s which she opted 
to have changed to a more comfortable, low profile seton.  The other two patients, 
with obstetric injuries, had undergone previous perineal repairs and one had anal 
stenosis following a Delorme’s-style advancement flap; both opted to keep a 
permanent loose seton.  No dyspareunia was reported. 
 
One patient underwent lay open following 5 failed attempts at repair (both before and 
at St Mark’s).  Her stoma was reversed 4 months afterwards (23 months after 
creation) and, surprisingly, continence was acceptable. 
4.1.5.8 Stomas 
 
Twenty-four of thirty-five patients (67%) underwent creation of a stoma either before 
referral (11) or during treatment at St Mark’s (13).  Sixteen of these twenty-four (67%) 
underwent restoration of continuity or were referred back to their local unit for the 
procedure.   
4.1.5.9 Factors influencing outcome 
 
The use of a stoma, smoking, tissue loss, size and duration of fistula, the presence of 
IBD or obstetric injury, the patient’s age, and concomitant sphincter injury were not 
associated with healing.  
 
Success rates were similar whether the stoma was formed some time before an 
attempted repair (10 of 14 patients), or at the time of repair (5 of 7 patients). 
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4.1.5.10 Complications 
 
The principle complication was recurrence.  One third of patients with a defunctioning 
stoma never had it reversed.  Four patients had new or pre-existing dyspareunia, 5 
had transient anal stenosis that responded to regular Hagar anal dilatation over two 
months, and 3 developed wound problems following surgery.  There were no deaths. 
 
4.1.5.11 Crohn’s patients undergoing surgery 
 
The median age of the 10 Crohn’s patients who underwent surgery was 44 (range 
19-75).  Eight were tertiary referrals, one had sustained an obstetric injury, one had 
Bartholin’s sepsis, three smoked, and one had peripheral vascular disease.  Surgery 
performed included Delorme’s-style procedure in 3, perineal approach and sphincter 
repair in 1, ‘U’-shaped incision at introitus with direct repair and levatorplasty in 1, 
seton insertion or replacement in 4 and panproctocolectomy in 1.  Of the 3 patients 
who underwent Delorme’s-style advancement flap surgery, all three healed with no 
recurrence.   
 
Both of the patients undergoing a perineal approach had defunctioning stomas sited 
but suffered recurrence.  Four patients had setons inserted or replaced, one of whom 
had a defunctioning stoma at referral to St Mark’s.  Two patients were offered 
panproctocolectomy with end ileostomy formation and one patient underwent this 
procedure, the other opting to keep her seton in situ.  Two patients had their stomas 
reversed 4 and 6 months after surgery.   
 
Complications other than recurrence included anal stenosis in 4 patients (present in 3 
at referral).  Wound problems were reported by two patients; one ileostomy wound 
suffered delayed healing and in one patient who underwent proctocolectomy, the 
perineal wound required further EUA and marsupialisation. 
 
Eight patients used medication for Crohn’s disease either before or during the study 
period.  Four used anti-TNF agents, seven Azathioprine, six antibiotics 
(metronidazole and ciprofloxacin), seven steroids, two 5 ASA agents and one patient 
used methotrexate.  None of these medications led to successful closure of the 
fistula in any patient although all produced some improvement in most patients.  
Complications of drug use included an allergic reaction to infliximab, neutropenia, 
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fever and suspected pneumonitis in three patients on azathioprine, nausea and 
diarrhoea on ciprofloxacin, low mood on steroids and nausea on methotrexate. 
 
 
4.1.6 Discussion 
 
Surgical results are uncertain, which means that women with few symptoms, such as 
flatus only vaginally and with a pinhole fistula, should be counselled to try to avoid an 
operation, although few will actually heed such advice, the presence of a fistula being 
abhorrent to most. 
 
Given the uncertainty, it is wise to consider the possibility of failure from the outset 
and the woman’s likely response to that.  This study, as well as others, has failed to 
demonstrate a benefit of a stoma.  But most multiply failed cases will at some stage 
or other end up having an attempt at repair covered with a stoma, whatever the 
evidence.  Among other things, a woman confronted by unsuccessful surgery may 
wonder whether earlier use of a stoma might not have made a difference.  The fistula 
already being abhorrent, many women, being made aware of this possible future 
conundrum, will choose to have a stoma from the outset.  For them, handling any 
future failure may be easier if they know they have ‘given their all’ when repair 
attempts have been made. 
 
Many strategies are needed.  Abdominal approaches are probably best when 
anastomotic fistulae to the vagina have a sufficient residual rectal cuff below them, 
permitting a pull through (or ‘Soave’-type) operation with mucosectomy and endo-
anal anastomosis; success rates are also highest. 
 
Much more difficult is when there is an anastomosis and a cuff, but the fistula actually 
arises below this at the dentate line (as may be the case with an ileo-anal pouch in 
IBD).  A permanent seton may be the least bad option, permitting continual natural 
defecation with prevention of worsening of sepsis. 
 
In a young and highly motivated individual with a colo-vaginal anastomotic fistula 
without a distal cuff to permit a standard pull-through, the Turnbull-Cutait operation 
may be tried (although not used here) (286), with reasonable success in highly 
selected cases.   
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There is no ‘one-size fits all’ perineal approach.  It does not seem logical to raise an 
advancement flap while ignoring a significant underlying anal sphincter injury, nor 
point in damaging an intact anal sphincter by performing some sort of lay open and 
repair.  Anal ultrasound seems key to a rational approach. 
 
Modern technology has supplied a number of new options that were not tested in this 
group of patients, from glues through fistula plugs to supporting biological 
membranes.  On the whole, fistulae to the vagina are short and frequently 
epithelialised, a group not faring well with glues.  Fistula plugs are simple to use but 
published experience is limited (Table 14).  The rectovaginal septum is very thin in 
many patients with a rectovaginal fistula, making the idea of additional support with a 
biological membrane attractive to some surgeons (Table 14) yet abhorrent to other 
surgeons contemplating an avascular foreign body in a contaminated wound. 
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4.2 The clinical course of rectovaginal fistula in Crohn’s 
disease in the infliximab era 
 
4.2.1 Abstract 
 
Introduction 
Crohn’s disease related rectovaginal fistulae (RVF) are common and very 
unpleasant.  They frequently recur after both medical and surgical treatment.  There 
are limited data describing the natural history of Crohn’s RVF in the infliximab era.   
 
Methods 
A retrospective review of patients with Crohn’s disease and rectovaginal fistula seen 
at St Mark’s hospital between 2000 and 2008 was carried out.  Demographic, clinical, 
surgical and outcome data were obtained. 
 
Results 
Crohn’s rectovaginal fistulae were healed in 35% (13/37) of women, following 
multiple surgical and medical interventions.  Surgery healed half (6/13) of these 
fistula with others palliated by seton insertion or defunctioning stomas.  Only half 
(6/13) the stomas created were reversed.  Most medical interventions induced 
improvement in patients’ symptoms but robust healing occurred in only 7 women and 
side effects, although mostly minor, were common.   
 
Discussion 
Rectovaginal fistulae still represent a difficult problem for clinicians and are very 
unpleasant for their sufferers.  Further research in techniques already identified may 
produce improved outcomes in the near future and should be pursued. 
 
4.2.2 Introduction 
 
Rectovaginal fistula (RVF) occur in up to 10% of women with Crohn’s disease and 
are extremely unpleasant (209).  Predominant symptoms include the passage of 
wind, discharge or stool from the vagina.  They are more common in colonic (23%) 
than small bowel (3.5%) disease (210;241).   
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Surgical repair is difficult and recent studies report success rates of around 40-60% 
at first repair rising to 60-80% after multiple attempts (235;260;261).  Crohn’s RVF 
were more likely to recur than those of obstetric origin (235).  Immunomodulator use 
may be associated with success and smoking with failure (261).  Diversion and 
proctectomy are sometimes required.  Proctectomy rates have fallen in recent years, 
perhaps due to improved medical treatment, but rates in excess of 20% have been 
reported (13;131;133;229;230). 
 
Medical treatment of Crohn’s RVF is also of limited efficacy although infliximab 
shows promise in producing robust remission in some patients.  Thiopurines and 
cyclosporine produce a limited and brittle response in most patients 
(94;231;284;285).  The Accent II trial (A Crohn’s Disease Clinical Trial Evaluating 
Infliximab in New Long-term Treatment Regimen in Patients with Fistulising Crohn’s 
Disease) examined maintenance infliximab use and included a subset of RVF 
patients who experienced remission in 60% of cases with a longer duration of 
cessation of symptoms than placebo (233). 
 
Combined infliximab and surgical therapy has also shown promising results (234). A 
study of 51 patients undergoing staged or definitive surgery for Crohn’s rectovaginal 
fistula with an arm receiving preoperative infliximab induction and a second without, 
found that 11 of 25 (44%) surgery only patients healed compared to 16 of 26 (62%) 
in the infliximab + surgery group although the difference was not statistically 
significant.  Time to healing was significantly reduced in the infliximab group, 
however, from 8.1 to 2.9 months, from which it is reasonable to infer that perhaps a 
larger group might have demonstrated improved healing with infliximab.  
Interestingly, all patients who underwent seton insertion before definitive surgery 
healed.  Faecal diversion did not improve remission rates.  Proctectomy was 
undertaken in 36% of the surgery only group and 19% of the infliximab plus surgery 
group, although again the difference was not significant (p=0.25).   
 
A previous report on the natural history of RVF in Crohn’s disease treated at St 
Mark’s Hospital during the pre-infliximab era found that of 27 patients followed for 
over 5 years, 22 (81%) were healed at final follow up, the majority following surgical 
intervention, after a median  26 months of treatment.  Eight of these healed patients 
(30%) required proctectomy.  Only 3 of 27 were healed by medical treatment alone 
(13). 
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4.2.3 Aims 
 
We aimed to examine the natural history of Crohn’s RVF in the era of anti-TNF 
agents and identify the outcome that these women currently experience. 
 
 
4.2.4 Methods 
 
Patients with Crohn’s disease and a rectovaginal fistula, seen at St Mark’s hospital 
between 2000 and 2008, were identified using computerised patient correspondence, 
operating diaries and the Clinical Information System.  A retrospective review of their 
notes was carried out and demographic, clinical, surgical and outcome data were 
obtained. 
 
4.2.5 Results 
 
4.2.5.1 Demographic and baseline disease data 
 
Thirty-seven women with a median age of 44 years (range 19-75) were treated for 
rectovaginal fistula associated with Crohn’s disease at St Mark’s Hospital between 
2000 and 2008.  Twelve women were smokers and four had peripheral vascular 
disease but none had diabetes, HIV or other immunosuppressive diseases.  The 
majority of the fistula were small although 3 women had large (>1cm diameter) 
openings.  Thirteen (35%) had a family history of inflammatory bowel disease. 
 
The median duration of luminal and perianal Crohn’s disease were 14.5 and 11 years 
(range 3-45 and 3-45 years) respectively.  Disease was colonic in 58%, ileo-colonic 
in 30%, terminal ileal in 9% and restricted to the perineum in 3%.  
 
Operations to repair or palliate the RVF or associated anal fistula had been 
undertaken in 14 women before referral and included advancement flap repair, seton 
insertion, fistula glue and fistulotomy.  Nine patients had undergone segmental 
colectomy for luminal Crohn’s disease.  Five women had a defunctioning stoma in 
situ on referral to St Mark’s. 
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4.2.5.2 Overall success 
 
During the study period, 23 women underwent 56 operations (mean 2.4 operations 
per patient) for their RVF or the sequelae of RVF surgery.  Thirty-two were treated 
with medications including infliximab (14), thiopurines (28), antibiotics (28), steroids 
(27), 5 ASA agents (13), Methotrexate (8), Thalidomide (2), Mycophenylate (1) and 
Adalimumab (1). 
 
Success was achieved in 13 (35%) patients.  Seven were cured of their fistula during 
medical treatment and six following surgical intervention. A further 3 patients were 
satisfied with the palliation achieved through seton insertion.  One patient ultimately 
underwent proctectomy and a further 3 were offered the procedure.  Thirteen patients 
underwent stoma formation during the course of their treatment and of these 6 either 
had the stoma reversed or were awaiting reversal.   
 
Most patients had multiple medical interventions in addition to surgery, including 
several different drugs sometimes in combination, so it is difficult to ascribe benefit to 
any individual agent.  However, 7 patients went into clinical remission during drug 
treatment including 2 patients on infliximab alone, 1 on azathioprine alone, 1 taking 
azathioprine with metronidazole, 1 on methotrexate alone, 1 on salazopyrin alone 
and 1 on prednisolone and metronidazole. Of 14 patients treated with infliximab, 4 of 
14 (28%) achieved remission, but 2 of these patients suffered a recurrence. Six of 
fourteen (47%) infliximab treated patients, some on concomitant immunomodulators, 
responded without achieving full remission, at a median of 4 weeks (range 1-8 
weeks). Of 28 patients treated with thiopurines, 3 of 28 (11%) achieved remission, 17 
of 28 (60%) responded. 
 
In addition to those patients experiencing remission, improvement in symptoms 
occurred in between 40% and 60% of patients at some point during their treatment.   
 
 
4.2.5.3 Complications 
 
Adverse events, although mostly minor, were common, particularly with infliximab 
(43%), thiopurines (54%) and steroids (26%).  Infliximab was responsible for 3 
anaphylactoid reactions, headaches in 1 patient, palpitations in another and 
reactivation of pulmonary TB in a third.  Patients on thiopurines experienced 
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neutropenia in 4 cases, fever symptoms in 5, nausea in 3 and headaches, 
pneumonitis and septicaemia in 1 each.  Steroids produced osteoporosis in 4 
women, low mood in 1, erratic blood sugar levels in 1 and nausea in 1.  Antibiotics 
led to nausea in 5 patients.  5 ASA agents caused nausea in 2 patients and 
methotrexate produced a flu-like illness in 1 patient and nausea in another. 
 
 
4.2.6 Discussion 
 
Women with Crohn’s rectovaginal fistula achieved overall success in around a third 
of cases, following multiple surgical and medical interventions.  Surgery healed half 
of these fistula and others were palliated by seton insertion or defunctioning stomas.  
Only half the stomas created were reversed.  Most medical interventions induced 
improvement in the patient’s symptoms but robust healing occurred in only 7 women 
and side effects, although mostly minor, were common.   
 
In this retrospective study, patients were followed for the duration of their care in the 
colorectal and gastroenterological departments during the study period and 
thereafter.  Patients were followed, on average, for 5.6 years (range 7-138 months) 
during which time they may have undergone several medical and/or surgical 
interventions.  It is impossible to determine the exact timings of each medical 
intervention, whether they overlapped and what period of observation followed them.  
Rather than demonstrating the efficacy of any individual intervention, the value of this 
study is in describing the natural history of women with Crohn’s rectovaginal fistulae 
experiencing standard care at a tertiary centre, and, in particular, their outcome 
which can assist in informing patients of their likely disease course. 
 
At first glance, the results achieved by Bell and colleagues a decade ago seem better 
than those presented here; 81% (22 of 27) healed at final follow up vs. 35% (13 of 
37).  Bell's successes came from proctectomy in more than a third of cases and 
medical treatment alone in only 3.  Our results point to a different pattern of 
treatment.  Medical treatment alone was responsible for healing in 7 of 37 women 
and around half gained significant benefit from medical treatment. Only 1 patient 
underwent proctectomy and several achieved adequate symptom control from 
reparative surgery or medical treatment such that they declined further surgical 
intervention.  It may be that improved medical treatment and palliative surgery protect 
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women from ablative surgery and a permanent stoma; lower healing rates in this 
study do not necessarily correlate with patient dissatisfaction or an unsuccessful 
outcome. 
 
In fact, proctectomy is considered by many to be a failure rather than a success in 
the management of perianal Crohn’s disease and this is, perhaps, increasingly the 
case.  Whilst there is certainly a place for proctectomy in patients who are blighted by 
disease and in whom a great improvement in quality of life may follow the procedure, 
we might hope that a similar improvement may be found without resorting to ablative 
surgery in most patients.  With this in mind, our success rate falls to 32% and Bell’s 
to 52%. 
 
The present study ran during the first decade of increased infliximab use and the use 
of infliximab has now changed (from episodic to scheduled use). Anti-TNF therapy, 
surgery and the two combined have the greatest efficacy in the literature at the 
present time. Combining anti-TNF therapy and surgery shows great promise but high 
quality evidence is lacking. 
 
Crohn’s rectovaginal fistulae still represent a difficult problem for gastroenterologists 
and coloproctologists as well as their sufferers.  Further research examining 
combined medical + surgical treatments, such as augmenting surgery with 
preoperative infliximab induction and the benefits of faecal diversion and 
preoperative seton use, may produce improved outcomes and can be undertaken in 
the near future based on the early work in this area if adequate interest and funding 
can be found. 
 
4.3 Limitations 
 
These studies examining rectovaginal fistulae suffer from several factors which limit 
their applicability and usefulness.  The patients studied are a complex group of 
mainly tertiary patients with a long duration of Crohn’s disease and/or rectovaginal 
fistulation behind them. 
 
We have studied them retrospectively, capturing them through imperfect databases 
and reviewing their notes which may not describe all events with complete and 
particularly temporal accuracy.  This is especially important when considering which 
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treatments led to improvement or healing in our patients and so conclusions around 
these factors were not drawn.  
 
Defining healing in this group is also difficult.  The absence of symptoms is taken to 
be synonymous with healing unless a defect is found on clinical examination.  
Imaging is rarely of use here.  Several different clinicians were involved with the 
medical patients and exactly how they individually defined healing cannot be known. 
 
The patients in these studies were heterogeneous, particularly with regard to fistula 
anatomy, and it is this difference which enabled me to discuss the various options for 
surgery but which also limits the sample size within each group.  Comparisons 
between techniques or with others, cannot be drawn.  As a single surgeon’s 
experience, the applicability of these results outside our unit is hard to define. 
 
Patients were mostly seen as tertiary referrals and may have also seen secondary 
providers in either gastroenterology or surgery.  Any intervention undertaken in this 
setting can only be gleaned from correspondence which may be deficient.  Patients 
who experience recurrence after referral back to secondary care may not represent 
to St Mark’s so some failures may be missed. 
 
 167 
5 Long-term MRI-guided combined anti-TNF and 
thiopurine therapy for Crohn’s perianal fistulae 
 
5.1 Abstract 
 
Background 
Anti-tumour necrosis factor therapy heals many Crohn’s anal fistulae clinically but the 
rate, extent and durability of deep tissue healing, and factors influencing long term 
outcome, are unknown. 
 
Methods 
Consecutive patients with Crohn’s disease-related perianal (anal, rectovaginal, ano-
labial) fistulae treated with infliximab or adalimumab were monitored prospectively 
both clinically and radiologically using MRI. 
 
Results 
Forty-one consecutive patients with Crohn’s-related perianal fistulae were treated 
with infliximab (n=32) or adalimumab (n=9; following infliximab failure) in combination 
with a thiopurine (unless intolerant). Fifty-eight percent of all patients, comprising 66 
percent and 43 percent of infliximab and adalimumab treated patients respectively, 
demonstrated remission or response at 3 years. Thirty-three percent of infliximab 
treated patients maintained clinical remission at 3 years. Radiological healing lagged 
behind clinical remission by a median of 12 months. The likelihood of clinical 
remission at any time was five times greater in patients who had early clinical 
response within 6 weeks than those without. The number of fistula tracts was 
associated with reduced clinical remission. All patients who achieved radiological 
healing maintained healing on infliximab treatment, whilst only 43% maintained 
healing after cessation of anti-TNF therapy.  
 
Conclusions 
Combination anti-TNF and thiopurine therapy provides sustained benefit in patients 
with perianal Crohn’s fistula. Early clinical response is associated with subsequent 
clinical remission. Radiological healing is slower than clinical healing. Radiologically 
healed fistula tracts maintain healing on infliximab but can recur after cessation of 
therapy. 
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5.2 Introduction 
 
Anal fistulae occur in approximately one third of patients with Crohn’s disease (2), 
represent a distinct phenotype of disease (4), cause significant morbidity, and are 
associated with a severe and disabling disease course requiring multiple medical and 
surgical interventions (2;9;24).  
 
Antibiotics (metronidazole and ciprofloxacin) and immunosuppressive drugs 
(thiopurines) temporarily reduce symptoms but do not lead to radiological healing of 
anal fistulae (14;17;25). The anti-TNFα therapies, infliximab and adalimumab, have 
been shown to maintain clinical remission in approximately a third of patients after 
one year of treatment (4;18) with reduced hospitalisations and operations (96) but 
recurrence of fistulae can occur during treatment and at a rate of 66% 1 year after 
cessation of therapy (5;18). 
 
Clinical remission (closure of the external opening, sustained for four weeks and 
resistant to gentle finger pressure, in all tracts open at baseline) does not reflect true 
deep tissue healing as demonstrated with MRI (13;15;20;28) and EUS (20). Early 
cessation of treatment, after clinical healing but before complete eradication of the 
tract, may be responsible for many recurrences. 
 
A cooperative approach between physicians, surgeons and radiologists is needed to 
manage Crohn’s anal fistulae and algorithms describing such an approach have 
been published (287). Adequate drainage before treatment with anti-TNF agents 
improves outcome by increasing initial response rate by almost a fifth (134).  A non-
randomised study which examined the impact of preoperative infliximab on the 
outcome of surgical treatment of Crohn’s anal fistulae found that time to healing was 
reduced by half and in some surgical subgroups healing was more frequent in the 
infliximab group (138).  Radiology-guided surgical intervention before and during 
infliximab treatment has produced high remission rates (7;22;26) although these 
studies were small and radiological proof of healing was not always obtained.  
 
St Mark’s Hospital has previously published data on 34 patients with Crohn’s anal 
fistulae treated with infliximab, adalimumab or thalidomide, assessed both clinically 
and using serial MRI scanning to determine deep tissue healing of the fistula tract 
(80). At 1 year, clinical remission was seen in 53% of infliximab treated patients, and 
29% of adalimumab treated patients (adalimumab was the second anti-TNF therapy 
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used). Radiological healing was seen in 28% of all anti-TNF treated patients. In that 
study, radiologically healed patients remained healed on maintenance treatment. The 
length of fistula history and fistula complexity did not influence healing. Proctitis 
reduced the clinical benefit of anti-TNF therapy; response or remission was seen in 
60% with proctitis as opposed to 89% of those without proctitis (P = 0.054). 
 
A recent study showed that MRI improvement coincided with clinical and endoscopic 
improvement in 50% of patients treated with infliximab at a median follow up of 36 
weeks (288). Clinical benefit was seen in more than three quarters of patients but at 
longer follow up (median 94 weeks) only 1 of 13 patients had no fistula tracts seen on 
MRI.  
 
Another study, using EUS to guide combination therapy (using antibiotics, thiopurines 
and anti-TNF agents), demonstrated clinical remission in 76% of patients and 
radiological healing in 52% at a median of 68 weeks, with a lag time of 3 months 
between clinical and radiological healing (20). 
 
Besides these studies, maintenance treatment with anti-TNF drugs monitored 
radiologically beyond 1 year has not been adequately described and studies using 
radiological assessment of follow up as an end point are lacking. Several groups 
have published such studies using the van Assche scoring system (13;19;28).  This 
considers the number of fistula tracts, their anatomy, extensions, collections, proctitis 
and hyperintensity on T2-weighted images. One study found that it was insensitive to 
change in some patients (13) and another noted that T2 hyperintensity was the factor 
most clearly associated with clinical benefit (289). 
 
The long term follow up to 3 years in the earlier-reported prospective cohort 
described above (80), expanded to 41 through consecutive recruitment, of patients 
treated with infliximab or adalimumab for perianal Crohn’s fistulae will next be 
reported. Patients have been assessed longitudinally both clinically and 
radiologically.  
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5.3 Hypothesis and Aims 
5.3.1 Hypotheses 
 
 Infliximab and Adalimumab maintenance provide long term remission in the 
majority of Crohn’s anal and rectovaginal fistula patients; 
 Healing as diagnosed on MRI occurs later than healing as diagnosed 
clinically; 
 Radiologically healed patients can safely stop maintenance treatment. 
5.3.2 Aims 
 
The aims were to (i) optimise treatment of Crohn’s perianal fistulae using surgical 
intervention and a combination of anti-TNF and thiopurine therapy under MRI 
guidance according to a previously published treatment algorithm; (ii) determine the 
rate and extent of healing both clinically and radiologically; (iii) characterise the time 
lag between clinical and radiological healing; (iv) determine whether an early clinical 
response relates to subsequent clinical or radiological healing; and (v) determine the 
effect of stopping anti-TNF therapy, in clinically and radiologically healed fistulae, on 
the subsequent disease course. 
5.4 Methods 
 
5.4.1 Patients 
 
Consecutive patients seen at St Mark’s Hospital, London and commenced on 
combined anti-TNF and thiopurine therapy between 2006 and 2008 for Crohn’s 
disease with perianal (anal, ano or rectovaginal or labial) fistulae according to our 
initial study protocol (Figure 38) were included. The diagnosis of CD was confirmed 
previously on endoscopy, radiology or histology.   
 
Patients with symptomatic luminal obstruction and other major comorbidities were 
excluded. Patients with undrained perianal sepsis were included only after adequate 
drainage had been achieved.  
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5.4.2 Study design 
 
This was a prospective observational cohort interventional study, which took place in 
a specialist centre receiving primary and secondary referrals. Standard clinical care, 
defined in an algorithm ( 
Figure 38), was followed for all patients.   
 
Baseline data including demographic information, luminal disease location and 
duration, the anatomy of draining external openings, Crohn’s Disease Activity Index 
(CDAI), Perianal Disease Activity Index (PDAI) (290) and the presence of proctitis 
were recorded. Examination under anaesthesia with abscess drainage and seton 
insertion was performed if fistulae were complex or if there was undrained sepsis on 
clinical examination or MRI scanning. 
 
 
 
Figure 38 - Initial study algorithm for treatment of Crohn’s perianal fistulae used in this cohort 
of 41 patients started in 2006 
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5.4.3 Radiology 
 
An MRI scan was performed in all patients at baseline according to a standardised 
fistula protocol, using a Siemens Avanto 1.5T MR scanner (Siemens, Erlangen, 
Germany). High resolution sagittal, axial and coronal T2 sequences with fat 
saturation (axial and coronal perpendicular and parallel to the plane of the anal canal 
respectively) were obtained, (TR / TE, 8670 / 96; Matrix 256 × 512; field of view, 300; 
flip angle, 150, slice thickness 4 mm; two excitations with IPAT factor of 2).  
 
Patients were scanned supine using a phased-array surface coil. The long axis of the 
anal canal, used to orientate the axial and coronal planes, was identified using a 
midline sagittal localising scan.  
 
On this baseline MRI scan the number, thickness or volume, and complexity of fistula 
tracts, anatomical classification, secondary extensions and hyper-intensity on T2 
weighted images were determined. 
 
5.4.4 Fistula complexity 
 
Simple fistulae were defined as superficial fistulae, intersphincteric or trans-
sphincteric fistulae with one primary tract and no additional tracts and / or extensions 
or abscesses and ano-labial fistulae. Complex fistulae were defined as inter-
sphincteric or trans-sphincteric fistulae with extensions or abscesses, 
suprasphincteric, extrasphincteric and recto-vaginal fistulae (291). 
 
 
5.4.5 Treatment 
 
Patients received infliximab treatment (if anti-TNF agent naïve) or adalimumab 
treatment, if infliximab therapy had failed previously due to lack of efficacy or adverse 
reactions. Standard induction courses (infliximab: 5mg/kg at weeks 0, 2 and 6; 
adalimumab: 160mg at week 0, 80mg at week 2) were followed by maintenance 
treatment (infliximab: 5mg/kg 8 weekly; adalimumab: 40mg every 2 weeks) until 
week 22 at which point patients were classified as a clinical responder (who 
continued maintenance treatment) or a clinical non-responder (who were offered a 
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change to adalimumab if initially on infliximab). Patients were commenced on 
azathioprine at a dose of 2-2.5mg/kg/day or, if azathioprine intolerant, on 6-
mercaptopurine 1-1.5mg/kg/day from week 0.  Episodes of acute perianal abscess 
were treated surgically and often with antibiotics (metronidazole 400mg po tds and/or 
ciprofloxacin 500mg po bd).  However, maintenance antibiotics were not used due to 
the risk of adverse effects and lack of supportive evidence in long term use. 
5.4.6 Clinical follow-up 
 
Clinical follow up took place at weeks 2, 6, 22, 34 and 52, then 6 monthly to two 
years and annually thereafter. MRI scanning was undertaken at the start of treatment 
and at the same intervals as clinical follow up from week 34 onwards. Any clinical or 
symptomatic improvement noted between weeks 2 and 6 (or thereafter) prompted 
seton removal, with the aim of achieving fistula healing with anti TNF agents.  
 
At clinical follow up visits an assessment of the number of external openings, fistula 
healing, development of new external openings, degree of fistula drainage and pain 
was made. CDAI, PDAI and Inflammatory Bowel Disease Questionnaires (
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Appendix 2) were completed by the patients during the initial 18 months of treatment. 
 
Clinical remission was defined as cessation of drainage on history, absence of 
perianal drainage to gentle finger compression of all external openings and 
surrounding tissues, and absence of spontaneous drainage between two consecutive 
visits. Clinical response was defined as (i) closure of ≥50% in the number of 
externally draining fistulae, or (ii) marked reduction in drainage of fistula(s) together 
with less pain and induration as reported by the patient, sustained for at least two 
consecutive visits compared with baseline evaluation.  
 
If a patient did not respond clinically, required surgical intervention or discontinued 
study medication due to lack of efficacy, they were deemed to have had a lack of 
response. 
 
5.4.7 Radiological follow-up 
 
MRI scanning was undertaken at 6 monthly intervals for the first 2 years and annually 
thereafter, as part of routine clinical care of these patients. Each MRI was reviewed 
in consensus by two experienced gastrointestinal radiologists. The radiologists were 
blinded to both treatment arm and outcome. Each subsequent MRI scan was 
compared to both the baseline scan and the previous scan and classified as healed, 
improved, unchanged or worse. 
 
Radiological healing was defined as complete resolution of the previous high signal 
tract or a subtle, narrow calibre intermediate signal residual tract (frequently with low 
signal borders resembling a train track appearance). Radiological improvement 
was defined as reduction in the number and/or volume (with an estimated reduction 
of 10% or more) in the fistula tracts or abscesses.  No radiological change was 
defined as a similar number of tracts and volume (any reduction less than 10%). 
Worsening of the radiological appearance was defined as the development of new 
tracts or collections, or an increase in the volume (of at least 10%) of any previous 
cavities or fistula tracts. 
 
Assessment of around 3/4 of these patients for the first 18 months was undertaken 
and published by other members of the group (Ng).  All other clinical and radiological 
assessment (taken out to up to 4.5 years) forms part of this thesis. 
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5.4.8 Statistical Analysis 
 
The Stata software package - version 9.2 (StataCorp LP, Texas, USA) was used for 
performing all appropriate statistical analyses. Continuous variables were 
summarised by the medians and inter-quartile range (IQR) due to the skewed 
distribution of most variables. The number and percentage of subjects in each 
category were used for categorical variables. The Chi-square test was used to 
compare categorical outcomes between groups. Additionally, logistic regression was 
used to jointly examine the effect of several factors upon the binary categorical 
outcomes. The size of effects of these analyses were given in the form of odds ratios. 
Differences in continuous outcomes between independent groups were evaluated 
using the Mann-Whitney U test to compare between two groups, or the Kruskal-
Wallis test to compare between more than two groups. These non-parametric tests 
were used due to non-normal distribution of most outcomes. For differences between 
paired groups the Wilcoxon signed rank test was used. Cox regression or multilevel 
linear regression were used for the detection of any factors predicting therapy 
outcome. Linear regression was used for continuous outcomes, whilst Cox 
regression was used for survival outcomes. A P value of 0.05 was considered 
significant. 
 
5.4.9 Ethical considerations 
 
All patients were treated on the basis of clinical need according to standard clinical 
care at our institution, on an open label basis and according to licensed or published 
regimes. Ethics Committee approval was therefore not sought, but the study was 
approved by the hospital Drugs and Therapeutic Committee and Medical Director. All 
patients were treated only after full and informed consent. 
 
 
5.5 Results 
 
5.5.1 Baseline data 
 
Forty-one Crohn’s patients with draining anal or rectovaginal fistulae were included in 
the study.  Their baseline characteristics are shown in Table 15. 
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Table 15 - Baseline characteristics 
 
Characteristic Number 
Age (median, range) 36 21-64 
Male:female 16:25 
Disease duration in years (median, range) 10 1-29 
Disease location  
 L1 9  22% 
 L2 21  51% 
 L3 8  20% 
 L4 only 2  5% 
 p only 1  2% 
Fistula duration in years (median, range) 6 1-29 
Fistula location  
 anal 31  75% 
 vaginal 8  20% 
 both 2  5% 
Number of fistulae (median, range) 1  1-5 
Concurrent immunomodulator   
 Azathioprine 21 51% 
 6-Mercaptopurine 4 10% 
Smoking status   
 Smoker 11 27% 
 Non or ex-smoker 28 68% 
 
Thirty-two patients were commenced on infliximab and nine on adalimumab (after 
failing infliximab treatment before the study began). Seven of the infliximab patients 
were changed to adalimumab during the study due to loss of response or an adverse 
reaction to infliximab.  
 
Median follow up was 2.5 years. At the time of this report, 13 infliximab treated 
patients and 7 adalimumab treated patients had reached 3 or more years of follow 
up. 
5.5.2 Clinical and radiological outcome up to three years 
 
Fifty-eight percent of all patients derived clinical benefit (remission or response) up to 
the end of follow-up, including 66% and 43% of infliximab and adalimumab treated 
patients respectively. Adalimumab treated patients had previously failed infliximab 
therapy with adalimumab used as second line agent. 
 
For those patients who had reached a minimum of 3 years follow-up, 21% were in 
remission and 37% had achieved a response. On infliximab, 33% were in remission 
and 33% had achieved response.  On adalimumab, none were in remission and 43% 
had achieved response.   
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Tables 2-4 show the clinical and radiological results for infliximab (Table 16), 
adalimumab (Table 17) and all anti-TNF treated patients ( 
Table 18). 
 
Table 16 - Clinical and radiological outcomes for combination treatment with infliximab and 
thiopurine over three years 
Infliximab 
6 months 
n=32 
12 months 
n=32 
18 months 
n=26 
24 months 
n=22 
36 months 
n=12 
clinical remission 31% 44% 35% 36% 33% 
radiological healing 25% 25% 23% 27% 42% 
      
clinical response 38% 38% 38% 32% 33% 
radiological 
improvement 38% 41% 27% 9% 8% 
      
clinical loss of response 16% 13% 15% 18% 33% 
radiological loss of 
response 22% 16% 19% 27% 42% 
 
 
 
 
 
 
 
 
 
 
Table 17 - Clinical and radiological outcomes for combination treatment with adalimumab and 
thiopurine (previous infliximab failure) over three years 
Adalimumab 
6 months 
n=11 
12 months 
n=10 
18 months 
n=9 
24 months 
n=9 
36 months 
n=7 
clinical remission 9% 40% 22% 11% 0% 
radiological healing 9% 20% 11% 22% 14% 
      
clinical response 54% 60% 67% 44% 43% 
radiological 
improvement 54% 60% 55% 44% 43% 
      
clinical loss of response 27% 0% 11% 44% 43% 
radiological loss of 
response 18% 0% 22% 11% 43% 
 
 
Table 18 - Clinical and radiological outcomes for all patients treated with combination thiopurine 
and anti-TNF therapy over three years 
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5.5.3 Delay between clinical remission and radiological healing 
 
Twelve patients achieved both clinical remission and radiological healing. 
Radiological healing lagged behind clinical remission by a median of 12 
months (interquartile range 3 to 30 months) (Figure 39). 
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Figure 39 - Kaplan Meier plot showing delay between clinical remission and radiological healing 
All Anti-TNFα agents 
6 months 
n=43 
12 months 
n=42 
18 months 
n=35 
24 months 
n=31 
36 months 
n=19 
clinical remission 26% 43% 31% 29% 21% 
radiological healing 21% 24% 20% 26% 32% 
      
clinical response 42% 43% 46% 35% 37% 
radiological improvement 42% 45% 34% 19% 21% 
      
clinical loss of response 19% 10% 14% 26% 37% 
radiological loss of 
response 21% 17% 20% 23% 42% 
 179 
5.5.4 Factors influencing clinical and radiological outcome 
 
On univariate analysis, the number of fistulae at baseline and fistula complexity were 
related to the clinical outcome. Patients with 3 or more fistulae were less likely to 
achieve clinical remission than those with fewer fistulae (HR 0.54 [95% CI = 0.33, 
0.89] P = 0.02). The number of fistulae did not relate to radiological healing (P=0.09).  
 
Patients with more complex fistulae were less likely to achieve clinical remission than 
those with simple fistulae (HR 0.38 [095% CI = .14, 0.98], P = 0.04). Fistula 
complexity did not relate to radiological healing (P = 0.06). 
 
Multivariable analysis showed that only the number of fistulae at baseline was related 
to clinical remission.  
 
On univariate analysis, the presence of a defunctioning stoma at commencement of 
treatment was associated with a decreased chance of clinical remission (p=0.04). 
 
The choice of anti-TNF agent, age, gender, duration of Crohn’s disease, duration of 
fistula, site of luminal disease, smoking status, and number of previous operations 
did not influence clinical or radiological improvement or healing.  
 
CDAI and PDAI were used to assess symptomatic improvement in response to anti-
TNF treatment. However, the initial change over 6 months in either score did not 
relate to clinical or radiological response or remission.  
 
5.5.5 Effect of early response to treatment on disease course 
 
An early clinical response (within 6 weeks) was significantly associated with future 
clinical remission. Patients with an early response within 6 weeks had a likelihood of 
remission at any time that was 5 times greater than those with no early response 
(P=0.004). Early clinical response was not associated with radiological healing. 
 
5.5.6 Surgical procedures during treatment 
 
Eighteen (44%) of the forty-one patients underwent 25 operations during the study 
period (Table 19, Figure 40, Figure 41).  The remaining 23 patients (56%) underwent 
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no surgical procedures.  Twenty one (84%) of the operations performed were 
perianal fistula related and are detailed below (Table 20, Figure 42). 
 
 
Table 19 - Number of procedures performed during study period 
 
Number of 
procedures 
Patients having any 
procedure 
Patients having a fistula 
related procedure 
0 23 26 
1  12 10 
2 5 4 
3  1 1 
 
 
Number of patients undergoing n 
procedures during study period
23
12
5
1
0 procedures
1 procedure
2 procedures
3 procedures
 
 
Figure 40 - Number of patients undergoing n procedures during study period 
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Number of patients undergoing n fistula 
related procedures during study period
26
10
4 1
0 procedures
1 procedure
2 procedures
3 procedures
 
 
Figure 41 - Number of patients undergoing n fistula related procedures during 
study period 
 
 
 
 
Table 20 - Procedures performed during study period 
 
Fistula related procedures Crohn's related procedures 
I+D abscess 5 EUA (proctitis) 1 
Lay open fistula 1 Proctectomy for cancer 1 
Seton +/- I+D 11 Ileocaecal resection 1 
Defunctioning stoma 2 EUA 1 
Proctectomy 2   
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Fistula related procedures during study 
period
24%
5%
51%
10%
10%
I+D abscess
Lay open fistula
Seton +/- I+D
Defunctioning
stoma
Proctectomy
 
 
Figure 42 - Fistula related procedures during study period 
 
5.5.7 Stopping treatment 
 
Fifteen patients stopped or changed anti-TNF agents during the study period after a 
median duration of treatment of 17 months.  Ten patients stopped anti TNF 
treatment; 8 were on infliximab and 2 adalimumab. Of these 10 patients, cessation 
was due to clinical remission in 5, a failure to achieve remission in 2, and side 
effects, pregnancy and rectal cancer in 1 each.  
 
In addition to the 2 who never achieved remission, a further 5 of the 15 patients 
developed recurrent anal fistulae after clinical and, in 3 cases, radiological remission 
after a median of 8 months.  Six of the 10 patients were on azathioprine throughout 
treatment and after cessation, including 4 of the 7 with either failure to respond or 
recurrence of fistulae; the remainder were intolerant of thiopurines.  A dose 
escalation was attempted in 3 and was partially successful in 2 patients.   
Surgery was required in 7 patients including all recurrent fistulae, one of the fistulae 
that never responded and the patient who developed a rectal cancer.  This last 
patient and one other required proctectomy whereas the other patients underwent 
drainage of sepsis with or without seton insertion.   
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Five patients changed treatment from infliximab to adalimumab.  Two did so due to 
lack of response of perianal disease and 3 due to the development of active luminal 
disease.  Treatment was for a median of 11 months before switching.  All 3 who 
switched for luminal disease had both clinically and radiologically healed perianal 
disease before switching and one of these developed fistula recurrence 11 months 
after switching. The other two have had only limited follow up since the switch. Two 
patients required proctectomy following treatment failure with two anti-TNF agents. 
 
5.5.8 Maintaining radiological healing after treatment cessation 
 
Fifteen patients achieved radiological healing on either infliximab (n=12) or 
adalimumab (n=3), of whom 10 were on combination with azathioprine (thiopurines 
not tolerated in 5). To the end of follow-up, seven of these fifteen had a recurrence of 
their fistula.   
 
Treatment was maintained in 7 patients who had achieved radiological healing, of 
whom 5 were on infliximab and 2 adalimumab.  All of the infliximab treated patients 
who achieved radiological healing and continued on treatment maintained healing.  
Both adalimumab patients lost response despite maintenance treatment.  
 
Eight of the fifteen patients who had achieved radiological healing stopped their anti-
TNF treatment or switched to an alternative agent after luminal disease flare or due 
to side effects, of whom 5 then lost response.  Of these five patients, three were on 
maintenance azathioprine and two were intolerant of thiopurines.   
 
In this subset of 15 patients, predictors of maintaining radiological remission were 
assessed. None of the following was associated with loss of radiological remission: 
whether treatment was maintained, duration of disease or fistula, number of fistulae, 
previous operations, initial change in PDAI, gender, age, smoking status, fistula 
complexity, presence of a stoma, presence of a seton at induction or 
immunomodulator use.  All 3 patients on adalimumab failed to maintain radiological 
healing compared to 4 of the 12 infliximab patients although this difference did not 
reach statistical significance (P=0.08). 
 
In the 12 infliximab treated patients, a trend was seen if patients stopped treatment; 
all 5 patients who continued infliximab maintenance maintained radiological healing 
compared to only three of seven (43%) who stopped treatment (P = 0.08).   
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Figure 43 demonstrates serial MRI-imaging in a patient whose perianal disease 
improved clinically and radiologically on combination therapy, but who developed 
clinical and radiological recurrence within 4 months of stopping the anti-TNF therapy. 
5.5.9 Adverse events 
 
An abscess occurred in 14 patients.  Sixteen procedures for drainage of perianal 
sepsis were performed, including seton insertion 11 times.  One patient stopped 
infliximab due to side effects and one developed rectal cancer. 
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Figure 43 - T2 weighted axial MRI with fat suppression demonstrating a. perianal fistula, b. 
improvement on combination thiopurine and anti-TNF therapy, c. radiological healing of fistula 
tract and d. recurrence after cessation of anti-TNF therapy. 
 
 
5.6 Discussion 
 
Combination anti-TNF and thiopurine therapy provides sustained benefit in patients 
with perianal Crohn’s fistula using MRI imaging to monitor outcomes and deep 
healing. Early clinical response is associated with subsequent clinical remission. 
Radiological healing is slower than clinical healing with a time lag of up to one year. 
Radiologically healed fistula tracts maintain healing on infliximab but can recur after 
cessation of therapy. 
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In this prospective open interventional study, MRI has been shown to be a useful tool 
to monitor fistula healing. The study highlights real life practice of treated patients, 
prospectively recruited and followed carefully based on predefined algorithms. 
Approximately one third of infliximab treated patients with perianal Crohn’s disease 
maintained clinical remission at 3 years of follow up. More patients on adalimumab 
lost response over time but these patients had previously failed infliximab, and 
adalimumab was the second anti-TNFα agent used.  
 
Clinical remission occurred earlier than radiological healing, the latter occurring on 
average a year later. This is the first study to have demonstrated the temporal 
relationship between clinical and radiological response or healing on MRI in patients 
with perianal Crohn’s fistulae treated in the long term. 
 
Factors associated with failure or maintenance of healing were also examined.  An 
increasing number and complexity of fistulae, and the presence of a stoma at 
induction, tended to be associated with a decreased chance of long-term healing. 
These findings contrast with those from the 18 month follow-up data on this cohort 
published in 2009 but are consistent with surgical and natural history data, which 
suggest that complex fistulae are associated with a worse prognosis (13). The 
presence of a stoma at induction suggests a particularly severe disease phenotype, 
which is likely to be the factor that reduced the chance of clinical fistula healing, 
rather than the presence of the stoma per se.  
 
Smoking status and pre-anti-TNF therapy induction seton placement were not 
associated with an altered outcome. A recent study has suggested that baseline MRI 
characteristics, such as single-branched fistulae and collections, are associated with 
a worse outcome, with these patients more likely to undergo surgery (288).  
 
Early clinical fistula response (within 6 weeks) is associated with a 5 times increased 
likelihood of achieving clinical remission. Early radiological changes in response to 
treatment, or rate of improvement, may also be helpful in predicting outcome, and 
therefore influencing therapeutic management.   
 
In order to assess radiological parameters, such as extent or rate of improvement, for 
their suitability as prognostic indicators, it will be necessary in the future to identify 
parameters of interest and develop standardised, robust methods of assessment of 
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these parameters. A simple, computer-aided method of serial assessment would be 
valuable. The previously described scoring system published in 2003 by van Assche 
et al. was initially used in this cohort (79). However, in the 18 month follow up data, 
the scoring system was insensitive to change in some patients (80). For example, 
those who had a 50-80% reduction in tract volume, a reduction in hyperintensity in 
secondary tracts but not the primary tract, or reduced volume of sepsis across all 
tracts but maintaining the same number of tracts, could have an unchanged van 
Assche score despite improvement.  
 
Another study using the van Assche scoring system with long term follow-up 
suggested that MRI monitoring is only useful in the first year of follow-up and that 
after this time clinical surveillance alone is valid (288).  However, in this study there 
was no evidence of improved concordance between clinical and radiological 
assessment in the latter years and clinical remission was often maintained for more 
than a year before radiological healing occurred. It is possible that the scoring system 
used is less sensitive after one year of treatment but the assessment of volume and 
use of radiological monitoring per se do not seem to diminish in utility through long 
term follow up.  On the contrary, after an external orifice has healed, radiological 
assessment may be the only way of determining when the tract is completely 
eradicated. 
 
A recent study noted that a change in T2 hyperintensity was the most valuable factor 
associated with clinical benefit (289). In the present study, an assessment of the 
change in fistula volume based on T2 signal intensity was used to determine whether 
a patient had improved, healed or failed to improve. This method was sensitive to 
change over time and was clinically useful for determining management but lacks the 
objectivity of a volume measurement.  Refinement of assessment of the volume of 
the fistula complex and changes in the volume or signal intensity as well as the 
magnitude and rapidity of these changes might predict ultimate outcome. This would 
be a fruitful avenue for future research. 
 
Twenty-one operations were performed for anal fistula during the study.  The need 
for surgery indicated clinical loss of response. The majority of operations were 
performed to drain perianal sepsis. Although abscess formation is known to 
complicate anti-TNF therapy in some patients, this has not been a significant problem 
in most studies. Our treatment algorithm required drainage of all sepsis, using setons 
where necessary, and the presence of undrained pus was sought whenever clinical 
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deterioration occurred. Proctectomy and defunctioning stoma formation for fistula 
were each required in two patients. All but 3 patients had undergone surgery before 
enrolment, the majority for drainage of perianal sepsis, mostly with seton insertion, 
although 4 had failed previous advancement flap surgery, fibrin glue insertion or 
fistulotomy.  Seventeen patients had undergone previous colonic resection. 
 
Further work is required to determine the feasibility of stopping anti-TNF treatment 
when deep tissue healing is deemed to have taken place. These data suggest that 
stopping treatment can lead to recurrence even when the fistula appears 
radiologically healed (Figure 43). 
 
Several factors may account for this. Firstly, the accuracy of a healed fistula tract on 
MRI is unknown. The radiological definition in this study was either the absence of a 
visible tract or the reduction in signal intensity and volume of a tract such that it was 
no longer hyperintense on T2 weighted images and was visible as either a very thin, 
intermediate or low signal intensity line which was taken to be a scar.  The resolution 
of MRI scanning and the assumptions used may be inadequate for ruling out tiny 
residual foci of infection which may increase risk of recurrence. This may also 
account for the slightly higher rate of radiological than clinical remission seen at 3 
years. Further analysis of the nature of a healed fistula tract on MRI is required. 
Secondly, although the fistula is treated and may be fully healed, the underlying 
disease process persists and new fistulae may be created.  If a new fistula does 
occur, it may do so through the path of least resistance which might often be the 
transition between scar and normal fat at the site of an old tract. Finally, it may be 
that full healing of Crohn’s fistula tracts is very unusual on anti-TNF agents and that 
the majority of patients will require long term maintenance treatment (perhaps with 
surgical drainage at intervals) in order to sustain clinical benefit either in the form of 
remission, or at least a response sufficient to provide a reasonable quality of life. 
 
Whatever the reason for recurrence following radiological healing, there was a trend 
towards association between stopping maintenance infliximab treatment and the loss 
of radiological healing even in the small subgroup available.  Although not statistically 
significant, further analysis of this finding in larger cohorts to identify or exclude an 
association is crucial as the questions of long term maintenance treatment and cost-
effectiveness are explored.   
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In the GETAID conducted STORI cohort study, which focussed on patients with 
luminal CD, there was a 50% relapse rate over 30 months in 115 patients who 
stopped infliximab after achieving long term remission under combined therapy with a 
thiopurine (292). Complete endoscopic mucosal healing and normal CRP were 
predictive of a lower chance of relapse. It was postulated here that a healed fistula 
tract on MRI may have a similar prognostic significance to luminal mucosal healing, 
although the results suggest that this may not be the case. 
 
Domenech and colleagues found that 83% of patients with luminal disease were free 
of relapse compared to 34% of patients with perianal disease one year after 
cessation of anti-TNF therapy (98). Identifying those patients who will develop 
recurrence of their fistula after cessation of anti-TNF treatment is important and the 
prospective analysis of these patients continues. In those patients who did not obtain 
clinical or radiological remission, substantial clinical benefit was still often achieved 
with improved quality of life (97).  
 
 
5.7 Summary 
 
The clinical remission rate of combined infliximab and thiopurine treatment of Crohn’s 
perianal fistulae is one third at 3 years. A larger number of fistula tracts and the 
presence of a stoma at induction, the latter a marker of more severe disease, are 
associated with reduced clinical remission. Early clinical response increases the 
likelihood of developing clinical remission. Radiological healing lags behind clinical 
remission. Radiologically healed fistula tracts maintain healing on infliximab but are 
at risk of recurrence after cessation of therapy. 
 
Further work examining clinical and radiological factors (such as changes in fistula 
volume) which predict success and failure of anti-TNF treatment of Crohn’s perianal 
fistulae, further characterisation of healed fistula tracts on MRI, and assessment of 
the safety of stopping anti-TNF treatment after successful healing are required to 
optimise the management of these patients. 
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5.8 Limitations 
 
This study is prospective in recruitment but some observations were made 
retrospectively.  The group is small and although follow up is long (and the longest 
yet published) the cohort which has experienced 3 or 4 year follow up is smaller still.   
 
No control group was used.  This is because our aim is to examine the proportion of 
patients who remain healed throughout their treatment with anti-TNF agents, 
examining the difference between clinical and radiological healing and the rate at 
which efficacy falls over time.   
 
The lack of a placebo arm limits the value of our results in terms of an expression of 
the overall success in the use of these agents as it means that we cannot know how 
many of these patients might have been healed at the end of follow up without 
treatment. 
 
Defining clinical healing is difficult as I have explained above, but even radiological 
healing is problematic; the appearance of a healed fistula tract on MRI scan is also 
unknown.  Conclusions about recurrence following the finding of a healed tract on 
MRI must therefore be considered carefully and further work to clarify this is required. 
 
Given the relatively small group of patients and the number of factors examined for 
their influence on clinical and radiological healing a type 1 error due to multiple 
testing remains a possibility. 
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6 Discussion 
 
In this thesis, I have investigated several aspects of Crohn’s and idiopathic anal 
fistulae. The basis of understanding any disease must be its aetiology and 
pathogenesis.  It is not known why anal fistulae occur, why they persist or why they 
become complex.  It is known that all three are more common in Crohn’s than 
idiopathic anal fistulae, lending logic to the comparative studies conducted in this 
thesis. 
 
A number of novel discoveries have been made, including an absence of bacteria 
lying beside the mucosa in anal fistula tracts. In the gut, it is mucosa-associated 
bacteria which interact with the host immune system via dendritic cells, driving the 
inflammatory process.  It is true that an inability to find the bacteria does not 
necessarily mean they are not present in vivo, since the lack of a mucosal surface 
and adjacent mucus layer may mean that (perhaps tenuous) associations in vivo are 
lost after any manipulation, such as during the washing phase of the experiments.  
However, were that to be the case, the SEM experiments, conducted as they were 
without washing might have been expected to detect more bacteria, which they failed 
to do.  A larger SEM study with consideration of other techniques that might avoid the 
problem of disturbing bacteria in a fragile relationship with the fistula tract wall, is 
planned. 
 
If it is assumed that the microbiological findings are correct, the presence of 
inflammatory cells close to the luminal aspect of the fistula tract wall may imply the 
presence of another luminal factor driving the inflammatory process in the fistula 
tract.  Endotoxin, bacterial proteins adherent to the tract wall or other pathogens are 
all possible and would not have been detected by the experiments presented here.  
Investigation along these lines is also planned in tandem with the microbiological 
study mentioned above. 
 
Alternatively, one might anticipate that an efficient host, lining a disturbed surface 
with appropriate immune-competent cells, might prevent adherence of potentially 
invasive bacteria onto that surface, thereby resulting in the findings presented here.  
If this were indeed a sine qua non of the competent host, then other granulation 
tissue-lined wounds not connected to fistula disease could be examined to see if they 
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are similarly sterile on their immediate surface.  The problem may be one of a failure 
to epithelialise an otherwise properly prepared wound.   
 
Epithelialised surfaces swarm with bacteria.  An intact epithelium is energy efficient 
for the host, as a permanently mobilised defensive immune force does not need to be 
stationed at the frontier.  It is also in the interests of the bacteria, which have a place 
to feed and multiply.  It may be that the host and bacteria together work 
synergistically to epithelialise a surface, and the absence of bacteria from the depths 
of a fistula wound may actually harm the final phase of epithelialisation. 
 
Next, the similar levels of TNFα in Crohn’s and idiopathic fistula tracts, and the 
known efficacy of anti-TNFα agents in Crohn’s anal fistulae, suggests that a trial of 
infliximab in chronic, inoperable, refractory anal fistulae may be warranted. 
 
As the fistula tracts studied here were chronic and well established, it may be that the 
findings represent the biology of persistence rather than of pathogenesis.  
Investigation in a group of new, acute anal fistulae in both Crohn’s and idiopathic 
patients alongside established fistulae may generate interesting differences both 
between the Crohn’s and idiopathic patients and also between these findings from 
chronic fistulae compared to the microbiology and immunology of acute fistulae.   
 
The search for aetiological factors is important in order to improve treatment options 
and limit the compromise faced by patients.  If a fistula can be laid open with an 
acceptable risk of minor incontinence, then fistulotomy offers the best chance, and a 
very good chance, of cure.  If a risk of minor incontinence is not acceptable to the 
patient, or the impairment suffered following lay open would be greater than this, the 
patient faces options including palliation with a loose seton, potentially similar 
incontinence with a tight seton, or with the vagaries of an advancement flap, glue or 
plug.   
 
LIFT shows promise as a simple, effective and low risk treatment and appears to be 
the best alternative to fistulotomy at the present time.  Larger studies are required to 
prove its value, particularly in complex, refractory or Crohn’s related fistulae. 
 
In surgery, when many procedures exist for the same condition, none is satisfactory.  
This is certainly the case for anal fistula surgery.  Like Helicobacter Pylori eradication 
or Enhanced recovery Programs, anal fistulae may well be multi-faceted beasts 
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requiring treatment of every factor in order to achieve success.  Fistulotomy is 
successful; it eradicates the tract, its lining and contents, the intersphincteric space 
and internal opening.  The wound is exposed to repeated abrasion by dressings and 
the normal processes of locomotion and altering posture.  The ‘distal obstruction’, 
necessary to promote fistula persistence elsewhere in the body, is disrupted. 
 
The alternative operations perform only one or two of these functions.  Infill materials 
for example, fill the space and disconnect the tract from the bowel, but they do little to 
disrupt the environment of the tract itself and any residual space; extrusion of glue or 
epithelium left behind may lead to recurrence.  
 
Without a full understanding of the aetiological aspects of anal fistulae, including 
cytokine milieu, pathogens, immune dysfunction, space, ramifications, inflammation, 
epithelium, not to mention so called ‘unknown unknowns’, it will be difficult to create a 
regimen that treats every aspect of fistula pathology. 
 
However, infill materials such as plugs, glue and microspheres, may offer a scaffold 
upon which to hang this multifaceted treatment.  With adequate removal of epithelium 
and granulation tissue, such as with a reaming device, closure of the internal 
opening, followed by instillation of a collagen based infill material which can be 
impregnated with agents targeted to the pathogenic features of an individual’s fistula 
tract, such as infliximab, gentamicin and autologous fibroblasts, one can begin to see 
a treatment which not only treats all aspects of pathology but is tailored to a given 
patient. 
 
Antibiotic impregnated fibrin glue offered disappointing results.  Local injections of 
infliximab in small studies of Crohn’s anal fistulae had limited success.  Microspheres 
have been shown to hold and release drugs over time.  Autologous fibroblasts 
improve healing in an animal model.  Several elements of this treatment have been 
considered but a combination based on the concept of countering every aetiological 
factor has not.  The next step in this process, a study of autologous fibroblast 
enhanced collagen paste after reaming, is planned in the fistula research unit at St 
Mark’s shortly. 
 
At the present time, many complex or refractory anal fistula patients come to St 
Mark’s following failed treatment elsewhere.  Many of them are suitable for 
fistulotomy and leave cured of their fistula with only a modest risk of worsening their 
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incontinence.  In some patients, earlier fistulotomy has caused a degree of 
impairment of continence which is not worsened by a small additional sphincter injury 
whilst 1cm or more of cephalad functioning muscle remains.  In others, years of 
disappointment and recurrence present a more accepting patient to clinic who is 
willing to risk flatus incontinence for a 95% chance of cure. 
 
Crohn’s patients are less commonly suitable for fistulotomy and for those who cannot 
undergo surgery, anti-TNFα agents offer the best chance of fistula healing.  
Infliximab is expensive and has significant side effects in some patients with only 
around a 1 in 3 chance of lasting remission whilst on maintenance therapy.  
However, this is significantly better than any other drug currently available, there is 
no risk of incontinence, and even if remission is not achieved, improvement in fistula 
symptoms and quality of life is very common. 
 
Some patients will never gain a significant benefit and will certainly never heal.  
Some will improve for a time and then relapse.  Some will heal if given a sufficient 
course of treatment.  It is very difficult to prejudge which of these groups patients will 
fall into based on demographic or baseline disease data.  The data presented in this 
thesis have shown that a rapid early clinical response increases the chance of a 
patient achieving clinical remission, but no radiological prognostic features have been 
identified so far.  The prospective study continues but the radiological parameters for 
assessing improvement are blunt. 
 
The best measure of a physical response in a fistula tract on MRI scanning may well 
be the change and rate of change of volume of the tract itself.  Clinically, a healed 
external opening may obscure a growing rabbit warren of extensions and tract 
expansion.  On MRI, this would be obvious. More subtle changes in volume are also 
detectable on modern scanners but quantifying and delineating change over time is a 
very labour intensive process.  A prototype computer program able to read DICOM 
images from MRI scanners, semi-automatically measure fistula tract volume on serial 
scans, and plot changes in volume over time is under development. 
 
Such a programme has two immediate potential uses.  Firstly, it might help clinicians 
to decide when it is appropriate to stop treatment, either because response is being 
lost or because treatment is complete and the chance of recurrence on cessation is 
very low.  Secondly, change in volume and the rate of change in volume may be 
useful predictive factors.  For example, a future infliximab regimen might benefit from 
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the knowledge that a reduction in tract volume of 50% or more in the first 6 months 
suggested a 95% chance of radiological healing at 2 years, or that a change in 
volume of less than 25% in the first 6 months suggested a 95% chance of relapse 
within 18 months and no prospect of healing; and so on.  This kind of prognostic 
information could prevent exposure to expensive and potentially harmful drugs in 
patients with little chance of benefit, and encourage perseverance in those patients 
who may heal if only treated for long enough. 
 
The large group of patients who gain some clinical benefit from anti-TNF agents 
without obtaining remission may nevertheless warrant ongoing treatment.  Further 
work is needed to delineate the personal, social and economic cost and benefit of 
these agents as a ‘palliative’ intervention to consider whether such treatment is 
beneficial and cost effective for these patients who are often keen to continue 
treatment in spite of the risks and a failure fully to heal because an improved family 
and working life is gained. 
 
Like anal fistulae in Crohn’s disease, rectovaginal fistulae do not heal consistently in 
response to drugs or surgery.  Even non-Crohn’s RVF fare poorly at surgery.  
Preoperative placement of setons and stomas are sometimes used in spite of a lack 
of evidence, and whist several studies have commented on the latter as a secondary 
outcome, randomised data on the influence of a stoma on healing are lacking.  
Without this kind of trial, like will not be compared with like.  For example, a woman 
may be persuaded to accept a stoma to cover her third RVF repair attempt.  Whether 
or not that repair is successful, one is left asking whether at her first, perhaps best 
chance of successful surgery, a stoma might have made a difference.  It may also be 
the case that in order to glean a benefit from stoma use, a high rate of defunctioning 
may be necessary.  Other factors such as seton insertion to limit inflammation before 
surgery may also encourage healing.   
 
In Crohn’s disease, whilst stomas and setons may still be of value, preoperative 
infliximab treatment is probably the next valuable step to investigate.  Good pilot data 
have found that time to healing is improved in patients treated with infliximab before 
surgery.  A large randomised trial investigating the value of preoperative infliximab 
induction, along with preoperative seton insertion and, in some cases, defunctioning, 
in improving surgery for anal and rectovaginal fistulae in Crohn’s disease seems 
attractive. 
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6.1 The future 
 
With an improved understanding of the aetiological aspects of anal fistulae, a 
combined, multi-faceted treatment may represent the future of their management.  
An optimised approach should deal comprehensively with the factors underpinning 
fistula occurrence and persistence in both Crohn’s and complex idiopathic disease. 
Whilst improvements in outcome have been achieved in recent decades, a plateau 
above which success rates will not climb will be reached (if it has not already) without 
a shift in approach.   Identifying and treating the pathological factors in a combined 
way seems key. 
 
Consider a tract too high to lay open, perhaps in the presence of Crohn’s disease 
and with secondary ramifications.  Diagnostic laboratory tests might determine 
bacterial colonisation, TNFα levels, T lymphocyte and DC function and other 
immunological variables. A period of seton treatment to drain the system might be 
followed by systemic infliximab induction (+/- maintenance) with MRI monitoring to 
determine improvement in the ramifications and identify the lone tract that remains.  
After this priming of the tract it might be reamed to remove any epithelium and the 
luminal surface of the tract itself and a collagen based infill material impregnated with 
antibiotics, infliximab, autologous fibroblasts and other agents tailored to the 
individual to counter each defect in the immunological and repair systems might be 
instilled. 
 
This thesis provides novel microbiological and immunological findings to stimulate 
and guide further aetiological analysis as well as a description of the benefits and 
limitations of some of the current aspects of fistula management. A move towards the 
combined management of these patients by surgeons, gastroenterologists and 
radiologists is crucial with shared goals and simultaneous intervention, rather than 
the alternative of simply passing patients between the two specialities when options 
from one side become exhausted. This move should govern both clinical and 
research approaches with combined clinics and academic units, such as the Fistula 
Research Unit at St Mark’s. 
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7 Appendix 1 
7.1 Histology and IHC materials and protocols 
7.1.1 Histology and IHC materials 
 
Product  Company/Components 
   
Gill’s Haematoxylin  Surgipath Europe Ltd, Peterborough 
Harris Haematoxylin  Surgipath Europe Ltd, Peterborough 
Eosin  Pioneer, UK 
2.5% ready to use normal horse serum  Vector laboratories, UK 
Anti-mouse Ig ImmPRESS Reagent  Vector laboratories 
ImmPACT DAB peroxidise substrate  Vector laboratories 
Hydrogen Peroxide (30%w/v in water)  Sigma Aldrich, UK 
Phosphate buffered saline  Sigma Aldrich 
Tris Buffered Saline 0.05M, pH 7.4 
 Trizma base 6.06g, NaCl 8.06g, KCl 0.20g 
(all Sigma) in 500ml dH2O 
TRS  DAKO, UK 
Methanol  Sigma 
Acid Alcohol, 1% HCl in 70% IMS  Fisher Scientific, UK & Genta Medical, UK 
Sirius Red, F3B, 1g in 1000ml Picric 
Acid (Sigma) 
 
BDH lab, UK 
Calcium Chloride  VWR, UK 
1M Sodium Hydroxide  Sigma 
Miller’s Elastin  Surgipath 
CD3 antibody (M7254)  DAKO 
Ab-1 antibody (MS 148P1)  Thermo Fisher Scientific 
Citrate buffer 10mM  2.5g in 1000ml dH2O, pH 6.0 
Anti-rabbit Ig ImmPRESS Reagent  Vector laboratories 
Weigert’s Haematoxylin  Pioneer Research Chemicals (PRC), UK 
Acid K permanganate, 0.5% KMnO4 in 
3% H2SO4 
 
Sigma 
1% Oxalic Acid  Sigma 
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7.1.2 Histology and IHC protocols 
7.1.2.1 Tissue processing 
 
After gross cut up, tissue is fixed in 10% neutral-buffered formalin and then 
processed in graded alcohols, xylene and wax (Table 21) before being embedded in 
paraffin wax prior to sectioning. 
 
 
Table 21 - Protocol for tissue processing 
 
Solution Time (hours) Temperature (°C, RT = 
Room temperature) 
10% neutral-buffered 
formalin 
2 RT 
70 % IMS (Alcohol) 1 RT 
90% IMS 1 RT 
100% IMS 1 RT 
100% IMS 1 RT 
100% IMS 1 RT 
50% absolute IMS/Xylene 1 RT 
Xylene ½ RT 
Xylene 1 RT 
Xylene ½ RT 
Paraffin wax ½ 60 
Paraffin wax 1 ½ 60 
Paraffin wax 1 ½ 60 
 
 
7.1.2.2 H&E protocol 
 
Dewax with Xylene 1 5m 
Dewax with Xylene 2 2m 
Absolute IMS (Industrial Methylated Spirit) 2m 
95% IMS 2m 
70% IMS 2m 
Running tap water 2m 
Gill’s Haematoxylin 90s 
Running tap water 5m 
Differentiate in 1% hydrochloric acid in 70% IMS 3s (dip 3 times) 
Running tap water 4m 
0.5% aqueous Eosin 5m 
Running tap water 20s 
70% IMS 30s 
95% IMS 30s 
Absolute IMS 2m 
Xylene 1 2m 
Xylene 2 Until ready to mount 
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7.1.2.3 PM protocol 
 
Dewax with Xylene 1 5m 
Dewax with Xylene 2 2m 
Absolute IMS (Industrial Methylated Spirit) 2m 
95% IMS 2m 
70% IMS 2m 
Running tap water 2m 
Acid potassium permanganate 5m 
Distilled water 1m 
1% oxalic acid 2m 
Distilled water (fresh) 5m 
95% IMS 1m 
Miller’s Stain 60m 
95% IMS 1m 
Tap water 2m 
Weigert’s haematoxylin 10m 
Tap water 1m 
1% hydrochloric acid in 70% IMS 5s 
Tap water 5m 
Distilled water (fresh) 30s 
Picro Sirius red 45m 
70% IMS 10s 
95% IMS 10s 
Absolute IMS 10s 
Xylene 1 2m 
Xylene 2 Until ready to mount 
 
 
7.1.2.4 Ab-1 protocol 
 
1. Xylene1 5 mins 
2. Xylene2 2 mins 
3. IMS 2 mins 
4. 95% IMS 2 mins 
5. 70% IMS 2 mins 
6. Running tap water 2 mins 
7. Hydrogen peroxide 3%, 30 minutes 
8. 2xdH2O 
9. 3xPBS 
10. NSB, Horse serum (2 drops) 30 minutes 
11. Primary antibody, dilution 1/1000: Thermo Fisher Scientific: O/N  
12. 3xPBS 
13. Immpress kit, anti-mouse (2 drops), 45 minutes 
14. 3xPBS 
15. DAB, Neo Marker 3 mins 
16. Distilled water 5 min 
17. Harris Haematoxylin, 30 seconds 
18. Running water 7 minutes 
19. 1% Acid Alcohol 3x3 seconds 
20. Running water 5 minutes 
21. 70% IMS 30 secs 
22. 95% IMS 30 secs 
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23. IMS 30 secs 
24. Xylene1 2 mins 
25. Xylene2 until mounted 
 
 
7.1.2.5 CD3 protocol 
 
1. Xylene1 5 mins 
2. Xylene2 2 mins 
3. IMS 2 mins 
4. 95% IMS 2 mins 
5. 70% IMS 2 mins 
6. Running tap water 2 mins 
7. AR: 98° in Dako TRS 30 mins 
8. Cool in PBS 
9. Hydrogen peroxide 3%, 30 minutes 
10. 3xPBS 
11. NSB, Horse serum (2 drops) 45 minutes 
12. Primary antibody, dilution 1/50: Dako: 60 mins  
13. 3xPBS 
14. Immpress kit, anti-mouse (2 drops), 30 minutes 
15. 3xPBS 
16. DAB, Neo Marker 3 mins 
17. Distilled water 5 min 
18. Harris Haematoxylin, 15 seconds 
19. Running water 7 minutes 
20. 1% Acid Alcohol 3x3 seconds 
21. Running water 5 minutes 
22. 70% IMS 30 secs 
23. 95% IMS 30 secs 
24. IMS 2 mins 
25. Xylene1 2 mins 
26. Xylene2 until mounted 
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7.2 FISH materials and protocols 
7.2.1 FISH materials 
 
Product  Company/Components 
   
DePC water  
1ml DePC (Sigma, UK) per litre of deionised water, 
shake vigorously, incubate overnight at room temp, 
autoclave 
Hybridisation buffer  
4.78gL Tris-HCL (Sigma, UK), 79.69g/L NaCl (VWR, 
UK), deionised water, autoclave, 15ml/L 10%SDS, 
adjust to pH 7.2, filter at 0.2μm 
Hybridisation wash  
3.15gL Tris-HCL (Sigma, UK), 52.60g/L NaCl (VWR, 
UK), deionised water, adjust to pH 7.2, autoclave, filter 
at 0.2μm 
4% paraformaldehyde  
500ml PBS, 20g paraformaldehyde (Sigma, UK), heat 
to 65°C, add NaOH to clear and filter at 0.2μm 
Tris buffer, 10mM, pH6.5  Sigma, UK 
 
 
7.2.2 FISH protocols 
 
7.2.2.1 Probe dilution protocol 
 
The desiccated probe is re-suspended with a microlitre volume of Tris Buffer 
(10mM, pH6.5) equal to the microgram mass supplied (found on datasheet 
accompanying probe).  This produces a 1μg/μl stock solution which is diluted 
to a 5ng/μl working concentration solution with hybridisation buffer at the time 
of hybridisation by adding 1μl of stock solution to 199μl of hybridisation buffer. 
 
7.2.2.2 Hybridisation protocol 
 
1. Remove slides from -20°C storage 
2. Warm at RT for 10 minutes 
3. Fix in 4% paraformaldehyde for 10 minutes 
4. Wash in DePC water for 5 mins x2 
5. Add 20μl filtered, warmed hybridisation buffer to each well and place in oven 
in sealed, humidified box, at appropriate hybridisation temperature for 30 
mins 
6. Add 18μl probe (5ng/μl) in hybridisation buffer to each well 
7. Cover with 13mm round cover slip 
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8. Place back in oven in sealed, humidified box at same temperature overnight 
9. Remove slides from box and tap off coverslips 
10. Place slides into filtered hybridisation wash and agitate for 20mins at room 
temperature (in foil wrapped Coplin jars) (Bif and Bac only) 
11. Place in DePC water for 5 mins 
12. Mount 
13. Store in fridge and protect from light 
 
 
7.3 FACS materials and protocols 
7.3.1 FACS materials 
 
Product  Company/Components 
   
Complete medium 
 RPMI-1640 Dutch Modification (Sigma 
Aldrich, UK) containing 10% Fetal Calf 
Serum, 100 µg/ml streptomycin, 100 units/ml 
penicillin 
FACS Buffer 
 PBS with 2% FCS, 0.02% sodium azide and 
1mM EDTA 
Phosphate Buffed Saline (PBS)  Sigma, UK 
Fetal calf serum (FCS)  Tissue culture systems 
Ficoll-Paque 
 Amersham Pharmacia Biotech AB, Uppsala, 
Sweden 
Flow-countTM Fluorospheres  Beckman Coulter, Bucks 
Optilyse C  Immunotech, Marseille 
Paraformaldehyde (PFA) 1%  BDH chemicals, Poole 
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Antibody Colour 
  
CD11c FitC 
γ1 FitC 
CD65 FitC 
γ2a FitC 
rIgM FitC 
mIgM FitC 
CLA FitC 
  
β7 PE 
CD19 PE 
γ1 PE 
CD3 PE 
CD16 PE 
r γ2a PE 
γ2a PE 
Lineage cocktail PC5 
CD14 PC5 
Gamma 1 PC5 
  
HLA-DR APC 
β7 APC 
r γ2a APC 
CD3 APC 
γ1 APC 
 
 
7.3.2 FACS protocols 
 
7.3.2.1 Walk out protocol 
 
1. Remove tissue from complete medium 
2. Cut in Petri dish to 2mm3 pieces 
3. Wash with complete medium 
4. Remove any blood using scalpel 
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5. If sufficient pieces of tissue (at least 3), place 1-2 pieces into a test tube, add 
1ml complete medium and incubate overnight at 37°C, 5% CO2 
6. Place remaining pieces into single well of 24 well plate 
7. Add 1ml of complete medium 
8. Incubate overnight at 37°C, 5% CO2 
9. Remove supernatant from test tube and place in cryovial, store at -80°C for 
multiplex analysis 
10. Remove supernatant from 24 well plate and label  
 
7.3.2.2 Labelling protocol 
 
1. Remove supernatant from 24 well plate and place in test tube 
2. Wash well  with 1ml FACS buffer x3 putting wash fluid with supernatant 
3. Centrifuge test tube at 1400 rpm for 5 mins 
4. Tip out fluid and flick to disperse cells in remaining fluid 
5. Make up to 100μl per tube plus 50μl with FACS buffer 
6. Divide equally between FACS tubes 
7. Add antibodies to appropriate tubes using 10μl of FitC antibodies, 12μl of 
lineage cocktail and 5μl of all other antibodies 
8. Refrigerate for at least 20 minutes 
9. FACS buffer wash: add 1ml of FACS buffer to each tube, centrifuge at 1400 
rpm for 5 mins, tip out supernatant and flick to disperse cells 
10. Add 200μl of 1% paraformaldehyde 
11. Add 20μl of fluorospheres 
12. Perform flow cytometry 
 
7.3.2.3 Compensation tube protocol 
 
1. Add an equal volume of RPMI medium to whole blood 
2. Slowly pipette mixture onto equal volume of Ficoll 
3. Centrifuge at 2000 rpm for 25 mins 
4. Extract PBMCs as interface 
5. Add FACS buffer to PBMCs up to 35ml 
6. Centrifuge at 1500 rpm for 5 mins, tip out supernatant then flick to disperse 
cells 
7. Repeat FACS buffer wash with 10ml at 1500 rpm for 5 mins, tip out 
supernatant and flick to disperse cells 
8. Make up to 500μl with FACS buffer 
9. Add antibodies to appropriate tubes using 10μl of FitC antibodies and 5μl of 
all other antibodies 
10. Refrigerate for at least 20 minutes 
11. FACS buffer wash: add 1ml of FACS buffer to each tube, centrifuge at 1400 
rpm for 5 mins, tip out supernatant and flick to disperse cells 
12. Add 500μl of 1% paraformaldehyde 
13. Perform flow cytometry 
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7.4 Results data 
 
7.4.1 Tract immunohistochemistry results 
7.4.1.1 Acute and chronic inflammation 
7.4.1.1.1 Acute inflammation 
 
Table 22 - Tract acute inflammation results 
Variable  Category Acute Inflammation 
Median (IQR) 
P-value 
    
Sex Male 0 (0, 2.5) 0.80 
 Female 0.5 (0, 1)  
    
Smoker No 0 (0, 1) 0.08 
 Yes 1 (0, 3)  
    
Disease location L1 1 (0, 2) 0.44 
 L2 0 (0, 0)  
 L3 2.5 (0, 5)  
    
Stoma No 0 (0, 2) 0.39 
 Yes 0 (0, 0)  
    
 Seton No 0 (0, 0) 0.03 
 Yes 1.5 (0, 3)  
    
Immunomodulators No 0 (0, 1) 0.44 
 Yes 1 (0, 3.5)  
    
 
Table 23 - Tract acute inflammation results 
Variable  Correlation Coefficient P-value 
   
Age -0.32 0.17 
Duration luminal disease 0.91    0.005 
Duration perianal disease -0.15 0.53 
Number of previous operations 0.05 0.85 
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7.4.1.1.2 Chronic inflammation 
 
Table 24 - Tract chronic inflammation results 
Variable  Category Chronic Inflammation 
Mean (SD) 
P-value 
    
Sex Male 2.6 (1.3) 0.57 
 Female 2.3 (1.1)  
    
Smoker No 2.1 (1.0) 0.07 
 Yes 3.1 (1.4)  
    
Disease location L1 2.7 (0.6) 0.68 
 L2 2.0 (2.8)  
 L3 3.3 (1.5)  
    
Stoma No 2.7 (1.1) 0.07 
 Yes 1.0 (1.4)  
    
 Seton No 2.4 (1.2) 0.56 
 Yes 2.7 (1.3)  
    
Immunomodulators No 3.3 (1.0) 0.43 
 Yes 2.4 (1.8)  
    
 
7.4.1.2 Luminal vs. deep immune cells 
 
Table 25 - Tract Macrophages and T-lymphocytes by zone 
Cell type Luminal cells 
(z1) 
Median (IQR) 
Deep cells (z2) 
Median (IQR) 
Difference (z1 – 
z2) 
Median (IQR) 
P-value 
     
Ab-1 
(macrophage) 
10.8 (1.7, 
38.8) 
2.5 (1.5, 7.5) 10.2 (0.0, 35.4) 0.02 
CD3 (T-
lymphocyte) 
16.6 (13.1, 
22.8) 
5.0 (2.9, 6.2) 11.6 (7.3, 23.8)   0.002 
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7.4.1.3 T-lymphocytes 
 
Table 26 - Tract Macrophages and T-lymphocytes by aetiology 
Cell type Variable Idiopathic 
Median (IQR) 
Crohn's 
Median (IQR) 
P-value 
     
Ab-1  Naurea 5.5 (0.9, 13.8) 7.3 (1.3, 22.1) 0.76 
(macrophage) Na z1 (lumen) 10.8 (1.7, 38.8) 18.0 (2.9, 42.8) 0.99 
 Na z2 (deep) 2.5 (1.5, 7.5) 4.5 (1.7, 7.9) 0.88 
      
CD3 Naurea 7.7 (3.0, 17.1) 4.5 (3.5, 15.5) 0.75 
(T-
lymphocyte) 
Na z1 (lumen) 14.4 (11.1, 
20.0) 
21.7 (16.6, 44.9) 0.05 
 Na z2 (deep) 4.5 (2.9, 5.3) 9.1 (6.2, 9.1) 0.04 
     
 
7.4.2 Rectal Fluorescent in situ Hybridisation results 
7.4.2.1 EUB/Panbacteria 
 
Table 27 - Rectal bacteria results: EUB 
Variable Category Median (IQR) P-value 
    
Group IPD 54 (17, 72) 0.24 
 CPD 26 (14, 46)  
    
Group (combined) IPD / CPD 37 (14, 61) 0.75 
 CD 34 (9, 83)  
    
Group (combined) CPD / CD 26 (12, 61) 0.23 
 IPD 54 (17, 72)  
    
 
7.4.2.2 Bacteroides - Prevotella 
 
Table 28 - Rectal bacteria results: BAC 
Variable Category Median (IQR) P-value 
    
Group IPD 15 (17, 72) 0.05 
 CPD 0 (0, 0)  
    
Group (combined) IPD / CPD 0 (0, 61) 0.56 
 CD 5 (0, 83)  
    
Group (combined) CPD / CD 0 (0, 19) 0.14 
 IPD 15 (0, 47)  
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Table 29 - Rectal bacteria results: BAC 
Variable Correlation Coefficient P-value 
   
Duration of perianal 
disease 
-0.07 0.71 
Duration of luminal disease 
(*) 
0.45 0.02 
   
(*) Crohn's patients only 
 
7.4.2.3 Bifidobacteria 
 
Table 30 - Rectal bacteria results: BIF 
Variable Category Median (IQR) P-value 
    
Group IPD 32 (0, 88) 0.02 
 CPD 0 (0, 8)  
    
Group (combined) IPD / CPD 0 (0, 49) 0.15 
 CD 0 (0, 7)  
    
Group (combined) CPD / CD 0 (0, 8)   0.005 
 IPD 32 (0, 88)  
    
 
7.4.2.4 Clostridium coccoides – Eubacterium rectale 
cluster 
 
Table 31 - Rectal bacteria results: EREC 
Variable Category Median (IQR) P-value 
    
Group IPD 0 (0, 27) 0.76 
 CPD 0 (0, 15)  
    
Group (combined) IPD / CPD 0 (0, 15) 0.53 
 CD 0 (0, 67)  
    
Group (combined) CPD / CD  0 (0, 15) 0.99 
 IPD 0 (0, 27)  
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7.4.2.5 Escherichia coli  
 
Table 32 - Rectal bacteria results: E COLI 
Variable Category Median (IQR) P-value 
    
Group IPD 0 (0, 0) 0.74 
 CPD 0 (0, 9)  
    
Group (combined) IPD / CPD 0 (0, 8) 0.40 
 CD 0 (0, 0)  
    
Group (combined) CPD / CD 0 (0, 0) 0.98 
 IPD 0 (0, 0)  
    
 
7.4.2.6 Faecalibacterium prausnitzii 
 
Table 33 - Rectal bacteria results: F PRAU 
Variable Category Median (IQR) P-value 
    
Group IPD 0 (0, 28) 0.29 
 CPD 0 (0, 4)  
    
Group (combined) IPD / CPD 0 (0, 9) 0.55 
 CD 0 (0, 17)  
    
Group (combined) CPD / CD 0 (0, 8) 0.55 
 IPD 0 (0, 28)  
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7.4.3 Flow cytometry results 
 
 
Table 34 – Tract flow cytometry results 
Variable Group Variable Crohn's 
Median 
(Range) 
Idiopathic 
Median 
(Range) 
P-value 
     
CD3 - T Cells % Positive 2 (0, 85) 16 (0, 84) 0.09 
 PCIR 3 (0, 248) 2 (0, 103) 0.70 
     
CD19 - B Cells % Positive 0 (0, 56) 21 (0, 71) 0.38 
 PCIR 0 (0, 6) 1 (0, 3) 0.92 
     
CD65 - Neutro % Positive 19 (0, 65) 15 (0, 42) 0.15 
 PCIR 6 (1, 93) 77 (0, 743) 0.04 
     
CD16  % Positive 6 (3, 9) 0 (0, 31) 0.20 
- Granulocytes PCIR 192 (2, 382) 0 (0, 20) 0.09 
     
CD14  % Positive 25 (0, 54) 0 (0, 45) 0.32 
- Monocytes PCIR 1 (0, 20) 0 (0, 2) 0.32 
     
B7 - Migration % Positive 0 (0, 45) 26 (0, 65) 0.15 
Cells All PCIR 1 (0, 532) 1 (0, 230) 0.72 
     
CLA - 
Migration 
% Positive 0 (0, 2) 0 (0, 40) 0.24 
Cells All PCIR 0 (0, 1) 0 (0, 42) 0.24 
     
DCs % DCs 14 (1, 57) 15 (0, 36) 0.77 
 % Myeloid 36 (5, 62) 53 (10, 93) 0.46 
 % 
Plasmacytoid 
64  (37, 94) 47 (7, 90) 0.46 
     
B7  % Positive 0 (0, 0) 16 (0, 96) 0.03 
- Migration 
DCs 
PCIR 0 (0, 0) 1 (0, 24) 0.03 
     
CLA DCs % Positive 0 (0, 0) 78 (0, 99) 0.03 
 PCIR 0 (0, 0) 1 (0, 18) 0.03 
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7.4.4 Cytokine results 
 
 
Table 35 – Tract cytokine results 
Variable Normal 
Median (IQR) 
CPD 
Median (IQR) 
IPD 
Median (IQR) 
P-value 
     
IL-2 2.25 (2.02, 
2.60) 
2.02 (1.80, 
2.32) 
1.93 (1.76, 
2.46) 
0.20 
IL-4 1.87 (1.50, 
2.08) 
1.87 (1.77, 
1.95) 
1.92 (1.87, 
2.14) 
0.58 
IL-6 350 (283, 
1213) 
334 (106, 
1345) 
1201 (250, 
4692) 
0.64 
IL-10 2.04 (1.46, 
2.81) 
1.86 (1.61, 
4.05) 
2.81 (1.35, 
6.22) 
0.68 
TNF 2.18 (1.65, 
2.85) 
1.61 (1.24, 
2.66) 
2.87 (2.09, 
6.61) 
0.48 
IFN-g 1.48 (1.43, 
2.48) 
1.43 (1.24, 
1.72) 
4.07 (1.72, 
7.47) 
0.11 
IL-17a 3.01 (0.00, 
3.86) 
2.63 (2.37, 
3.86) 
3.38 (3.13, 
4.59) 
0.05 
     
 
There was some evidence of an overall difference in IL-17a between the three 
groups, although this result was only of borderline statistical significance (p=0.05).  
 
As a result the Mann-Whitney test was used to perform pairwise comparisons 
between groups. The p-values from these analyses were given a Bonferroni 
adjustment to allow for multiple testing, and the adjusted p-values are shown in the 
next table. 
 
Table 36 – Tract IL-17a results after adjustment 
Variable Normal vs. CPD 
P-value 
Normal vs. IPD 
P-value 
CPD vs. IPD 
P-value 
    
IL-17a 0.04 0.29 0.04 
    
 
 
 212 
8 Appendix 2 
8.1 Fistula Drainage Assessment 
 
End Point Definition 
Improvement Closure of individual fistulae defined 
as no fistula drainage despite gentle 
finger compression.  Improvement 
defined as a decrease from baseline 
in the number of open draining 
fistulae of ≥50% for at least 2 
consecutive visits (i.e., at least 4 
weeks). 
Remission Closure of individual fistulae defined 
as no fistula drainage despite gentle 
finger compression. Remission 
defined as closure of all fistulae that 
were draining at baseline for at least 
2 consecutive visits (i.e., at least 4 
weeks). 
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8.2 Perianal Disease Activity Index 
 
Categories Score 
Discharge 
No discharge  
Minimal mucous discharge  
Moderate mucous or purulent discharge  
Substantial discharge  
Gross faecal soiling  
 
0 
1 
2 
3 
4 
Pain/restriction of activities 
No activity restriction  
Mild discomfort, no restriction  
Moderate discomfort, some limitation activities  
Marked discomfort, marked limitation  
Severe pain, severe limitation  
 
0 
1 
2 
3 
4 
Restriction of sexual activity 
No restriction in sexual activity  
Slight restriction in sexual activity  
Moderate limitation in sexual activity  
Marked limitation in sexual activity  
Unable to engage in sexual activity  
 
0 
1 
2 
3 
4 
Type of perianal disease 
No perianal disease/skin tags  
Anal fissure or mucosal tear  
<3 Perianal fistulae 
≥3 Perianal fistulae  
Anal sphincter ulceration or fistulae with significant undermining of 
skin  
 
0 
1 
2 
3 
4 
Degree of induration 
No induration  
Minimal induration  
Moderate induration  
Substantial induration  
Gross fluctuance/abscess  
 
0 
1 
2 
3 
4 
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8.3 Crohn’s Disease Activity Index 
 
Clinical or laboratory variable 
Weighting 
factor 
Number of liquid or soft stools each day for seven days x 2 
Abdominal pain (graded from 0-3 on severity) each day for seven 
days 
x 5 
General well being, subjectively assessed from 0 (well) to 4 (terrible) 
each day for seven days 
x 7 
Presence of complications
*
 x 20 
Taking Lomitil or opiates for diarrhoea x 30 
Presence of an abdominal mass (0 as none, 2 as questionable, 5 as 
definite) 
x 10 
Absolute deviation of Hematocrit from 47% in men and 42% in 
women 
x 6 
Percentage deviation from standard weight x 1 
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9 Appendix 3 
 
9.1 Prospective database data collection forms 
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